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In approximately 23% of AML patients, Fms-like tyrosine kinase 3 (FLT3) 
contains a gain-of-function, internal tandem duplication (ITD) mutation that is 
associated with an unfavourable prognosis. FLT3 is therefore seen as a 
promising therapeutic avenue for AML and as a result, a more complete 
understanding of its function and signalling may lead to additional targets and 
resistance mechanisms being identified. To date, several FLT3 inhibitors 
including Quizartinib (AC220), a second-generation ITD-selective tyrosine 
kinase inhibitor, have been developed, but single-agent clinical trials have not 
been overwhelmingly successful. In most preclinical studies, the inhibitory 
effects of FLT3 inhibitors are mainly evaluated using mutant-expressing 
models, however, most AML patients harbour both a wild-type and mutant 
FLT3 allele as well as presenting with high plasma levels of FLT3 ligand 
(FLT3L). We hypothesized that FLT3L could act through WT-FLT3 to influence 
the efficacy of FLT3 inhibitors in cells with heterozygous mutations. In this 
study, we have examined the role of FLT3 inhibition and FLT3L activation on 
the cellular localisation and downstream signalling in several AML cell lines, 
some of which express ITD mutations. We also looked at mechanisms by 
which FLT3L could impair the efficacy of FLT3 inhibitors. Our results revealed 
that the majority of FLT3 in the MV4-11 and MOLM-13 cells was intracellular. 
Inhibition of ITD-FLT3 with quizartinib led to a dramatic relocalisation of FLT3 
to the cell surface. This effect was more pronounced in MV4-11 (FLT3ITD/ITD) 
than the heterozygous MOLM-13 (FLT3ITD/WT) cells that also express WT. This 
was accompanied by inhibition of ERK, AKT and STAT5 signalling pathways 
and resulted in cell death. Quizartinib induced cell death only in AML lines 
expressing FLT3-ITD mutations (MOLM-13 and MV4-11), and this could be 
antagonised by FLT3 ligand (FLT3L). The largest inhibitory effects were seen 
in heterozygous cells expressing a mutated and wild-type allele. FLT3 
inhibition was associated with downregulation of the anti-apoptotic protein Mcl-
1 and upregulation of the pro-apoptotic BH3-only protein, Bim. Our 
experiments indicated that both of these proteins were regulated by both WT 
and ITD-FLT3 through the MAPK pathway. These results suggest that 
activation of FLT3 signalling by FLT3L confers resistance to quizartinib 
through upregulation of Mcl-1 and suppression of Bim expression.  
Taken together, our data suggest that FLT3 cell surface localisation and 
expression are controlled by ITD mutations and are key components of drug 
resistance. The data also suggests a novel therapeutic approach in patients 
with high plasma FLT3L levels, especially when using type II inhibitors such 
as quizartinib, is to co-target the MAPK/ERK pathway to abrogate the FLT3L-
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1.1 Acute myeloid leukaemia 
1.1.1 Haematopoiesis 
Haematopoiesis is the process of blood cell formation which occurs during 
embryonic development and throughout adulthood to produce and replenish 
the cellular blood components. All hematopoietic lineages originate from the 
common pluripotent hematopoietic stem cell (HSC)(Baum et al., 1992). HSCs 
have a long-term self-renewal capability and give rise to multiple 
hematopoietic types including the myeloid and lymphoid lineages, which 
possess a limited differentiation capacity (Zhang et al., 2018). Normal 
haematopoietic cells are organised in a hierarchy, in which long-term 
reconstituting HSCs (LT-HSCs) differentiate into short-term reconstituting 
HSCs (ST-HSCs). LT-HSCs are a relatively rare, quiescent population in bone 
marrow and have full long-term (>3~4 months) reconstitution capacity and are 
responsible for maintaining self-renewal and multi-lineage differentiation 
potential throughout life, whereas ST-HSCs can differentiate into multipotent 
progenitors (MPPs) with reduced self-renewal ability but only have a short-
term (< 1 month) reconstitution ability (Orkin and Zon, 2008, Yang et al., 2005). 
Common myeloid progenitors and common lymphoid progenitors are then 
derived from MPPs. Common myeloid progenitor cells can differentiate into 
terminally differentiated haematopoietic cells such as erythrocytes, 
granulocytes, macrophages, platelets and dendritic cells. Lymphoid 
multipotent progenitor cells can differentiate into B-cells, T-cells, natural killer 




Haematopoiesis occurs in two waves; the primitive wave and the definitive 
wave (Galloway and Zon, 2003). The primitive wave occurs primarily in the 
yolk sac during the early stages of foetal development and functions to 
produce primitive red blood cells and macrophages. The main purpose of the 
primitive wave is to provide and facilitate tissue oxygenation for the rapidly 
dividing embryonic cells (Palis, 2014). The primitive wave is transitory as these 
erythroid progenitors are not pluripotent and lack self-renewal capability. By 
contrast, definitive haematopoiesis occurs later in development and, although 
it begins in the yolk sac it has the potential to migrate towards the liver and 
then to the bone marrow which is the final destination for HSCs in adults 
(Jagannathan-Bogdan and Zon, 2013).  
 
 
Figure1.1: Haematopoiesis – Schematic of haematopoiesis indicating the 




Over the past several years, the use of single cell sequencing technologies 
has led to increased understanding of haematopoiesis and has highlighted 
more than had previously been appreciated, the complexity of hematopoietic 
differentiation. In the classical tree-like hierarchy, the HSCs go through defined 
stages of differentiation as oligo-, bi- and uni-potent progenitors according to 
their CD34 expression (Kondo et al., 1997, Manz et al., 2002). This model was 
based on the analysis of predefined flow-sorted cell populations. Single cell 
sequencing has challenged this classical view and suggested that lineage 
commitment can bypass the discrete hierarchically organized early progenitor 
populations (Velten et al., 2017). Sanjuan-Pla et al demonstrated that distinct 
subsets of HSCs exist that are biased towards platelet generation and sit at 
the apex of the hierarchy (Sanjuan-Pla et al., 2013). Using single cell RNA-
Seq (ScRNASeq), another study indicated that megakaryocyte-erythroid 
progenitors, a unipotent myeloid lineage-committed progenitor, can be directly 
derived from HSCs (Yamamoto et al., 2013). Also it was also suggested that 
MPPs are a heterogeneous population with a potential different lineage-biases 
and can be sub-divided into MPP1, MPP2, MPP3 and MPP4. MPP1 is similar 
to IT-HSC and can give rise to all lineages. MPP2/3 are myeloid-biased and 
MPP4 is lymphoid-biased and exhibit short-term reconstitution ability (Wilson 
et al., 2008, Pietras et al., 2015). These findings change the view towards the 
from a step-wise haematopoietic hierarchical pattern to a more fluid continuum 
model, in which HSCs exhibit a differentiation bias towards different mature 





Figure 1.2: Models of HSC Lineage Commitment – A) The step-wise model 
suggests HSCs differentiation to mature lineages is a stepwise process and 
with equal contribution to each lineage. (B) Recent revised model suggesting 
haematopoiesis represents a fluid continuum and HSCs exhibit differentiation 
biases towards one lineage. Reprinted with permission from Protein and Cell, 
“New paradigms on hematopoietic stem cell differentiation” (Cheng et al., 
2020). 
 
1.1.2 Regulation of haematopoiesis by extrinsic and intrinsic factors 
During haematopoiesis, key extrinsic and intrinsic factors can 
precisely maintain the balance between the undifferentiated stem cell state 
and differentiation into multiple lineages (Trompouki et al., 2011, Zhang and 
Lodish, 2008). The extrinsic factors include cytokines, growth factors and other 
environmental factors that can activate multiple cell signalling pathways and 
trigger changes in a haematopoietic cell’s lineage fate. Intrinsic factors include 
transcription factors that drive key haematopoietic processes, including self-
renewal and differentiation. Examples of cytokines and growth factors that 
regulate haematopoiesis include, Granulocyte-macrophage colony stimulating 
factor (GM-CSF) which supports the development of macrophages and 
dendritic cells (Gasson, 1991), Thrombopoietin (Tpo) which is important for 
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megakaryocyte and platelet production and regulates HSC quiescence 
(Kaushansky, 1995), Interleukin-1 (IL-1) that regulates the response following 
injury (Pietras et al., 2016). Tyrosine kinase receptors; such as FLT3 and c-
KIT also contribute to lineage determination (Mooney et al., 2017). Cell surface 
expression of FLT3, and binding of FLT3 ligand control 
megakaryocyte/erythrocyte lineage development (Tsapogas et al., 2014). 
Cytokines also activate transcription factors such as C/EBPα and PU.1 that 
regulate the myeloid progenitor cell’s commitment (Iwasaki et al., 2005). 
Additionally, the balance between the PU.1 and GATA1 transcription factors 
(TFs) governs the myeloid or the erythroid lineage fate and unbalanced 
expression of either leads to hematopoietic lineage distortion (Hoppe et al., 
2016). As a result, the balance between extrinsic and intrinsic factors needs 
to be tightly regulated for normal haematopoiesis. 
 
1.1.3 Regulation of HSCs in the bone marrow niche 
The primary site of haematopoiesis in adults is the bone marrow (BM), where 
the HSCs reside, self-renew and differentiate under tightly controlled but 
dynamic process (Sánchez-Aguilera and Méndez-Ferrer, 2017). The BM has 
two niches; the endosteal niche and vascular niche. These niches have a 
complex microenvironment composed of different cell types,  growth factors, 
cytokines, osteoblastic cells, extracellular matrix molecules, and vascular 
network (Wei and Frenette, 2018). The niche’s microenvironment regulates 
HSC and progenitor cell key processes including survival, differentiation, self-
renewal and adhesion (Tamma and Ribatti, 2017) . The osteoblast cells are 
termed CXCL12-abundant reticular (CAR) cells and as they produce the 
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soluble and membrane-bound chemokine, CXC chemokine ligand 12 
(CXCL12), which promotes the differentiation and proliferation of short-term 
HSCs (Konopleva and Jordan, 2011). The CAR cells also overexpress 
vascular cell adhesion molecule-1 (VCAM-1), interleukins (ILs), and platelet-
derived growth factor (PDGF), all of which have regulatory roles in cell 
adhesion and angiogenesis. Pathophysiologically, the environment has also 
been  found to mediate chemotherapy resistance through different 
mechanisms (Chagastelles and Nardi, 2011, Guerrouahen et al., 2011). In 
haematopoietic malignancies, interaction of leukaemic cells with the 
haematopoietic niche is altered. For instance, induction of tumour necrosis 
factor (TNF)-expression in endothelial cells and the reduction of normal HSC 
in FLT3-ITD-transgenic mice in transplantation experiments has been linked 
to FLT3-ITD-induced myeloproliferation. The results indicate that leukaemic 
blast cells mediate death of stromal cells through the TNF pathway resulting 
in impaired haematopoiesis (Mead et al., 2017). Furthermore, osteoblasts 
have been shown to protect AML cells from CXCL12-induced cell death of 
CXCR4-expressing AML cells residing in the bone marrow (Kremer et al., 
2014). The binding of CXCL12 promotes the phosphorylation of CXCR4 and 
activation of downstream pro-survival signalling pathways, MAPK/ERK, 
JAK/STAT, and PI3K/AKT pathways. The FLT3-ITDsignalling enhances 
CXCR4 signalling in leukaemic cells through activation of the serine/threonine 
kinase Pim1 resulting in phosphorylation of the intracellular domain of CXCR4 
enhancing the signalling of the receptor and, enhanced recruitment and 
localization of FLT3-ITD expressing cells to the perivascular niche (Grundler 
et al., 2009).  Stromal cells can also are also a source of IL-3 and GM-CSF 
8 
 
and these cytokines have been shown to rescue FLT3-ITD cells from TKIs via 
upregulation of tyrosine kinase receptor, Axl (Dumas et al., 2019). These 
studies suggest that hematopoietic cells and cells in BM niches can interact 
with each other during haematopoiesis as well as in hematopoietic 
malignancies.  
 
1.1.4 Acute Myeloid Leukaemia 
Haematological malignancies (HMs) are blood cancers that arise from cells 
originating in the bone marrow. HMs can be categorised into leukaemia, 
multiple myeloma, Hodgkin lymphoma, and non-Hodgkin lymphoma. Acute 
myeloid leukaemia (AML) is an aggressive haematological malignancy arising 
from genetic alterations in normal HSCs and is characterised by the presence 
of at least 20% leukemic blasts in the peripheral blood or bone marrow (Kumar, 
2011a, Dohner et al., 2010). The defining feature of AML is an accumulation 
of undifferentiated myeloid blast cells which would normally mature to 
hematopoietic cells. As a result, the immature, highly proliferative myeloid cells 
accumulate in the bone marrow, peripheral blood and other sites including 
liver, lung, central nervous system and spleen (Grove and Vassiliou, 2014). 
The primary symptoms of AML include bone marrow failure and leucocytosis. 
Other common symptoms include fatigue, anorexia, and weight loss. People 
with advanced AML are more vulnerable to excessive bleeding or infection 




1.1.5 Classification of AML 
As AML is a highly heterogeneous disease, it is classified into different 
subtypes based on cytogenetic and morphological characteristics. Two 
systems are used to classify AML. The French-American-British (FAB) 
classification, was devised in 1976 (Bennett et al., 1976) and revised in 1985 
(Bennett et al., 1985). It divides AML into eight subtypes (M0-M7), based on 
morphological appearance, cytochemical staining and how mature the cells 
are (Table 1.1). In the FAB classification, the diagnosis of AML is confirmed 
by the presence of greater than 30% of myeloid blasts in the bone marrow.  
 
Table 1.1 – FAB classification of AML 
 
AML FAB designation Description 
M0 Undifferentiated acute myeloblastic leukemia 
M1 Acute myeloblastic leukemia with minimal maturation 
M2 Acute myeloblastic leukemia with maturation 
M3 Acute promyelocytic leukemia 
M4 Acute myelomonocytic leukemia 
M4 eo Acute myelomonocytic leukemia with eosinophilia 
M5 Acute monocytic leukemia 
M6 Acute erythroid leukemia 
M7 Acute megakaryocytic leukemia 
 
FAB classification does not consider prognostic information. In 2001, in order 
to integrate advances in the diagnosis and treatment of AML, the latest 
classification from World Health Organization (WHO) has largely replaced the 
FAB classification as it takes into account different clinical and cytogenetic 
features. WHO classification splits AML into six major categories including: 
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“AML with recurrent genetic abnormalities”, “AML with myelodysplasia related 
features”, “therapy related myeloid neoplasms”, “myeloid sarcoma”, “myeloid 
proliferation related to Down syndrome” and “AML not otherwise specified” 
(Arber et al., 2016). In the WHO classification, AML is defined as having at 
least 20% blasts in the bone marrow. In addition to this, patients with 
t(8;21)(q22;q22), inv(16)(p13q22) or t(16;16)(p13;q22), and t(15;17)(q22;q12) 
translocations are considered to have AML regardless of blast percentage. 
Further subtypes of these categories as well as genetic abnormalities can be 



















Table 1.2 – World Health Organization Classification of AML 
AML with recurrent genetic abnormalities 
AML with t(8;21)(q22;q22.1);RUNX1-RUNX1T1 
AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22);CBFB-MYH11 
APL with PML-RARA 
AML with t(9;11)(p21.3;q23.3);MLLT3-KMT2A 
AML with t(6;9)(p23;q34.1);DEK-NUP214 
AML with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOM 
AML (megakaryoblastic) with t(1;22)(p13.3;q13.3);RBM15-MKL1 
Provisional entity: AML with BCR-ABL1 
AML with mutated NPM1 
AML with biallelic mutations of CEBPA 
Provisional entity: AML with mutated RUNX1 
AML with myelodysplasia-related changes 
Therapy-related myeloid neoplasms 
AML, NOS 
AML with minimal differentiation 
AML without maturation 
AML with maturation 
Acute myelomonocytic leukaemia 
Acute monoblastic/monocytic leukaemia 
Pure erythroid leukaemia 
Acute megakaryoblastic leukaemia 
Acute basophilic leukaemia 
Acute panmyelosis with myelofibrosis 
Myeloid sarcoma 
Myeloid proliferations related to Down syndrome 
Transient abnormal myelopoiesis (TAM) 




1.1.6 AML Pathophysiology 
As mentioned previously, AML is a group of haematological diseases 
characterized by genetic heterogeneity among patients (Grove and Vassiliou, 
2014). Clonal transformation of hematopoietic precursors occurs through the 
acquisition of multiple chromosomal rearrangements and a range of mutations 
that confer a proliferative and survival advantage as well as impairing 
hematopoietic differentiation (Tamamyan et al., 2017). Understanding the role 
of these genetic abnormalities play in disease progression would improve the 
prognosis and treatment of AML. In majority of cases, AML appears as de 
novo malignancy in previously healthy patients. However, it can also arise in 
patients as a consequence of prior therapy or in patients with an underlying 
haematological disorder (Sill et al., 2011). 
 
Studies of key oncogenic events led to the development of the (Knudsen) “two-
hit” model of leukemogenesis  based on the molecular characterization of 
leukemic cells from AML patients (Kelly and Gilliland, 2002). This model 
suggests the development of AML depends on a collaboration between two 
broad classes of mutations, depending on the type of cellular processes that 
are affected (Gilliland and Griffin, 2002b, Kihara et al., 2014). The first group 
of mutations, referred to as class I mutations, are those that promote survival 
and proliferation. Examples of gain-of-function class I mutations include: FLT3 
(internal tandem duplications (ITD), and tyrosine kinase domain (TKD) 
mutations), c-Kit, BCR-ABL, TP53, K-RAS and N-RAS activating mutations 
(Network, 2013).  The second group of mutations, the class II mutations, are 
mutations that impair transcription factors essential for differentiation. 
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Examples include: fusion transcripts such as RUNX1/ETO, CBFβ/MYH11 and 
PML/RARα, which are generated by recurring chromosomal translocations 
t(8:21), t(15:17), and inv(16) (Gilliland and Griffin, 2002b, Takahashi, 2011). 
The resulting disruption of differentiation and proliferation caused by the 
cooperation of those two groups of mutations results in the transformation of 
blood forming cells to neoplastic cells and eventually the development of AML.  
 
Recent studies have identified several groups of mutations that do not fit into 
this framework but still play a crucial role in the leukaemogenesis (Chaudry 
and Chevassut, 2017, Abdel-Wahab and Levine, 2013). These mutations have 
been allocated to a new class of epigenetic modifications. These are found in 
more than 40% of AML cases and include mutations in DNA-methylation and 
histone modification-related genes such as TET2, IDH1/2, ASXL1 and 
DNMT3A (De Kouchkovsky and Abdul-Hay, 2016). A revised model of myeloid 
malignancy pathogenesis has been proposed which considers the mutations 
in these epigenetic modifiers and the effect on the class I and II mutations  
(Shih et al., 2012) (Fig 1.3).  
 
The FLT3-ITD is a driver mutation and in itself, does not cause AML rather it 
acts in cooperation with other oncogenes.  In murine and zebra fish models, 
FLT3 ITD itself is not sufficient to induce AML and another oncogenic event 
was required to induce leukemogenesis (Skayneh et al., 2019). Using a murine 
bone marrow transplant model, FLT3 ITD has shown to cooperate with other 
oncogenic mutations such as the MLL-AF9 fusion protein to initiate and 
accelerate the onset of human AML-like syndromes (Stubbs et al., 2008). 
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Another study showed that FLT3-ITD cooperates with mutations in the 
multifunctional nucleolar protein, nucleophosmin (NPM1) resulting in rapid 
leukaemogenesis that closely recapitulates the human disease (Mupo et al., 
2013). The third most common coincidental mutation is in DNA 
methyltransferase 3α (DNMT3A). A knock-in mouse harbouring an ITD alone 
developed a fatal myeloproliferative neoplasm (MPN) rather than full AML. The 
same group investigated potential cooperativity between ITD and mutant 
DNMT3A in the same mouse model and showed that genetic deletion of 
DNMT3A along with subsequent expression of FLT3-ITD in adult mice resulted 
in the development of AML (Poitras et al., 2016). The clonal heterogeneity of 
the disease is being elucidated using Single-cell DNA sequencing (scDNA-
seq) analysis. In one study, 154 AML samples from 123 patients with different 
clinical characteristics were analysed. The most frequently detected mutations 
were in NPM1 (40%), FLT3 (38%) and, DNMT3A (37%) (Morita et al., 2020). 
Data also showed at the cellular level the co-occurrence and mutual exclusivity 
among driver mutations. For example, NPM1-FLT3-ITD and DNMT3A-NPM1 
often co-occurred, however, IDH1-IDH2 is mutually exclusive. This and similar 
work would allow systematic investigation of the prognostic impact of clonal 





Figure 1.3: Revised model of leukaemogenesis – Myeloid malignancies 
result as a consequence of multiple mutations in genes involved in the 
regulation of cell proliferation, survival, and differentiation. The Circos 
diagrams above indicate the two novel classes of epigenetic modifier genes 
together with the class I and II alterations that have been found in AML 
patients. Reprinted with permission from Nature Reviews Cancer, “The role of 




1.1.7 Prognostic impact of ITD mutations 
The unfavourable impact of FLT3-ITD on AML progression is well established 
and is keenly associated with a poorer clinical prognosis, high risk of relapse, 
and shorter overall survival (Port et al., 2014). Mutant-to-wild-type allelic ratio, 
insertion site, ITD length, as well as co-occurrence with mutations in other 
AML-mutated genes such as NPM1 and DNMT3A, all appear to have a 
prognostic impact on newly diagnosed patients presenting with ITD mutations 
(Garg et al., 2015). In some studies, a higher ITD allelic ratio has been 
associated with a worse outcome, however, other studies did not support that. 
For example, a threshold of mutant-to-wild-type ratio of >0.78 was significantly 
associated with shorter overall survival (Thiede et al., 2002). In another study 
however, analysis of a large number of patients demonstrated that the ITD 
allelic ratio did not correlate with risk of relapse in both NPM1-mutated and 
wild-type cases (Linch et al., 2014).  
 
In addition, the National Comprehensive Cancer Network consensus panel 
indicates AML patients with FLT3-ITD (low allelic ratio < 0.5) and NPM1 
mutations have a favourable prognosis similar to patients with NPM1 
mutations in the absence of FLT3-ITD (O'Donnell et al., 2017a). Conversely, 
other studies have shown that patients who present with either a high or low 
ITD allelic ratio have a poor prognosis regardless of NPM1 mutational status 
(Boddu et al., 2019, Sakaguchi et al., 2018). Taken together, the 
remarkable heterogeneity of AML complicates the prognosis. The European 
Leukaemia Net (ELN) guidelines are a widely used AML risk stratification 
guideline and based on cytogenetics and molecular abnormalities (Döhner et 
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al., 2017). The ELN guidelines stratify AML patients into three risk groups: 
favourable, intermediate, and poor/adverse (Table 1.3). 
 
Table 1.3 – 2017 ELN risk stratification by genetics  
Risk status Genetic abnormality 
Favourable t(8;21)(q22;q22.1); RUNX1-RUNX1T1  
inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11  
Mutated NPM1 without FLT3-ITD or with FLT3-ITDlow 
Biallelic mutated CEBPA  
Intermediate Mutated NPM1 and FLT3-ITDhigh 
Wild-type NPM1 without FLT3-ITD or with FLT3-ITDlow 
t(9;11)(p21.3;q23.3); MLLT3-KMT2A 
Cytogenetic abnormalities not classified as favourable or 
adverse 
Adverse t(6;9)(p23;q34.1); DEK-NUP214 
 t(v;11q23.3); KMT2A rearranged 
 t(9;22)(q34.1;q11.2); BCR-ABL1  
inv(3)(q21.3q26.2) or 
t(3;3)(q21.3;q26.2);GATA2,MECOM(EVI1) 25 or del(5q); 
27; 217/abn(17p)  
Complex karyotype, monosomal karyotype 
 Wild-type and NPM1 and FLT3-ITDhigh 
Mutated RUNX1  








1.1.8 AML Epidemiology 
AML is one of the most common types of leukemia in adults. Despite this, the 
occurrence is relatively rare, accounting for only about 1 % of all new cancer 
cases in the UK in 2017 (CancerResearchUK 2015-2017). In the UK, the 
incidence rate of AML was 4.8/100,000 in 2016, and it has been estimated that 
around 3,152 new cases are diagnosed with AML leading to around 2,598 
deaths in the UK every year with the highest mortality rates in the 85-89 age 
group (CancerResearchUK 2015-2017). Although AML can develop at any 
age, it is predominantly a disease of the elderly (average age, 68 years) and 
its incidence clearly increases with age. In the UK in 2015-2017, 42% of new 
cases were in people aged 75 and over. AML is also more common in males 
than females. Based on Cancer Research UK data, the overall 5-year relative 
survival rate for AML in the UK is only 14% for men and 16% for women. The 
5-year survival rate for people aged 65 or older is about 5%. For people 
younger than 65, this changes to a survival rate of around 40-65%. These 
survival statistics are poorer than other forms of leukaemias, making AML 
(although not the most prevalent form of leukaemia) the deadliest. Clearly, the 
difficulties in successfully treating patients (often elderly) indicate there to be 
a serious need for much better therapeutic options to be available in the clinic. 
 
1.1.9 Therapy/Therapeutic Options 
Accurate assessment of prognosis is a central to AML management. 
Stratifying patients into well-defined risk groups helps decide the most 
beneficial therapeutic options (Bloomfield et al., 2018). Although clinical 
factors like resistance to treatment, comorbidities and age, have proven to play 
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an important role in therapeutic decisions, cytogenetics has been shown to be 
strongest prognostic factor of patient outcomes and overall survival 
(Grimwade et al., 1998, Grimwade et al., 2010). Accordingly, cases with AML 
can be stratified based on their cytogenetic profile into favourable (good 
survival), intermediate, and adverse (poor survival) (Estey, 2018). 
 
Induction and consolidation Therapy 
The backbone of AML treatment is based on two chemotherapy regimens, 
induction therapy and consolidation therapy. For induction therapy, patients 
are given an intensive combination of chemotherapy to achieve a complete 
remission. This combination is underlined by the “7+3” regimen, which 
consists of an anthracycline such as daunorubicin or idarubicin and high dose 
cytarabine, the deoxycytidine analogue. Cytarabine (100 or 200 mg/m2) is 
usually given as a continuous infusion for seven days together with either 
daunorubicin (45-60 mg/m2) or idarubicin (12 mg/m2) intravenously, daily, for 
three days (O'Donnell et al., 2017b). This regimen is given to patients with a 
favourable or intermediate prognostic risk, in particular younger (< 60 years) 
and fit elderly patients (Estey, 2018). The aim of induction chemotherapy is to 
achieve complete morphologic remission and it generally achieves this in 
approximately 50% of patients above the age of 65 and up to 80% of of young 
patients (Seval and Ozcan, 2015, De Kouchkovsky and Abdul-Hay, 2016). 
These rates are not observed in older patients or patients that fall into the 
adverse prognostic risk group, which subsequently lead to advancement in 




The consolidation regimen is usually given after achievement of complete 
haematological remission (5% or less of leukemic blasts in the bone marrow) 
to eradicate any remaining leukemic cells and prevent relapse (Medeiros et 
al., 2019). Consolidation therapy often includes repeated high doses of 
cytarabine given to patients with a favourable or intermediate prognosis. There 
is no established optimal approach for elderly patients who are more likely to 
present with an adverse prognostic risk profile. Individuals over the age of 65 
are considered not healthy enough to receive combination therapy and are 
instead given a low intensity chemotherapy with hypomethylating agents 
(HMA), or low dose cytarabine, despite this, the prognosis is still poor. 
Alternatively, Bone Marrow Stem Cell transplant is a consolidation option for 
elderly patients as well as patients with high risk cytogenetics (Hecker et al., 
2018, Almeida and Ramos, 2016). Due to poor prognosis and lack of 
increased survival rate in elderly AML patients, new therapeutic approaches 
are required. This can be achieved by targeting specific genetic abnormalities 
in AML. Hence, FLT3 inhibitors are being investigated in combination with less 
intensive chemotherapeutic approach as well as monotherapy. The targeted 
therapy can be used as a front-line, post-transplant maintenance, and in 
relapse/refractory patients. Such an approach has been used successfully in 
the treatment of chronic myeloid leukaemia (CML). Targeting the Bcr-Abl 
fusion protein using TKIs, such as Imatinib, has revolutionized treatment of 
CML and increased five-year survival rate from ~40% in the pre-imatinib age 
(1989–2001) to ~90%  post-imatinib era (2001–2013) (Beinortas et al., 2016, 
Brunner et al., 2013). Overall, chemotherapy is tailored by the aggressiveness 
of the disease, fitness of the patient, and the availability of a stem cell donor. 
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Alternative treatment strategies 
As an induction treatment, decitabine and azacitidine are hypomethylating 
agents demonstrated to be beneficial for older patients with AML who are not 
eligible for intensive chemotherapy (Fenaux et al., 2009). The role of 
hypomethylating agents in the treatment of elderly patients with refractory AML 
is still not fully understood and is the subject of ongoing, phase II and III 
studies.  
 
Novel targeted therapies 
More recently, the identification of recurrent genetic mutations in AML has led 
to the development of new inhibitors and selective treatment approaches. 
Many promising drug candidates have been tested in clinical trials and 
demonstrated the ability to improve the survival rate either alone or in 
combination with standard chemotherapy. We will briefly discuss some of the 
most common targeted therapy for AML.  
 
FLT3-ITD inhibitors 
Given the poor prognostic impact of FLT3 mutations and the high incidence in 
new AML cases, inhibition of FLT3 represents a promising therapeutic 
avenue. FLT3 inhibitors will be discussed in more detail later. 
 
 
IDH1/IDH2 small molecule inhibitors 
Gain-of-function mutations in the isocitrate dehydrogenase (IDH) 1 and 2 
genes are found in about 20% of new AML cases (Network, 2013). Both AG-
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120 and AG-221 are IDH inhibitors currently in clinical trials. Preliminary 
results of phase I/II trials demonstrated an overall response rate of 37% with 
AG-221 and 31% with AG-120 in relapsed/refractory AML patients (Stein et 
al., 2015, DiNardo et al., 2015). In 2019, the FDA approved ivosidenib for 
newly diagnosed AML with IDH1 mutations. Enasidenib was also approved for 
patients with IDH2-mutated relapsed/refractory AML (Galkin and Jonas, 
2019). 
 
Immune therapies  
Monoclonal antibodies exert their cytotoxicity either directly or indirectly 
through conjugation with chemotherapeutic agents or radioactive particles. 
Monoclonal antibodies being explored for AML treatment include gemtuzumab 
ozogamicin which binds to CD33, a transmembrane protein expressed on cells 
of myeloid lineage (Castaigne et al., 2012). The antibody is linked to the potent 
cytotoxic agent calicheamicin, which is internalized by cells following binding 
to CD33. In 2017, the FDA approved gemtuzumab ozogamicin for treatment 
of relapsed or refractory CD33-positive acute myeloid leukaemia in patients 2 
years of age and older. Chimeric antigen receptor modified T cells (CAR-T) 
are T cells engineered to express a receptor that recognizes a specific cell-
surface antigen. The antigen binding domain binds to cell surface molecules 
on the leukaemia, triggers TCR activation which results in cytotoxicity to the 
leukaemia (Gill et al., 2014). CD33 and CD123 are two attractive antigens in 
AML as they are predominantly overexpressed in AML blasts (Mardiros et al., 




1.2 FMS-like tyrosine kinase 3 (FLT3)  
1.2.1 RTKs in hematopoiesis 
The receptor tyrosine kinase (RTK) class III, formerly known as the PDGFR 
(platelet-derived growth factor receptor) family is a most important family 
involved in HSC function and haematopoiesis. Members of this family include: 
PDGFR, colony stimulating factor-1 receptor (also known as c-FMS), c-
Kit (stem cell factor receptor), and FLT3 (FMS-like tyrosine kinase 3) 
(Claesson-Welsh et al., 1989, Yarden et al., 1987, Coussens et al., 1986, 
Rosnet et al., 1993). These receptors span the plasma membrane and contain 
five immunoglobulin-like domains in the extracellular region, a transmembrane 
domain, a juxtamembrane (JM) domain and a split tyrosine kinase domain in 
the intracellular space. RTKs play a pivotal role in normal haematopoiesis 
through promoting survival, proliferation, and differentiation of early 
hematopoietic progenitor cells.  
 
FMS-like tyrosine kinase 3 (FLT3) 
FMS-like tyrosine kinase 3 (FLT3), also known as cluster of differentiation 
antigen 135 (CD135) receptor shares ~30% homology with other class III 
family members. In 1991, two independent groups cloned murine FLT3 from 
fetal liver and placental cDNA libraries and it was mapped to chromosome 5 
(Matthews et al., 1991, Rosnet et al., 1991a). In 1993, the human gene was 
isolated from a pre-B cell cDNA library and a CD34 HSC enriched library 
(Rosnet et al., 1993). The human FLT3 gene is located on chromosome 13 
(13q12) and consists of 24 exons (3,848 bp) extending over more than 100 kb 
(Rosnet et al., 1991b) (Fig 1.4). The gene encodes for 
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a protein containing 993 amino acids, which presents as two species when 
detected by SDS-PAGE and Western blotting. A 160 kDa band is a result of 
N-linked glycosylation of the extracellular domain and this represents the 
membrane-bound form. A 130 kDa band is partially glycosylated and located 
intracellularly (Schmidt-Arras et al., 2005). Glycosylation occurs in two phases, 
following translation FLT3 undergoes partial glycosylation in the endoplasmic 
reticulum (ER) resulting in the immature receptor form. This is subsequently 
processed in Golgi where further modification occurs to produce the mature 




Figure 1.4: Genomic structure and domain arrangement of FLT3 – The 
human FLT3 gene consists of 24 exons. The translation initiation codon is 
located in second half of exon 1. An N-terminal signal peptide (SP) is encoded 
by exons 1 and 2 followed by the extracellular immunoglobulin-like (Ig-like) 
domains (exons 3–12).  Exon 13 encodes the transmembrane domain and the 
intracellular regions, including the juxtamembrane domain and the kinase 
domain, are mainly encoded by exons 14–23 and to some extent by exon 24. 
Reprinted with permission from Physiological reviews, “FMS-like tyrosine 







The extracellular domain of FLT3 consists of five immunoglobulin-like domains 
D1, D2, D3, D4, and D5 which are essential for ligand recognition. FLT3 also 
contains a transmembrane domain (TM), a juxtamembrane domain (JM), and 
two intracellular tyrosine kinase domains (TKD) linked by a kinase insert 
domain (Fig 1.5). The general structure of tyrosine kinases is composed of a 
N– and C-lobes flanking  an ATP binding pocket , and an activation loop that 
determines downstream signalling (Modi and Dunbrack, 2019, Kazi et al., 
2017).  
 
The juxtamembrane domain (JMD) follows the transmembrane sequence and 
it is located between lobes. The JMD can be divided into three distinct 
components; the JM binding motif (Tyr572-Met578), the JM switch motif 
(Val579–Val592) and a linker peptide (Asp593-Trp603). In the inactivated 
state, the JMD occupies the active site and prevents the activation loop from 
adopting an active conformation. The JM switch motif contains several key 
tyrosine residues (Tyr589 and Tyr591) whose phosphorylation is involved in 
activation of the receptor (Mol et al., 2003). Ligand-dependent activation 
causes conformational changes in the JMD, phosphorylation of either Y589 or 
Y591 and reverts the auto-inhibitory conformation (Griffith et al., 2004). Tyr589 
and Tyr591 can also act as a negative regulators of the kinase activity since 
dephosphorylation of these residues allows JMD to re-adopt  its autoinhibitory  
conformation preventing further catalytic activation (Chan et al., 2003).  
 
The tyrosine kinase domain (TKD) is the catalytic domain that transfers the γ-
phosphate of ATP to the hydroxyl group of serine, threonine, or tyrosine 
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residue on the target protein. The FLT3 kinase domain consists of N-terminal 
lobe (N lobe) and an α-helical C-terminal lobe (C lobe) linked by a hinge 
segment. The activation loop is the key conserved structural element required 
for catalytic activity (Schwartz and Murray, 2011). The structure of the 
activation loop, including that of a conserved Asp-Phe-Gly element, termed 
the DFG motif, can adopt active or inactive conformations of FLT3. In the 
“DFG-in” conformation, the aspartic acid residue, which lies at the N-terminus 
of the activation loop must be point into the ATP binding site, where it 
coordinates Mg2+ ions and ATP in the active conformation. In the “DFG-out” 
conformation and as a result of mutations the Asp and Phe residues swap 
positions and Asp side chain points away from the ATP binding pocket and the 
Phe points toward the ATP binding pocket keeping the receptor in an inactive 
state (Kornev et al., 2006). Understanding the different coordination of these 
residues is a fundamental basis for tyrosine kinase selectivity as Type I 
inhibitors are classified by this “DFG-in” conformation, whereas, Type II 
inhibitors are defined by the “DFG-out” conformation (Zhao et al., 2014, Zorn 
et al., 2015). 
 
Under physiological condition, FLT3 expression is restricted to hematopoietic 
progenitor cells (human granulocyte-monocyte progenitor (GMP) and common 
lymphoid progenitor (CLP) cells) in the bone marrow, however, this is usually 
lost upon differentiation. FLT3 expression has been also detected in thymus, 
lymph nodes, brain, placenta and liver where its function is unknown (Rosnet 
et al., 1993, Rosnet et al., 1996a). The expression of FLT3 ligand (FLT3L) is 
almost ubiquitous and it exists either in a membrane-bound or soluble form 
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(Hannum et al., 1994, Lyman et al., 1993). Consequently, the function of 
FLT3L is controlled by the restricted expression of its receptor, FLT3. FLT3 
knock-out mice appear healthy with little effect on life span or sign of 
haematological disease (Mackarehtschian et al., 1995). However, these mice 
do display a reduction in B lymphoid progenitors, natural killer, and dendritic 




Figure 1.5: Structure of FLT3 receptor – FLT3 consists of five 
immunoglobulin-like domains in the extracellular region, a transmembrane 
domain (TM), a juxtamembrane domain (JM), and two intracellular tyrosine 
kinase domains (TKD) linked by a kinase insert. 
 
Stem Cell Factor Receptor (c-Kit) 
As with FLT3, c-Kit (CD117) plays a pivotal role in haematopoiesis as early 
hematopoietic cells are dependent on c-Kit-mediated signals for proliferation 
and survival. The c-Kit gene located on human chromosome 4q11 contains 21 
exons, spanning more than 34 kb (Yarden et al., 1987). c-Kit is commonly 
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expressed in early hematopoietic cells (including stem cells and progenitor 
cells), and is downregulated following maturation (Ogawa et al., 1991). Mast 
and dendritic cells retain high levels of c-Kit expression even when fully 
differentiated and they rely on c-Kit for their survival and proliferation (Ray et 
al., 2010). 
 
1.2.2 FLT3 activation and signalling pathways 
Inactive FLT3 resides as monomer in the plasma membrane in a conformation 
described as a “closed” activation loop, and this is maintained by interaction 
between the juxtamembrane and kinase domains. In this form, 
phosphorylation sites including Y589, Y591, and Y599 and the ATP-binding 
site are blocked. The JM domain serves as a critical autoinhibitory loop 
preventing rotation of the N-lobe towards the C-lobe of the tyrosine kinase 
domain (TKD) so that dimerization is sterically unfavourable (Griffith et al., 
2004) 
 
Binding of FLT3L to the D3 IgG-like domain of two FLT3 monomers, results in 
dimerization and activation of the receptor. When activated, the receptor 
stabilizes its open conformation form leading to the activation of its intrinsic 
kinase activity. This results in exposure of different phosphorylation sites within 
the tyrosine kinase domain resulting in adoption of the active conformation of 
the receptor and activation of downstream signalling cascades. FLT3 activates 
three main signalling pathways: RAS/MAP-kinase, PI3-kinase/AKT and 




The RAS/MAP kinase pathway 
The mitogen-activated protein kinases (MAPKs) are a family of 
serine/threonine kinases that can be activated by FLT3. MAPKs are implicated 
in a variety of different cellular responses including cell survival, cell cycle and 
migration. In humans, several MAP kinase subfamilies have been identified 
including the ERK1/2 (extracellular signal-regulated kinase) family, the p38 
MAP kinases, c-Jun amino-terminal kinases (JNK), and the ERK5 family 
(Pearson et al., 2001). 
 
The MAP kinase pathway is initiated when the membrane-bound GTP-ase 
Ras is activated after interaction with adaptor proteins such as GRB2/ Sos 
(Seger and Krebs, 1995). Ras activates a key downstream effector protein 
Raf-1, which in turn phosphorylates and activates MEK1/2. MEK1/2 in turn 
phosphorylates ERK1/2 (also known as p44MAPK and p42MAPK) on serine and 
threonine residues. Activated ERK1/2 can then phosphorylate many 
substrates leading to nuclear translocation of cytosolic transcription factors 
such as AP-1, which result in diverse biological responses. FLT3 activates the 
ERK1/2 pathway through the interaction of GRB2/Sos with tyrosine residues 
(Y768, Y955 and Y969) on FLT3. Association of GRB2 with GAB2 recruits 
SHP-2 which binds to phosphorylated Y599 in the juxtamembrane region 
(Masson et al., 2009). The protein tyrosine phosphatase SHP2 (PTPN11) 
positively regulates Ras activation and therefore mediates ERK1/2 activation 
by FLT3 (Chong and Guan, 2003). Many studies have shown that ERK is 
essential for normal haematopoiesis and has been shown to be important for 
thymocyte differentiation (Miranda et al., 2002, Pagès et al., 1999). Another 
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study indicated that that ERK plays a crucial role in IL-2 receptor-mediated 
lineage conversion in common lymphoid progenitors (Hsu et al., 2007).  
 
The PI3-kinase/AKT pathway 
Phosphoinositide 3-kinase (PI3-kinase/AKT) is involved in the regulation of a 
variety of cellular processes including proliferation, cell cycle, survival and 
differentiation. The PI3K family is divided into three classes  but  to date, only 
class I A/B isoforms has been implicated in the regulation of haematopoiesis 
(Vanhaesebroeck et al., 2005, Buitenhuis and Coffer, 2009). Class I PI3K has 
been shown to be crucial for both hematopoietic stem cell and progenitor cell 
development (Polak and Buitenhuis, 2012). PI3-kinase class I A is a lipid 
kinase which transmits signals from tyrosine kinase receptors and consists of 
heterodimeric proteins made up of a catalytic p110-kDa α/ β and δ and p85-
kDa regulatory subunits. The class 1B isoform consists of a p110γ catalytic 
subunit and a p101 regulatory subunit and is specifically activated by G-protein 
coupled receptors and Ras (Anderson and Jackson, 2003). 
 
Activation of FLT3 results in tyrosine phosphorylation of adaptor proteins Gab-
1, Gab-2 and SHP-2, which in turn bind to the SH2-motif on p85 leading to 
activation of PI3-kinase at the plasma membrane (Rottapel et al., 1994). The 
most important substrate for class I PI3Ks is PIP2 which is converted to PIP3. 
The activity of PI3K can be inhibited by the tumour suppressor PTEN which 
dephosphorylates PIP3, resulting in the formation of PIP2. Similarly, 
Phosphoinositide phosphatases such as SHIP1 can also dephosphorylate 




Protein kinase B, AKT, has been found to be the most important downstream 
target of PI3K activated through FLT3. AKT is cytosolic protein which 
translocates to the plasma membrane through its pleckstrin homology (PH) 
domains resulting in its phosphorylation following binding to PIP3 (Boudewijn 
and Coffer, 1995). Activation of AKT requires phosphorylation on both Thr308 
by PDK1 and Ser473 by the MTORC2 complex (Alessi et al., 1997, Sarbassov 
et al., 2005). HSCs derived from AKT knockout mice revealed that it plays an 
important role in the maintenance of the long-term, repopulating function of 
HSCs. Mice deficient in AKT exhibit a persistence of long-term HSCs in the 
G0 phase of the cell cycle, suggesting that the functional defects observed in 
these mice is likely caused by increased quiescence (Juntilla et al., 2010). 
 
AKT substrates include; glycogen synthase kinase 3B (GSK3B), the Forkhead 
family of transcription factors (FOXO proteins), and serine/threonine kinase 
mammalian target of rapamycin (mTOR). Inactivated FOXO transcription 
factors contribute to apoptosis and phosphorylation of FOXO proteins by AKT 
leads to disruption of its activity and ultimately to induced cell growth (Brunet 
et al., 1999). Deletion of FOXO proteins in mice results in in a defective long-
term HSCs repopulating capacity (Tothova et al., 2007). GSK3B negatively 
regulates cyclin D1, however, AKT can phosphorylate GSK3B and promote 
G1/S-phase entry to cell cycle (Manning and Cantley, 2007). The third 
important mediator of AKT is mTOR which unlike GSK-3 and FOXO is 
activated by AKT. The GTPase activating protein TSC2/TSC1 complex 
suppresses mTORC1 activation through hydrolysis of GTP- to GDP-bound 
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Rheb. AKT inhibition of TSC1/2 leads to a subsequent activation of mTORC1 
complex (Sengupta et al., 2010). Studies in TSC1 and GSK3-deficient mice 
demonstrated that these proteins are essential for HSC maintenance and 
lineage development (Huang et al., 2009, Chen et al., 2008).  
 
JAK/STAT5 signalling pathway 
The Janus-activated kinase (JAK/ STAT5) pathway is also activated by FLT3 
however, not by the wild-type receptor, but exclusively through ITD mutations 
(Choudhary et al., 2005). Signal transducer and activator of transcription 
(STAT5) is phosphorylated by JAK proteins following binding of cytokines such 
as IL-2/-4 to their cognate receptors. Activated JAKs phosphorylate tyrosine 
residues in the receptor, resulting in binding of monomeric STAT5 through its 
SH2 domain. Recruited STAT5 is phosphorylated on Y641/699 by JAKs, 
undergoes dimerization then translocates to the nucleus (Calò et al., 2003, 
Benekli et al., 2003). Studies in STAT5 knockout mice reveal the importance 
of STAT5 during foetal erythropoiesis. Embryos from mice with STAT5A/B 
knock-out develop foetal anaemia due to decreased responsiveness to the 
anti-apoptotic effect of Epo (Socolovsky et al., 1999). STAT5 is also require 
for IL-7 signalling during early B-cell development through induction of Mcl-1 
and knock-out mice display severe B cell developmental arrest, likely due to 
loss of Mcl-1 expression (Yao et al., 2006). 
 
1.2.3 FLT3 ligand (FLT3L) 
FLT3L is a member of a small family of growth factors that stimulate the 
proliferation of hematopoietic cells. This family includes the colony-stimulating 
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factor 1 (CSF-1), interleukin-3 (IL-3) and granulocyte macrophage colony-
stimulating factor (GM-CSF)  (Lyman and Jacobsen, 1998). Similar to stem 
cell factor (c-Kit ligand), FLT3L can exist as membrane-bound or soluble form 
as a result of proteolytic cleavage from the cell surface (McClanahan et al., 
1996). Both are biologically active and able to activate FLT3. FLT3L consists 
of a signal peptide which is absent from the mature protein, an extracellular 
domain, a transmembrane domain, and a cytoplasmic tail.  
 
FLT3L is produced by many hematopoietic cells and regulates early 
hematopoiesis through FLT3. Its release is tightly regulated as the T- 
lymphocytes produce and store FLT3L for release upon certain stimuli 
(Chklovskaia et al., 1999). FLT3L can act synergistically with other growth 
factors to enhance the cell growth and proliferation. In contrast to the receptor, 
the expression of FLT3L is ubiquitous, and as mentioned previously its 
function is most likely determined by restricted receptor expression. Under 
normal physiological conditions, the plasma level of soluble FLT3L is low (14 
±31 pg/ml), but it is elevated during pathological conditions or following 
chemotherapy (Lyman et al., 1995). Normally, FLT3L promotes survival and 
proliferation of haematopoietic progenitors. Mice deficient in FLT3L are viable 
but exhibit a reduction in all leukocytes including: B cell progenitors, dendritic 
cells and natural-killer cells (McKenna et al., 2000). 
 
1.2.4 RTKs in Leukaemia – c-KIT and FLT3 
c-Kit activating mutations have been observed in 2-5% of total AML cases, 
however, the most frequent observed gain-of-function RTK mutations occur in 
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FLT3 (Speck and Gilliland, 2002).  Several studies observed increased 
expression of c-Kit in AML cases (60–80%) (Cole et al., 1996). c-KIT is 
commonly mutated in core-binding factor acute myeloid leukaemia (CBF-
AML), which occurs in patients with inv(16) and t(8;21) and is associated with 
high relapse risk and poor prognosis (Paschka et al., 2006). 
 
The most common receptor involved in AML pathogenesis is FLT3 which is 
overexpressed in 90% of leukemic blasts (Drexler, 1996). Two different 
alterations in FLT3 lead to a change in its signalling. In the presence of its 
ligand, overexpression of the wild-type receptor results in elevated activation 
in malignant cells. The other is mutations are in FLT3 itself and result in 
constitutive activation of the receptor and these are considered the strongest 
single predictor for AML relapse after intensive chemotherapy (Ozeki et al., 
2004). Mutated FLT3 is observed in about 30% of AML patients (Meshinchi et 
al., 2001).  
 
1.2.5 Mutations and oncogenic signalling of FLT3 in AML 
There are two types of FLT3 mutations found in AML: internal tandem 
duplications within the juxta-membrane domain (FLT3-ITD) and point 
mutations in the activation loop in the kinase domain (FLT3-TKD).  
 
FLT3-ITD 
In 1996, Nakao et al. described the presence of a novel mutation in 
the FLT3 gene in a small number of AML patients. These mutations were 
reported as in-frame tandem duplications (ITDs) of 3–400 base pairs in the 
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juxta-membrane (JM) region and have been extensively studied since as they 
represent one of the most common mutations in AML (Nakao et al., 1996). 
ITDs are in-frame mutations caused by duplication of various fragments of 
sequence in exons 14 and 15 that code for the JM domain. The length of ITD 
insertion can differ between patients and influences prognosis with poorer 
outcomes generally associated with larger inserts. This may also explain the 
response of different mutations to FLT3 inhibitors. The ITD causes the 
receptor to lose its auto-inhibitory function and so it dimerizes, auto-
phosphorylates and activates the kinase domains in a ligand-independent 
manner (Kiyoi et al., 2002). The underlying mechanism of ITD mutation is still 
obscure, however, it has been proposed that it’s a result of DNA replication 
error (Kiyoi et al., 1998a). Although ITD mutations have been identified in wider 
regions of the intracellular domain, two main residues, Y589 and Y591 in the 
JM domain are found to be the crucial sites for FLT3 oncogenic activation 
(Vempati et al., 2008). Most of the mutations in the JM domain are ITDs, but 
there several studies reporting other deletions and insertion mutations in this 
region. 
 
To study the oncogenic signalling as a result of constitutive activation of ITD, 
many studies have used cell lines overexpressing the mutated receptor. 
Although there are signalling overlaps between wild-type and oncogenic FLT3, 
there are crucial differences between them. Wild-type FLT3 signals at the 
plasma membrane, however, ITD-FLT3 displays an altered 
localisation and ultimately initiates additional signalling pathways. Knockdown 
of FLT3 in MV4-11 and MOLM-14 AML cells was shown to prevent 
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phosphorylation of ERK1/2 and decrease proliferation and survival (Cauchy et 
al., 2015). PI3K activation by FLT3 leads to AKT activation and inhibition of 
the FOXO3a transcription factor in 32D myeloid progenitor cells. Restoration 
of FOXO3A expression reversed the effects of the ITD mutation (Brandts et 
al., 2005). PI3K also controls the AKT-MDM2-p53 axis, and targeting the 
negative regulator of p53, MDM2 is a novel approach to restore the crucial 
tumour suppressor function of p53 in AML cells (Kojima et al., 2005). 
Idasanutlin (RG7833) is a second generation MDM2 inhibitor and currently 
being investigated in phase III clinical trial as a combination therapy in relapse 
and refractory AML (Khurana and Shafer, 2019). 
 
As MAPK and PI3K/AKT signalling is initiated at the cell membrane, the WT 
and ITD receptors both activate those pathways (Kiyoi et al., 1998a). By 
contrast, ITD-FLT3 also localises to the ER and has been shown also to 
activate STAT5 (Fig 1.6) (Hayakawa et al., 2000, Mizuki et al., 2000). As a 
result, ITD-FLT3 activates STAT5 controlled cell-cycle regulating genes and 
myeloid differentiation transcription factors, such as PU1 and C/EBPα (Mizuki 
et al., 2003, Zheng et al., 2004). In addition, aberrant activation of STAT5 
appears to promote an overall elevation in reactive oxygen species which has 
been associated with genomic instability through enhancing the frequency of 
double-strand DNA breaks (Fan et al., 2010, Woolley et al., 2012). Another 
effect of STAT5 activation is to promote survival and proliferation of AML cells 
by inducing phosphorylation and subsequent suppression of the pro-apoptotic 





Figure 1.6: Schematic of WT and ITD-FLT3 signalling – binding of FLT3 
ligand to WT FLT3, causes activation of RAS/MAPK and PI3K/AKT pathways 
leading to a cascade of pathways promoting proliferation, growth, migration, 
and survival. FLT3-ITD signals via the RAS/MAPK and PI3K/AKT pathways 
but also activates STAT5. 
 
FLT3-TKD 
Point mutations in the tyrosine kinase domain are the second most common 
FLT3 mutation found in AML patients. The most common of these are 
missense mutations in residue D835 within the activation loop of TKD2 which 
results in an amino acid change (Abu‐Duhier et al., 2001). FLT3-TKD point 
mutations also promote ligand-independent activation of the receptor 
(Yamamoto et al., 2001). Although these mutations can have distinct biological 
functions, the downstream signalling appears to be different to ITD-FLT3 and 
they also have a weaker transforming potential (Choudhary et al., 2005). 
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Prognosis and overall survival are also significantly higher in patients with TKD 
compared to ITD mutations. Mice harbouring FLT3-TKD mainly develop an 
oligoclonal lymphoid disorder, in contrast to ITD-expressing mice which 
develop a myeloproliferative disorder (Grundler et al., 2005). In agreement 
with this, FLT3-TKD mice present with a less aggressive malignancy than 
FLT3-ITD. The reason behind this difference may be that TKD mutations do 
not activate STAT5 while ITD mutations do. 
 
1.3 Treatment of FLT3-driven leukaemia  
1.3.1 Chemotherapy 
AML is an intrinsically chemotherapy-resistant disease. Therapeutic 
approaches produce a relatively high remission rate, however, newly 
diagnosed patients, especially those who harbour FLT3 mutations and receive 
standard chemotherapy, commonly experience relapse. In case of a FLT3 
mutated patient, chemotherapy should be administered in combination with a 
FLT3 inhibitor. There are several early phase trials for using “7+3” induction 
chemotherapy in combination with FLT3-TKIs with high response outcome. 
 
Since the approval of midostaurin by the FDA in April 2017, chemotherapy is 
administered in combination with midostaurin for the treatment of adult 
patients with newly diagnosed FLT3-mutated AML. The recommended dose 
of midostaurin is 50 mg twice daily on days 8 to 21 of each cycle of induction 
with cytarabine and daunorubicin and days 8 to 21 of each cycle of 
consolidation with high dose cytarabine (Stone et al., 2017b). Table 1.4 
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summarises some of the clinical trial protocols of chemotherapy-combination 
therapy for newly diagnosed AML patients with FLT3 mutations (ITD/TKD). 
 
Table 1.4 – Studies of FLT3 inhibitors and chemotherapy for newly 
diagnosed FLT3-mutated AML patients 
Protocol Phase Endpoints Ref. 
7+3 induction followed by 2 
cycles of intermediate/ high 
dose cytarabine consolidation+ 
sorafenib or placebo 
Phase III Median overall survival: 
15 months for placebo 
vs 13 for sorafenib  
(Serve et al., 2013) 
1–2 cycles of induction 
chemotherapy followed by 3–4 
cycles cons + Lestaurtinib or 
placebo 
Phase III 5-year overall survival: 
lestaurtinib 46% vs 
placebo 45% 
(Knapper et al., 2017) 
 
Crenolanib + 7 + 3 
Phase II complete remission: 
83% 
(Wang et al., 2017) 
Gilteritinib+ induction (idarubicin/ 
cytarabine) 
Phase I composite complete 
remission: 100% 
(Pratz et al., 2018) 
 
 
Based on the  high response rate achieved with the next generation FLT3 
inhibitors, two phase III randomized trials are ongoing to investigate quizartinib 
combined with “7 + 3” chemotherapy, and crenolanib vs midostaurin and 7 + 
3 chemotherapy (Erba et al., 2016, Stone et al., 2019). A promising recent 
phase III study (ADMIRAL study) compared gilteritinib as a single therapy 
versus four salvage chemotherapy regimens. In this study, Gilteritinib a single 
oral agent at 120 mg daily led to significantly longer overall survival and 
increased safety profile (9.3 months) over salvage chemotherapy (5.6 months) 
(Perl et al., 2019a). This study may lead to a paradigm shift for using single 
oral agents to replace standard chemotherapy as the primary therapy for 




1.3.2 Tyrosine/ serine, threonine kinase inhibitors 
Targeted kinase inhibitors have been developed in the hope to improve 
selectivity with less side-effects than conventional chemotherapy. Here, we 
will discuss the main inhibitors that have been used or are being developed to 
interfere with abnormal signal transduction in acute leukaemia. 
 
FLT3 Tyrosine Kinase Inhibitors 
It has been reported that high-dose daunorubicin and gemtuzumab 
ozogamicin might help AML patients with FLT3-ITD mutations, and patients 
with unfavourable cytogenetics, however, a retrospective analysis showed that 
allogeneic hematopoietic stem cell transplantation (allo-HSCT) showed no 
beneficial effect  on the poor prognosis of FLT3-ITD mutation patients (Luskin 
et al., 2016, Schlenk et al., 2008). Therefore, Given the importance of FLT3  
mutations in AML pathogenesis, FLT3 inhibition is a key therapeutic target in 
AML, and clinical trials of FLT3 inhibitors have been ongoing for a decade 
(Pemmaraju et al., 2011). Small molecule inhibitors targeting FLT3 are 
categorised based on their mechanism of interaction with FLT3.  Type I 
inhibitors (such as midostaurin and gilteritinib) bind to the active or inactive 
conformation of the FLT3 receptor either near the activation loop or the ATP-
binding site, while type II  compounds (such as sorafenib and quizartinib) bind 
to the inactive receptor in a region adjacent to the ATP-binding site (Ke et al., 
2015). As a result, type I inhibitors are active against ITD and TKD mutations, 
while type II inhibitors have activity against ITD but not TKD mutations (Smith 
et al., 2015). The inhibitors can be further classified based on their specificity 
for FLT3 into first generation and second generation (Larrosa-Garcia and 
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Baer, 2017). First-generation FLT3 inhibitors, including lestaurtinib, sunitinib, 
sorafenib, ponatinib, and midostaurin are relatively nonspecific for FLT3 
receptor with additional activity involving other targets such as c-Kit, platelet-
derived growth factor receptor (PDGFR), vascular endothelial growth factor 
receptor (VEGFR) and JAK2 kinases (Weis et al., 2019)). The lack of 
specificity of first-generation FLT3 inhibitors may contribute to the higher 
toxicity profile and limited clinical efficacy, especially as monotherapy 
(Larrosa-Garcia and Baer, 2017). The plasma inhibitory activity (PIA) assay, a 
novel index for evaluating the clinical efficacy of FLT3, showed that the first-
generation FLT3 inhibitors did not effectively suppress the phosphorylation 
status of mutant FLT3 even at the desired blood concentration(Levis et al., 
2011). Therefore, using of these molecules as a monotherapy has been 
discontinued. However, when used as combination with chemotherapy the 
clinical outcome has improved and ended-up in the approval of midostaurin in 
combination with standard chemotherapy. On the other hand, second-
generation inhibitors, such as quizartinib, gilteritinib, and crenolanib, were 
designed to be more specific and potent against FLT3 receptor with improved 
tolerability. Small molecule kinase interaction maps for FLT3 inhibitors are 






Figure 1.7: KinomeScan binding plots for FLT3 TKIs – Red circles 
represent kinases inhibited by the indicated drug and the relative size of the 
circle is inversely proportional to the binding affinity. Compounds with a smaller 
number of binding sites are said to be more ‘specific’ with fewer ‘off target 
effects’. Reprinted with permission from Blood, The Journal of the American 
Society of Hematology, “AC220 is a uniquely potent and selective inhibitor of 
FLT3 for the treatment of acute myeloid leukemia (AML)” (Zarrinkar et al., 
2009a).  
 
Reviewed a data over 15 years (from 2000 to 2014) suggest that there was an 
improvement in outcome in poor prognostic, FLT3- ITD mutated AML patients. 
This is probably due to advancement in treatment strategies over time, 
including the incorporation of FLT3 inhibitors in the treatment approach (Badar 
et al., 2015). This lead to an increasing in the interest of using FLT3 inhibitors 
as first line therapy for FLT3 mutated AML with a new therapeutic paradigms 





Figure 1.8: History timeline of FLT3 to start times of clinical trials and 
practical use – Adapted from “FLT3 mutations in acute myeloid leukaemia: 
Therapeutic paradigm beyond inhibitor development” (Kiyoi et al., 2020). 
 
Quizartinib (AC220), is a novel second-generation type II FLT3 inhibitor with 
high selectivity for mutated FLT3 and additional inhibitory activity of KIT and 
PDGFR. Before quizartinib, numerous other compounds (lestaurtinib, 
midostaurin, tandutinib and sorafenib) were under investigation however they 
were not effective as single agents. In addition, most of them had short plasma 
half-life, which delays the efficacy (Levis, 2014, Pratz et al., 2009). Then, a bis 
aryl-urea derivative was identified as potent and selective FLT3 inhibitor. After, 
improving its pharmacokinetic profile, this compound was designated as 
AC220 or quizartinib which was the first small molecule to be identified and 
developed as an orally active FLT3 inhibitor. Also, quizartinib has long half-life 
and sustained inhibition against FLT3(Levis, 2014, Fathi and Chen, 2011). In 
contrast, quizartinib does not have an effect against TKD mutations when 
compared with other FLT inhibitors like midostaurin, crenolanib and gilteritinib 
which is due to resistance in quizartinib-treated patients (Smith et al., 2012a). 
Multiple independent studies shows that this drug is a promising agent in 
treatment of AML by inhibiting FLT3, however, there is a concern of side 
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effects and drug resistance among patients with high expression of RUNX1, 
which is mainly involved in cell proliferation and myeloid differentiation (Hirade 
et al., 2016). Clinical trials show that quizartinib is well tolerated with a 
favourable prognosis and demonstrates efficacy in improving clinical 
outcomes as a single agent in relapsed/ refractory AML patients. A phase II 
study showed that 44-53% of patients with ITD-FLT3 achieved the composite 
complete remission (Grunwald and Levis, 2013). The QuANTUM Phase III trial 
is ongoing to examine the efficacy of quizartinib as monotherapy or in 
combination with standard induction chemotherapy (Erba et al., 2016, Cortes 
et al., 2018b). The addition of quizartinib to standard chemotherapy is under 
study in the randomized phase 3 trial QuantumFirst and results expected in 
2022. In Japan, quizartinib has been approved for the treatment of relapsed 
or refractory AML patients with ITD mutations (Cortes et al., 2019). There are 
about ten ongoing clinical trials with quizartinib in the US, and quizartinib might 
be eventually obtain FDA approval as part of combination treatment in near 
future (Fletcher et al., 2020). 
 
Gilteritinib is a second-generation type I FLT3 inhibitor with activity against 
both ITD and TKD mutations, EML4-ALK as well as AXL (Ueno et al., 2014). 
Recent data reveals that gilteritinib has longer overall survival and remission 
in relapse or refractory FLT3 mutated AML patients than salvage 
chemotherapy (Perl et al., 2019b). In a phase I/II clinical trial in refractory or 
relapsed AML patients, the overall response rate was 55%, 17% and 62% in 
patients with ITD, TKD mutations or both, respectively (Perl et al., 2016). A 
phase III randomized trial is undergoing comparing gilteritinib to other salvage 
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chemotherapy. In 2018, as the first non-chemotherapy drug,  gilteritinib was 
approved as monotherapy to treat adult patients who have relapsed or 
refractory AML with mutated FLT3 (Perl et al., 2019b).  
 
Midostaurin (PKC-412), is a staurosporine derivative and first-generation type 
I FLT3 inhibitor capable of targeting ITD and TKD mutations. It displays 
multitargeted kinase activity against protein kinase C, vascular endothelial 
growth factor (VEGFR), c-KIT, and platelet derived growth factor (PDGFR) 
(Propper et al., 2001, Weisberg et al., 2002). Studies confirmed that synergy 
between chemotherapy and midostaurin, a phase 1b study of newly identified 
AML patients was performed and examined that oral midostaurin could be 
administered at a dose of 50 mg twice each day for 14 days. This regimen had 
promising efficacy in patients with a FLT3 mutation. Various other studies 
determined that midostaurin is safe and improved outcomes in younger 
patients with AML and FLT3 mutation (Stone et al., 2012). Midostaurin 
significantly extended the survival of FLT3-mutated AML patients in a phase 
III clinical trial (Schlenk et al., 2019). Kaplan–Meier curves for median overall 
survival of (RATIFY) trial in the midostaurin group and the placebo group 
showed 74.7 months vs 25.6 months, respectively (Stone et al., 2017a).  As a 
consequence, it is the first TKI to be approved by the FDA for treatment of 
newly diagnosed FLT3-mutated AML in combination with conventional 
induction and consolidation chemotherapy (Stone et al., 2017a). Data from the 
RATIFY trial showed patients with all FLT3 mutation subtypes (i.e., TKD, ITD 
low allelic ratio, and ITD high allelic ratio) benefited from midostaurin and this 
might be related to its multiple kinase activity along with FLT3 inhibition. 
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Furthermore, FLT3-TKD mutations can be found in about 7% of AML patients, 
however, the number of population in this study with FLT3-TKD mutation was 
about 23% which is larger than the percentage of TKD occurrence in AML and 
this could lead to a biased outcome in favour of patients with a FLT3-TKD 
mutation. Of note, median age of patients in this trial was 47.9 years which is 
younger than typical patients with newly diagnosed AML, highlighting the 
importance for more data regarding midostaurin safety and effectiveness in 
elderly fit and unfit patients (Schlenk et al., 2016). Despite limitations, the 
RATIFY trial was the first study to show significant improvements in overall 
survival and event-free survival with the addition of a targeted therapy to 
standard chemotherapy in AML population. 
 
Sorafenib is a first-generation type II FLT3 inhibitor again with multi-target 
kinase activity. Several studies indicate that sorafenib has greater activity 
against FLT3-ITD than the wild-type receptor (O'Farrell et al., 2003). A phase 
II trial of sorafenib combined with azacitidine showed an overall response rate 
of 46% in patients with relapsed or refractory AML. A recent study has shown 
that sorafenib administration in a post-hematopoietic stem cell transplant 
setting (SORMAIN study) lead to improved maintenance and prolonged 
relapse-free survival (Burchert et al., 2018). Table 1.5 summarises a panel of 
other TKIs in development for use in AML (Fernandez et al., 2019). 
 
Recently, a promising novel FLT3 inhibitor, FF-10101, has been designed to 
form a covalent binding between the C695 residue of FLT3. This covalent bond 
formation of FF-10101 maintains the ability to bind to both the active and 
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inactive conformations of FLT3 and shows high efficacy against AML cells 
with FLT3 mutations including quizartinib-resistant activation loop mutations 
and its effective against the gatekeeper mutation F691L. It also showed a 
potential growth inhibition of primary AML cells harbouring either FLT3-ITD 
or FLT3-D835 mutation in vitro and in vivo (Yamaura et al., 2018).  
 
Table 1.5 – Other TKIs in Development for AML 
Drug Main Target Development Status 
Crenolanib FLT3 Phase III 
Sunitinib FLT3 Phase II 
Lestaurtinib FLT3 Phase III 
FF-10101 FLT3 Phase II 
Dasatinib KIT Phase III 
SU5416 KIT Phase II 
Bemcentinib AXL Phase II 
Cabozantinib AXL Phase I 
Entospletinib SYK Phase II 
SAR103168 SFK Phase I 
Ibrutinib BTK Phase III 
Pacritinib JAK-STAT Phase II 
CG-806 FLT3 / BTK Phase I 
 
About 50% of AML patients with adverse prognosis are not candidates for 
intensive chemotherapy. Therefore, another interesting approach of using 
FLT3 inhibitors with hypomethylating agents has been emerged for unfit FLT3 
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mutated AML patients. The combination of sorafenib and azacitidine in FLT3 
mutated AML patients in a phase II trial lead to overall response rate of 78% 
and a median overall survival of 8.3 months (Ohanian et al., 2018). Similarly, 
other FLT3 inhibitors including quizartinib and gilteritinib in combination with 
azacitidine are being evaluated in different clinical trials, and the data showed 
that the combination appears safe and may improve both response rate and 
survival (Cortes et al., 2017, Swaminathan et al., 2017). Gilteritinib has been 
reported to be more effective in a combination with azacitidine (DiNardo et al., 
2019), and according to a presentation by Eunice S. Wang, MD, of Roswell 
Park Comprehensive Cancer Center, at the virtual 62nd American Society of 
Hematology (ASH) Annual Meeting and Exposition (2020), an ongoing, phase 
3, open-label, randomized trial investigating gilteritinib plus azacitidine in 
adults with newly diagnosed FLT3 mutated  AML who were ineligible for 
intensive induction chemotherapy  revealed a composite complete remission 
rate of 67%. 
 
The MAPK and PI3K/AKT/ mTOR have been described extensively in the 
literature as oncogenic pathways in AML. Targeting protein serine/threonine 
kinases in multiple pathways in combination with FLT3 inhibitors is therefore 
considered a promising strategy to improve AML therapy and minimize drug 
resistance. A summary of common serine/threonine kinase inhibitors in trials 






Table 1.6 – Ser/Thr kinase inhibitors in development for AML 
Drug Main Target Development Status 
Everolimus mTORC Phase I 
Temsirolimus mTORC Phase II 
Pimasertib MEK1/2 Phase II 
U0126 MEK1/2 Preclinical 
Trametinib MEK1/2 Phase II 
A674563 Akt/FLT3 Preclinical 
Mk-2206 Akt Preclinical 




1.3.3 Resistance to FLT3 inhibitors 
Despite the encouraging improvement in identification of molecular targets in 
AML and development of novel therapeutic strategies, relapse is a significant 
cause of treatment failure  (Daver et al., 2015). Due to the heterogeneity of the 
disease, mechanisms of resistance are multifaceted, but mainly involve 
emergence of kinase domain mutations and/or some other pathway 
adaptation that counteracts FLT3 inhibition. There are two potential 
mechanisms underlying drug resistance to FLT3 inhibition. Intrinsic 
mechanisms occur within leukemic blasts and can be a primary (occurring 
before treatment) or secondary resistance (induced by a FLT3 inhibitor). The 






Intrinsic mechanisms  
The primary mechanism of intrinsic resistance to FLT3 inhibitors is lack of 
addiction of leukemic cells harbouring FLT3-ITD to FLT3 signalling. This 
occurs due to the variation in levels of mutated FLT3 in leukemic clones. A 
study of five FLT3 inhibitors demonstrated that AML patients with a high allelic 
burden or those that have relapsed respond better to FLT3 inhibitors (Pratz et 
al., 2010). The presence of additional TKD mutations reduces affinity 
conferring resistance to type II FLT3 inhibitors such as quizartinib (Smith et 
al., 2012a). The presence of a FLT3-ITD627E mutation is linked to 
upregulation of antiapoptotic proteins such Mcl-1 resulting in resistance 
(Breitenbuecher et al., 2009a). Upregulation of the other anti-apoptotic 
proteins such as Bcl-2 through FLT3-independent pathways is also reported 
to confer resistance to FLT3-TKIs in AML (Kohl et al., 2007). 
 
Development of TKD secondary, intrinsic mutations confers resistance to type 
II inhibitors (e.g. quizartinib) that do not have significant activity against TKD 
mutations. These mutations usually occur following treatment with FLT3 
inhibitors and may include those at the activation loop (e.g. D835) or the gate-
keeper residue (F691) depending on type of inhibitor being used (Smith et al., 
2015, Daver et al., 2015). Non-FLT3 mutations also have been found to 
mediate resistance during FLT3 inhibitor treatment. For example, mutations in 
the TP53 and RAS pathways have been reported in R/R FLT3-ITD AML 
patients who relapsed after treatment with crenolanib or gilteritinib (Zhang et 




Rapid clonal evolution through genomic instability in AML patients treated with 
FLT3 inhibitors following relapse represents another potential mechanism of 
resistance (Fan et al., 2010). Upregulation of other oncogenic kinases has 
been implicated and these then serve as rational targets to combine with FLT3 
inhibitors. For example, increased phosphorylation of AXL was observed in 
cells expressing FLT3-ITD following treatment with FLT3 inhibitors and  AXL 
inhibition and/or knockout was shown to overcome resistance (Park et al., 
2015). Notably, AXL is also a target of gilteritinib, in addition to FLT3. 
Expression of Pim kinase, a signalling molecule downstream of ITD signalling, 
has been shown to upregulated in primary AML cells with acquired resistance 
to sorafenib, in these cells inhibition of Pim restored the sensitivity of ITD-
expressing cells to FLT3 inhibition (Green et al., 2015). Constitutive activation 
of PI3K/AKT/mTOR, MAPK/ERK and STAT5 pathways is known to contribute 
to resistance in both FLT3 inhibitor-resistant ITD-expressing cell lines and 
primary AML blasts (Lindblad et al., 2015). This suggest that at this stage of 
resistance, the survival of some cells is independent of FLT3 and these other 
pathways may serve as a potential therapeutic avenues. Targeting these 
pathways in combination with FLT3 inhibitors is also under investigation (Piloto 
et al., 2007). 
 
Extrinsic mechanisms 
The bone marrow microenvironment plays an important role in mediating 
extrinsic resistance to FLT3 inhibitors. Enhanced secretion of cytokines from 
bone marrow stromal cells has been shown to protect AML blasts from the 
cytotoxic effect of FLT3 inhibitors and conventional chemotherapy (Yang et 
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al., 2014). Serum levels of FLT3L were shown to increase after chemotherapy 
and FLT3 inhibitor treatment. AML cells remain responsive to FLT3L despite 
constitutive activation through the mutated receptors and this ligand-
dependent signalling subsequently decreases the sensitivity of cells to FLT3 
inhibition. In a recent study, large increases in FLT3L levels in the newly 
diagnosed patients were observed following intensive induction chemotherapy 
as well as after subsequent courses of treatment (Sato et al., 2011). Similarly, 
the stromal cells are sources of fibroblast growth factor 2 (FGF2) and CXCL12-
CXCR4. FGF2 binds to fibroblast growth factor receptor 1 in ITD-FLT3 AML 
cells and induces resistance to FLT3 inhibitors through activation of MAPK 
pathway (Traer et al., 2016). Upon chemotherapy treatment, CXCL12-CXCR4 
was reported to promote resistance to FLT3 inhibitors as a consequence of 
the highly expressed CXCR4 in FLT3-ITD AML which resulted in increased 
production of CXCL12, a pro-survival cytokine (Fukuda et al., 2005). Other 
extrinsic resistance mechanisms are through the hepatic enzymes which 
result in inadequate drug concentrations in the plasma leading to suboptimal 
efficacy of the FLT3 inhibitors. Several preclinical studies have demonstrated 
that CYP3A4 expressed primarily in hepatocytes and bone marrow stromal 






1.4 Regulation of cell death by the Bcl-2 family 
1.4.1. Apoptosis overview  
Apoptosis is a form of tightly regulated cell death that maintains cellular 
homeostasis, particularly of rapidly renewing cells such as those in the 
hematopoietic system. Evading apoptosis is seen as a crucial step for 
malignant tumour progression (Hanahan and Weinberg, 2000). Following 
detection of cellular abnormalities such as DNA damage or ER stress, different 
signalling pathways are initiated ultimately leading to activation of the 
apoptotic machinery (Kastan et al., 1991). During DNA damage, activation of 
tumour suppressor p53 is crucial for initiating specific cellular responses such 
as senescence, transient cell cycle arrest and apoptosis to determine 
ultimately the fate of the cell. Cancers arise as cells accumulate a series 
of mutations that result in uncontrolled growth and the avoidance of apoptosis 
(Muller and Vousden, 2013).  
 
Apoptosis occurs through two mechanisms; the intrinsic and extrinsic 
pathways (Fig 1.9). The extrinsic pathway is activated by external factors at 
the cell surface and typically involves binding of ligands of TNF family to their 
respective receptors which in turn activate downstream adaptor proteins, and 
the initiator caspases  -8 and -10 (Wallach et al., 1999, Sheikh and Huang, 
2004). The active initiator caspases then cleave and activate effector 
caspases -3 and -7 to induce apoptosis. In some cases, cells require the 
extrinsic pathway to combine with the intrinsic mitochondrial pathway through 
cleavage of the Bcl-2 protein, Bid (Li et al., 1998, Milhas et al., 2005). 
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Truncated Bid can then engage the mitochondrial apoptosis pathway 
amplifying a weak external stimulus.  
 
In contrast to the extrinsic pathway, the intrinsic pathway triggers apoptosis 
directly, as a result of changes in mitochondrial integrity. Diverse cytotoxic 
stimuli such as DNA damage, ER and oncogenic stress affect the delicate 
balance of anti-apoptotic and pro-apoptotic Bcl-2 family members ultimately 
tipping the balance towards initiation of apoptosis (Ashkenazi et al., 2017). 
Activation of the intrinsic pathway involves an increase in the permeability of 
the outer mitochondrial membrane, resulting in the release of proapoptotic 
factors such as cytochrome c, HtrA2, and SMAC that normally reside in the 
mitochondrial intermembrane space (Green and Reed, 1998). Of these, the 
key protein which activates the cell death pathway is cytochrome c (Saelens 
et al., 2004). For cytochrome c to be released from the mitochondria, the pro-
apoptotic Bcl-2 proteins Bak and Bax cluster into large oligomers forming 
pores in the outer mitochondrial membrane. Cytochrome c escapes through 
these pores into the cytosol where it binds to APAF-1, inducing its 
oligomerisation and subsequent recruitment of the initiator pro-caspase-9 in a 
complex known as the apoptosome (Bratton et al., 2001). Following activation, 
caspase-9 in turn activates the effector caspases -3 and -7 which are 
responsible for cleavage of many cellular proteins causing the morphological 
changes associated with apoptotic cell death (Volkmann et al., 2014). SMAC 
is also released from the mitochondria and acts to repress the inhibitor of 
apoptosis proteins (IAPs), which are believed to prevent  activation of some 






Figure 1.9: Schematic representation of the Extrinsic and Intrinsic 
apoptosis pathways – The intrinsic apoptotic pathway acts directly at the 
mitochondria leading to apoptosome formation, whereas the extrinsic pathway 
can activate caspases independently of the mitochondria. The two pathways 
can converge at the Bcl-2 protein, Bid, which when cleaved translocates to the 
mitochondria to activate Bax or Bak. Ultimately, activation of either pathway 
leads to cleavage of effector caspases, leading to the coordinated breakdown 
of the cellular structure and death.  
 
1.4.2 The Bcl-2 family and apoptosis induction 
Activation of the intrinsic pathway is controlled by Bcl-2 family members 
(Czabotar et al., 2014). The Bcl-2 family includes at least 25 members, which 
can be classified based on their function into either pro-apoptotic (promote 
activation of the apoptotic signalling pathway) or anti-apoptotic (prevent a cell 
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from death). The dynamic interactions of these different pro- and anti-apoptotic 
proteins under various physiological or pathological stimuli forms a central 
checkpoint to determine cell fate (Kale et al., 2018).  
 
Bcl-2 proteins share a strong structural homology due to the presence of highly 
conserved regions termed Bcl-2 homology (BH) domains. Anti-apoptotic 
members of the Bcl-2 family (Bcl-2, Bcl-xL and Mcl-1) contain BH1, BH2, BH3 
and BH4 domains. These proteins can bind and sequester the pro-apoptotic 
family members to prevent the initiation of apoptosis (Chan and Yu, 2004). 
The pro-apoptotic Bcl-2 family members can be subdivided into two 
functionally and structurally distinct classes, the effectors (multi-domain) and 
the activators and/or sensitisers (the BH3-only proteins). The effector proteins 
Bax and Bak contain BH1, BH2 and BH3 domains and when activated adopt 
a pro-death conformation to form pores in the outer mitochondrial membrane 
facilitating the release of cytochrome c (Shamas-Din et al., 2013). Other pro-
apoptotic Bcl-2 family members such as Puma, Bim, Bid, Bad, Bik, Bmf, Hrk, 
and Noxa contain only the BH3 domain. BH3-only proteins are able to bind to 
certain anti-apoptotic proteins antagonising their function. In addition to 
inhibiting anti-apoptotic members, BH3-only activator proteins such as Bid and 
Bim interact with, and activate Bax and Bak (Fleischer et al., 2003). Sensitiser 
BH3 proteins such as Bad and Noxa displace activator BH3-only proteins from 






The intrinsic apoptotic pathway in leukaemia 
Disrupting the delicate balance between cell proliferation and cell death is 
involved in the pathogenesis of several diseases including leukaemia 
(Hanahan and Weinberg, 2000). The key role of apoptosis in the pathogenesis 
of AML has been discussed since the 1990s with several papers implicating 
the role of Bcl-2 proteins in promoting leukaemogenesis (Delia et al., 1992, 
Bradbury and Russell, 1995). Bcl-2 family proteins have been reported to be 
overexpressed in AML and consequently confer resistance to conventional 
chemotherapy as well as more targeted therapies (Kornblau et al., 1999, 
Mehta et al., 2013). AML patients with the favourable t(8;21) karyotype display 
downregulation of the anti-apoptotic protein Bcl-2, and it was found to be 
overexpressed in AML patients with low rate of remission (Banker et al., 1998, 
Del Poeta et al., 2003). Additionally, a high Bcl-2:Bax ratio was found to be 
associated with poor prognosis (Venditti et al., 2004). The anti-apoptotic 
protein Mcl-1 has been shown to be a critical regulator of early hematopoietic 
development and overexpression of both Bcl-xL and Mcl-1 have been shown 
to play a crucial role in AML progression (Kaufmann et al., 1998). 
 
1.4.3 BH3 mimetics in cancer  
Over the past three decades, greater understanding of the intrinsic apoptotic 
pathway led to the development of BH3 mimetic drugs. Following on from 
successful results in lymphoid neoplasms, targeting the apoptotic pathway has 
been seen as a promising approach for the development of novel AML 
therapies to overcome the issue of acquired resistance. BH3 mimetics are 
small molecule inhibitors that mimic the pro-apoptotic BH3-only members by 
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docking into the binding groove of the anti-apoptotic  members to displace the 
sequestered pro-apoptotic proteins (Besbes et al., 2015, Hata et al., 2015). 
These compounds therefore induce apoptosis in a Bak/Bax-dependent 
manner by nature of their strong affinity for BH3 domains in the anti-apoptotic 
Bcl-2 family members (Lessene et al., 2008). 
 
ABT-737 (Oltersdorf et al., 2005) and ABT-263/navitoclax (Tse et al., 2008) 
represent a breakthrough in the development of BH3 mimetics and display 
high binding affinities for Bcl-2, Bcl-xL and Bcl-w but not Mcl-1. Both induce 
cytochrome c release and apoptosis in haematopoietic cancer cell lines and 
supress tumour growth in xenograft models. While ABT-263 improved 
patient’s survival its clinical usage was limited due to thrombocytopenia linked 
to Bcl-xL inhibition in megakaryocytes (Delbridge et al., 2016). To circumvent 
this, the drug was re-engineered to generate ABT-199/Venetoclax, a Bcl-2 -
specific inhibitor (Souers et al., 2013). ABT-199 is clinically successful and has 
been trialled extensively for treatment of many haematological malignancies 
including AML. ABT-199 shows promising activity as single agent or in 
combination with chemotherapy in primary AML samples and patient trials 
(Konopleva et al., 2014). ABT-199 binds poorly to Mcl-1, an essential regulator 
for AML cell survival, and as expected leukemic cells expressing high levels 
of Mcl-1 are resistant to ABT-199 as well as a variety of other 
chemotherapeutic agents (Gores and Kaufmann, 2012). Venetoclax is now 
approved by FDA in combination with Low-dose cytarabine or azacitidine in 
older AML patients ineligible for intensive chemotherapy. Development of 
selective and potent BH3 mimetics to inhibit Mcl-1 has become a key 
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therapeutic avenue for treatment of refractory malignancies (Yecies et al., 
2010). This has proved to be more difficult and progress has been slow as the 
Mcl-1 BH3 binding groove is more rigid compared to other anti-apoptotic Bcl-
2 family members (Czabotar et al., 2007). Additionally, Mcl-1 displays a strong 
binding affinity for its endogenous BH3-only protein binding partners (Lee et 
al., 2009). S63845 is a promising Mcl-1 inhibitor with several studies 
demonstrating its potency when used in synergy with other chemotherapeutic 

















1.5 Genome editing 
1.5.1 Introduction/Overview 
Genome editing technologies have advanced significantly over the past few 
years allowing us to manipulate precisely specific loci within the genome. 
These approaches using programmable nucleases can potentially correct or 
delete single genes responsible for disease (Capecchi, 1989, Capecchi, 
2005).  
 
In the last decade, three genome-editing platforms have been used to create 
DSBs: Zinc-Finger Nucleases (ZFNs), Transcription Activator-Like Effector 
Nucleases (TALENs) and Clustered Regularly Interspersed Short Palindromic 
Repeats (CRISPR)/Cas9 (Wood et al., 2011, Mali et al., 2013). Regardless of 
their differences, all three technologies share the common theme of targeting 
nucleases to cause double-strand cleavage of DNA at specific genomic loci. 
DSBs can be repaired by one of two distinct endogenous repair pathways: 
non-homologous end-joining (NHEJ) or homology-directed repair (HDR) with 
the opposing DNA strand or a template (donor). In the absence of an 
exogenous repair template, NHEJ is efficient but error-prone resulting in small 
insertions or deletions (indels) at the point of cleavage during the normal repair 
process (Rodgers and McVey, 2016). These indels can disrupt target genes 
by causing frame-shift mutations, resulting in an unstable mRNA or the 
introduction of a premature stop codon (Weterings and Chen, 2008). In 
contrast, HDR requires donor DNA strand that serves as a template to guide 
the repair enabling precise modification of the genomic sequences. HDR-
based gene editing can therefore theoretically be used to repair disease-
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causing mutations or to generate a “knock-in” of a desired sequence of DNA 
into the genome (Kakarougkas et al., 2014). Both repair mechanisms are used 
by cells to maintain genomic integrity. 
 
The difference between the editing methods employed is in the recognition of 
the genomic sequence. Sequence recognition by ZFNs and TALENs occurs 
through protein-DNA interactions. ZFN technology involves creating chimeric 
protein fusions of zinc-finger DNA binding domains with the catalytic domain 
of the FokI nuclease (Carroll, 2011). The binding domain can be engineered 
to target any defined sequence providing DNA binding specificity (Gaj et al., 
2013). In general, ZFNs are reported to have relatively low editing efficiency 
as they are very sensitive to epigenetic modifications such as methylation. 
 
TALENs, similar to ZFNs, use a sequence of transcription activator-like 
effector repeats for DNA binding coupled to the same FokI nuclease used in 
ZFNs (Joung and Sander, 2013). While TALENs have been effective, the 
design, construction and effective expression of these molecules in 
mammalian cells can be challenging due to their size and the repeated 
sequences have a high rate of recombination making them unsuitable for viral 
delivery methods (Wang et al., 2016b).  
 
1.5.2 CRISPR-Cas9 
Since the discovery of its basic components, Clustered regularly interspaced 
short palindromic repeats (CRISPR) and its associated Cas9 protein has 
emerged as a pioneering new tool for gene editing at the forefront of current 
62 
 
biological research. This system functions as an adaptive immune pathway in 
bacteria protecting them from viruses and invading plasmids (Wiedenheft et 
al., 2012). The invading viral DNA is cleaved by the Cas complex, into smaller 
fragments (spacers) which are integrated into the CRISPR locus in the 
bacterial genome. These are transcribed and the pre-cRNA is processed into 
shorter, separate crRNA, complementary sequences when invading viruses 
are recognised and targeted by Cas proteins (Rath et al., 2015, Koonin and 
Wolf, 2015). Through repurposing, CRISPR/Cas9 has recently emerged as 
the preferred system for achieving site-specific DNA targeting. 
 
CRISPR/Cas systems can be divided into two classes, Class 1 (which 
encompasses approximately 90% of Cas loci) and Class 2. Class 1 
(encompassing type I, III and IV) Cas systems requires several Cas proteins 
to form an effector complex that can target either DNA or RNA. By contrast 
Class 2 (encompassing type II, V and VI) only requires one Cas protein, 
making them useful for gene editing (Koonin et al., 2017, Makarova et al., 
2015). The most commonly Cas enzyme used in genome editing is that found 
in Streptococcus pyogenes (SpCas9) which belongs to the Class 2, type II 
system. The Cas9 endonuclease contains two nuclease domains, RuvC and 
HNH, responsible for cleavage of the non-complimentary and complimentary 
strand, respectively (Sternberg et al., 2015). The other two components 
required for this system, the CRISPR RNA (crRNA) and the trans-activating 
crRNA (tracrRNA) provide the DNA recognition (Deltcheva et al., 2011). The 
crRNA, also known as protospacer, possesses an 18–20-nucleotide guide 
sequence which recognises target sites within the genome, while the tracrRNA 
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hybridizes with the crRNA providing a scaffold for Cas9 binding (Pellagatti et 
al., 2016). The Cas9-tracRNA (trans-activating crRNAs) complex is directed 
to the region of DNA complementary to the corresponding crRNA sequence. 
The tracrRNA and crRNA can be fused by a short synthetic linker to create a 
single guide RNA (sgRNA) and is widely used in plasmid-based delivery 
systems (Jinek et al., 2012). 
 
A protospacer adjacent motif (PAM) is required for Cas9 DNA binding, with 
SpCas9 the target must be upstream of a 5’-NGG-3’ site. Assuming the crRNA 
sequence is complementary to the DNA sequence preceding the PAM site, 
Cas9 binding partially unwinds then cleaves the DNA 3 bp downstream of the 
PAM (Graham and Root, 2015, Jiang and Doudna, 2017). As mentioned 
previously once a DSB has occurred, cells employ one of two pathways to 
repair the damage, NHEJ or HDR (Ran et al., 2013). A single gRNA is 
commonly utilised for gene knockouts that result in non-homologous end 
joining (NHEJ) DSB repair. During NHEJ random insertion or deletion of 
nucleotides occurs which usually results in frameshift mutations potentially 
knocking out the gene of interest. However, these mutations can remain in-















Figure 1.10: Overview of Gene editing with CRISPR-Cas9 – A) Cas9 binds 
to DNA complementary to the sgRNA (in blue), upstream of an NGG PAM site. 
Triangles indicate location of double strand break. B) A Cas9 induced DSB 
can be resolved either through the NHEJ pathway resulting in random small 
insertions and deletions or via HDR in the presence of a suitable repair 
template allowing precise alterations to be made. Adapted with permission 





1.5.3 Therapeutic Applications of Gene Editing 
All three genome editing tools have been successfully used to modify the 
genome in human cells with different haematological abnormalities (Porteus, 
2015, Meissner et al., 2014). Targeted nucleases are being used in drug 
discovery and development to understand better molecular mechanisms of 
several diseases, including cancer. T-cell engineering and transduction using 
an array of genetic tools is currently the subject of many clinical trials. Recent 
work in ALL has shown the potential for TALENs in the treatment of 
chemotherapy-resistant B-ALL children where CAR-T cells with TALEN-
modified target TCRαβ, were used as a novel treatment option (Reardon, 
2015). An alternative approach utilises ZFNs to disrupt permanently CCR5 
expression. Mutations in CCR5, a crucial receptor for HIV entry, have shown 
to increase viability of CD4 T-cells, and provide resistance to HIV (Wang and 
Cannon, 2016). 
 
The CRISPR/Cas system has not yet been used for in vivo applications, 
however, in the past decade improved understanding of this system was a 
breakthrough in the study of cancer genes in human cells and mouse models. 
Recently the CRISPR-Cas9 system has been utilized to simultaneously 
disrupt up to eight alleles in mouse embryonic stem (ES) cells in a single step 
generating mice carrying multiple gene mutations (Wang et al., 2013). In vivo 
delivery of a CRISPR/Cas9 plasmid with single guide RNAs targeting the 
tumor-suppressor genes PTEN and p53 were successfully to derive a hepatic 
cancer model (Xue et al., 2014). Combining the CRISPR-Cas9 system with a 
lentiviral model to modify multiple genes in single mouse HSC and generating 
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AML model that can be used for better understating the complexity of human 
AML disease (Heckl et al., 2014).  
 
The potential of the CRISPR-Cas9 system as a powerful genome-editing 
platform has almost endless applications, and can be used to inhibit, repress, 
activate, translocate, invert or duplicate any target gene. This offers numerous 
exciting opportunities to better understand cancer biology by modelling the 
disease and potentially treating patients with an optimal targeted therapy 
(Kannan and Ventura, 2015). 
 
 
1.6 Thesis aims 
Fms-like tyrosine kinase 3 (FTL3) is mutated in approximately 23% of AML 
cases resulting in an internal tandem duplication (ITD) within Exons 14/15. ITD 
mutated FLT3 (FLT3-ITD) is constitutively activated and confers an 
unfavourable prognosis. Targeting FLT3-ITD is therefore seen as a promising 
therapeutic avenue. The overall aim of this work is to better understand the 
biochemical signalling and therapeutic relevance of the FLT3-ITD mutations 
present in human AML cells. We will gain a more complete understanding of 
its function and signalling hopefully leading to additional future strategies for 
treating AML, and assist in identifying potential drug resistance mechanisms. 
 
Quizartinib (AC220) is the first FLT3-ITD inhibitor to show excellent potency, 
selectivity and pharmacokinetic properties in clinical trials. The clinical 
response to TKI monotherapy remains limited by the high risk of relapse. To 
overcome this resistance it is crucial to improve the understanding of how 
67 
 
FLT3-ITD mutations affect cellular signalling in AML and how they respond to 
these targeted drugs, which this thesis aims to inform. 
 
In this study, we will investigate: 
- The effects of quizartinib and FLT3L on the expression, localisation and 
downstream targets of FLT3 and FLT3-ITD in human AML cell lines. 
- The effect of FLT3 mutational status on sensitivity to quizartinib and 
downstream FLT3L signalling.  
- The potential mechanisms of FLT3L-mediated drug resistance. 





















































2.1.1 Reagents and Kits 
A list of reagents and kits used in this thesis can be found in Appendix (Table 
A2). All regents and kits were purchased from either Sigma-Aldrich (Poole, 
UK) or Thermo Fisher (Loughborough, UK) unless otherwise stated. 
 
2.1.2 Buffers 
A list of buffers used in this thesis can be found in Table 2.1. 
Table 2.1 – Buffers and composition 
Name Constituents 
1 x Annexin V binding buffer 10 mM HEPES/NaOH (pH 7.4), 140 
mM NaCl, 2.5 mM CaCl2 
1 x TAE buffer 40 mM TRIS, 20 mM acetic acid 
and 1 mM EDTA 
10 x Running buffer 1% (w/v) SDS, 1.92 M glycine, 0.25 
M Tris 
10 x TBS 10 mM Tris-HCl, 150 mM NaCl, pH 
8.0 
10 x Transfer buffer 0.25 M Tris, 1.92 M glycine 
Resolving gel buffer 1.5 M Tris-HCl, 0.4% (w/v) SDS, pH 
8.8 
Stacking gel buffer 0.5 M Tris-HCl, 0.4% (w/v) SDS, pH 
6.8 
Tail lysis buffer 50 mM Tris/HCL (pH 7.5), 150 mM 
NaCl, 1 mM EDTA 
TBST 1 x TBS, 0.1% tween 20 





All primary and secondary antibodies were purchased from Cell Signalling 
Technology (CST) through New England Biotech (NEB, Hitchin, UK), Santa 
Cruz Biotechnology (Heidelberg, Germany) and Abcam (Cambridge, UK). A 
table of antibodies used in this thesis is found in Table 2.2. 
 
Table 2.2 – Primary and secondary antibodies 
Antibody Source Cat. No. Dilution MW 
(kDa) 
Species 
β-Actin Sigma A5316 1:20000 42 Mouse 
STAT5 CST 25656 1:1000 90 Rabbit 
STAT5A CST 4807 1:1000 90 Mouse 
STAT5B CST 34662 1:1000 90 Rabbit 
p-STAT5 CST 9351 1:1000 90 Rabbit 
p44/42 MAPK CST 9102 1:2000 42,44 Rabbit 
p-p44/42 MAPK Santa Cruz SC7383 1:2000 42,44 Mouse 
AKT CST 2920 1:2000 60 Mouse 
p- AKT CST 4060 1:2000 60 Rabbit 
FLT3 CST 3462 1:1000 130,160 Rabbit 
Mcl-1 Abcam ab32087 1:1000 35,40 Rabbit 
Bcl-2 CST 4223 1:2000 26 Rabbit 
Bax CST 5023 1:2000 20 Rabbit 
Bak CST 12105 1:2000 25 Rabbit 
Bim CST 2933 1:2000 12,15,23 Rabbit 
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Bcl-xL CST 2762 1:2000 30 Rabbit 
PARP CST 9532 1:1000 116 Rabbit 
Caspase-3 CST 9662 1:1000 32 Rabbit 
Cleaved-
caspase-3 
CST 9661 1:1000 17, 19 Rabbit 
Anti-rabbit IgG CST 7074S 1:3000 n/a Goat 
Anti-mouse 
IgG 
CST 7076S 1:3000 n/a Horse 
 
 
2.1.4 Cell lines 
AML cell lines U937, MV4-11, THP-1 and MOLM-13 were purchased from the 
Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (DSMZ) 
(Braunschweig, DE). Table 2.3 shows characteristics of the AML cell lines 
used as models in this study. Classification was according to France-
American-British Classification (FAB) that separates AML into 7 subclasses 












Table 2.3 – Characteristics of cell lines used in this study 








31/ Female AML FAB M5 30-40 
THP-1 Acute monocytic 
leukemia 
69/ Female AML FAB M5 35-50 
MV4-11 Biphenotypic B 
myelomonocytic 
leukemia 
61/ Male AML FAB M5a 50 
MOLM-13 Acute monocytic 
leukemia 
70/ male AML FAB M5a 50 
 
 
2.2 Maintenance of cell lines 
2.2.1 Cell culture 
Cells were maintained in Roswell Park Memorial Institute (RPMI) medium 
containing foetal bovine serum (10% v/v), penicillin (1000 units/ml) and 
Streptomycin (1 mg/ml) in a humidified incubator at 37°C with 5% carbon 
dioxide (CO2). All cell lines were cultured and maintained in vented flasks and 
handled under aseptic conditions within a Class II tissue culture cabinet.  
 
HEK-293T cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM), 
supplemented with 10% FBS and 1% Penicillin/Streptomycin. The adherent 
cell line HEK-293T had to be enzymatically treated to detach cells from the 
culture flask surface prior to passaging. When cells were confluent, the 
medium was removed, cells washed once in phosphate-buffered saline (PBS) 
before the addition of 2 mL of trypsin (0.05% w/v) EDTA (0.02% w/v). After 
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incubation for 5 min at 37°C / 5% CO2 an equal volume of growth medium was 
added to the cells to inactivate trypsin. Cells were then transferred to a 15 ml 
conical tube and pelleted at 113 x g for 3 min. The supernatant was removed, 
and cells were resuspended in 5 ml of growth medium. Part of the media 
containing cells was transferred to the culture flask and cells were further 
diluted with growth medium. 
 
2.2.2 Cell counting 
Cell counts were determined by dye exclusion assay. Trypan blue passes 
through ruptured cell membranes in non-viable cells, staining them dark blue. 
Live/viable cells with intact membranes are impermeable and appear as a 
shiny bright halo under the microscope. Cells are diluted 1:1 with trypan blue 
(0.1% (w/v)) in PBS and counted using a haemocytometer. 
 
2.2.3 Cryopreservation of cell lines 
Stocks of each cell line at low passage number were prepared for use 
throughout the study. For preservation, cells were harvested by centrifugation 
(2,000 x g, 5 min), culture medium was removed, the cell pellet resuspended 
in freezing media (10% DMSO in FBS) and transferred to cryovials (Corning, 
UK). Cells were placed in a ‘Mr Frosty’ freezing container (Thermo-Fisher) and 





2.2.4 Thawing of cryopreserved cell lines 
To recover cells from liquid nitrogen, cryovials were quickly thawed in a 37°C 
water bath. Cells were then transferred to a fresh tube and “washed” with 10 
ml of complete medium (to dilute out the DMSO in the freezing medium). 
Following centrifugation (2,000 rpm for 5 min) to remove dead cells and debris 
cells were resuspended in appropriate volume of complete media then 
transferred to appropriate cell culture vessel and incubated in a humidified 
incubator at 37°C with 5% CO2. 
 
2.2.5 FLT3 inhibitors and FLT3L treatment of AML cells 
AML cell lines were seeded in 6/12 well plates at density of 2 x106 cells per 
well in RPMI and incubated overnight at 37°C. The next day cells were treated 
with of FLT3L (100 ng/mL) or different concentrations of FLT3 inhibitors for 
indicated times and incubated at 37°C. After treatment cells were pelleted (500 
x g for 1 min) at 4°C and whole cell protein extraction performed as described 
in cell lysis section. Lysates were analysed by SDS-PAGE and Western 
blotting.  
 
 2.3 RNA interference 
All siRNAs (small interfering RNA oligoduplexes) were purchased from Qiagen 
(Cambridge, UK) (Table 2.5). Knockdowns were performed in Opti-MEM 
Reduced Serum Media (Life Technologies), using InterferinTM (Polyplus, 
Illkirch, France) (Table 2.6). Cells were seeded at optimal density and 
transfected with InterferinTM and the respective siRNA (10 nM final 
concentration) according to the manufacturer’s instructions. Cells were 
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incubated for 72h before protein knockdown efficiency was verified by Western 
blotting.  
 
Table 2.5 – siRNA sequences and target regions: targeted region is 
highlighted. Grey bars indicate the coding sequence of the gene. The negative 
control has no known target gene in the cells. 





Bim SI02655359 CGGAGACGAGTTTAACGCTTA 
 
STAT5A SI00048419 CGGCACATTCTGACAATGAA 
 
STAT5B SI00100408 CCGCTTGGGAGACTTGAATTA 
 









Table 2.6: – Volumes of siRNA, OptiMEM and Interferin used for siRNA 
transfection 
Well numbers Total volume/well OptiMEM siRNA 
(CONC) 
Interferin 
12 wells 1ml 200 μl 1.2 μl 4 μl 
6 wells 2 ml 400 μl 2.4 μl 8 μl 
10 cm dish 10ml 1000 μl 10 μl 24 μl 
  
 
2.4 NanoString nCounter analysis  
NanostringTM technology (NanoString Technologies, Inc) was used for kinase 
mRNA quantification. Cells were collected, counted, washed in PBS and snap-
frozen until required. Pellets were thawed and resuspended at a concentration 
of ~6,500 cells/µl in RLT buffer (Qiagen). The equivalent of ~10,000 cells (~1.5 
µl) was employed for direct kinase mRNA quantification, without the need for 
mRNA purification or amplification. mRNAs were hybridised to NanoStringTM 
human kinome barcode probes and control code sets, and mRNA levels 
quantified using the nCounter colour barcoding system after count 
normalisation with internal housekeeping genes and eight negative controls.  
 
2.5 Protein analysis 
2.5.1 Cell lysate preparation 
Lysates were prepared by harvesting cells in Eppendorf tubes on ice. 
Following centrifugation (550 × g for 5’) at 4°C, pellets were washed twice with 
0.5 ml ice-cold PBS and lysed with clear sample buffer (CSB) (125 mM Tris 
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(pH 6.8) containing 1% SDS (w/v), 5 mM EDTA and 10% (v/v) glycerol) 
containing CompleteTM protease inhibitor cocktail (Roche). Lysed cells were 
sonicated on ice and lysates cleared by centrifugation for 5 min at 14000 g. 
The protein concentration of samples was determined and lysates stored at -
20°C prior to use in Western blotting. 
 
2.5.2 Protein quantification by Bradford assay 
Total protein concentration was determined using a Bio-Rad DC protein assay 
kit (Bio-Rad laboratories Ltd, UK) according to the manufacturers’ instructions. 
In brief, a series of pre-made BSA protein standards were prepared. First, 5 
μL of sample or standard (in triplicate) was placed in a 96-well plate. Then, 
reagent A and reagent S were prepared at a 1:50 dilution and 25 μL of this 
mixture was added to each well followed by the addition of 200 μL of reagent 
B. The plate was gently agitated to ensure the reagents were mixed then 
plates incubated at room temperature for 15 minutes. The absorbance was 
measured at 650 nm using a plate reader (Bio-Tek, UK). 
 
2.5.3 Sample preparation 
The volume of cell lysate required to load 10 to 30 μg of total protein was 
calculated and the volume made up to 20 μL with CSB and 5x loading dye 
(625 mM Tris (pH 6.8) containing 5% SDS, 50% glycerol, 5% β-
mercaptoethanol and 0.04% bromophenol blue). Samples were heated at 




2.5.4 Protein separation by SDS-PAGE 
Proteins were separated by electrophoresis according to their molecular 
weight. Different percentages of polyacrylamide gels were used according to 
size of the target protein (Table 2.7).  
 
Table 2.7 – Resolving and Stacking gel recipes for 2 gels 
Ammonium Persulphate (APS) and Tetramethylethylenediamine (TEMED) 
were added last to initiate polymerisation. Resolving Buffer: 1.5 M Tris/HCl (pH 
8.8) containing 0.4% SDS. Stacking Buffer: 0.5M Tris/HCl (pH 6.8) containing 
0.4% SDS. 
 
 Resolving gel Stacking gel 
% 10% 12% 15% 5% 
ddH2O 8.3 ml 7 ml 5 ml 2.9 ml 
Acrylamide (30%) 6.7 ml 8 ml 10 ml 0.85 ml 
Resolving/Stacking buffer 5 ml 5 ml 5 ml 1.25 ml 
10% APS 250 µl 250 µl 250 µl 30 µl 
TEMED 25 µl 25 µl 25 µl 10 µl 
 
 
When polymerised, gels were assembled in the Mini-PROTEAN® Tetra 
Vertical Electrophoresis Cell (Bio-Rad) and placed into a tank filled with SDS 
running buffer (25 mM Tris, 192 mM glycine and 0.1% (w/v) SDS). Then equal 
amounts of protein (calculated as described previously) were added to the 
wells along with the Page Ruler PlusTM protein ladder (Thermo Fisher) in the 
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first lane of each gel. Empty wells were filled with an equal volume of 1X 
loading dye. Finally, the apparatus was connected to a power supply to run 
the gels at a constant voltage of 100 V for up to 2 hours.  
 
2.5.5 Western Blotting 
Following electrophoresis, the gels were soaked in transfer buffer (25 mM Tris 
and 192 mM glycine) (Geneflow, UK) for 10 min prior to transfer. Proteins 
resolved by SDS-PAGE were then transferred to Hybond-ECL nitrocellulose 
(Amersham) at 400 mA for 70 minutes. Following transfer, the membranes 
were washed with Tris-buffered saline containing 0.1% Tween 20 (TBST) then 
blocked in TBST containing 5% (w/v) non-fat milk or 5% (w/v) Bovine Serum 
Albumin (BSA) (TBSTB) for 1 hour at room temperature. Following this 
blocking step membranes were incubated with the appropriate primary 
antibody diluted TBSTB and incubated overnight at 4 ºC. The membrane was 
then washed three times with TBST prior to incubation with an appropriate 
horseradish peroxidase (HRP)-conjugated secondary antibody diluted in 
TBSTB for 1h at room temperature. Following this, membranes were washed 
three times with TBST followed by a wash with TBS before being developed 
with enhanced chemiluminescence (ECL) (Millipore). Membranes were 
visualized using the ChemiDoc imaging system (Bio-Rad). 
 
2.5.6 Quantification of protein expression by densitometry 
The relative abundance of specific proteins was determined by quantifying the 
immune reactive bands detected on ChemiDoc. Densitometric analysis was 
accomplished using ImageJ (National Institute of Health (NIH), Version 1.48n) 
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and plotted with GraphPad Prism. Densitometry was performed and phospho-
proteins were normalised relative to the respective total protein (eg. pERK with 
ERK). Mcl-1 and Bim were normalised to β-Actin. 
 
2.6 Functional Assays 
2.6.1 Annexin V and Propidium Iodide staining 
Apoptosis was measured by flow cytometry using Annexin V/ PI staining. Cells 
were harvested by centrifugation at 300 g for 5 min. The pellet was washed 
twice with PBS and resuspended in 100 µl Annexin V binding buffer (10mM 
HEPES, 140 mM NaCL, and 2.5 mM CaCl2). Then, 2 µl of Annexin V-FITC 
(BD Biosciences, UK) was added and tubes incubated for 8 min. 5 µl of 
propidium iodide (1 mg/ml) was then added followed by incubation in the dark 
at room temperature for a further 5 min. Annexin V/PI staining was measured 
using an Attune NxT flow cytometer (ThermoFisher) 10,000 events were 
captured per sample and at least three replicates were analysed for each 
experiment. The percentage of apoptotic cells was calculated by combining 
the early apoptotic (positive for Annexin V and negative for PI) and late 
apoptotic/secondary necrotic (positive for both PI and Annexin V) events. 
 
2.6.2 Measurement of cell proliferation 
Carboxyfluorescein succinimidyl ester (CFSE) staining was used to measure 
cell proliferation according to the manufacture instructions. The fluorescence 
intensity of the dye reduces as cells divide and this was monitored by flow 
cytometry at indicated time points. Cells were harvested at a density of 3 ×106 
cells/ml and re-suspended in PBS. CFSE stain (CellTrace™ Cell Proliferation 
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Kits (C34554) (Thermo Fisher Scientific, UK)) was added to the cells at an 
effective 1:1000 dilution (stock concentration: 0.5 mM), and cells incubated for 
30 min in a 37°C water bath. Cells were centrifuged at 500 g for 5 min, re-
suspended in fresh RPMI and incubated for 15 min at 37°C. Cells were further 
centrifuged and resuspended in RPMI at a concentration of 5 ×106 cells/ml 
and incubated overnight. The zero time-point was collected immediately 
following staining together with an unstained control. Time points were 
collected over 72h and analysed by flow cytometry. 
 
2.6.3 Cell cycle analysis 
Cell cycle analysis was performed with propidium iodide (PI) staining and flow 
cytometry. Cells were harvested, washed with ice-cold phosphate-buffered 
saline (PBS) and fixed in 70% ethanol for 30 minutes on ice. Samples were 
washed twice in PBS and treated with RNase (50 µl of (100µg/ml stock) at 
37˚C for 30 minutes. Samples were stained at room temperature with 20 µL of 
PI (1mg/ml stock) for 5 minutes under light-protective conditions and analysed 
by flow cytometry. 
 
2.6.4 Cell surface expression of FLT3 receptor by flow cytometry 
Cells were pelleted at 500 x g for 5 min then re-suspended in 100 μL of PBS. 
To assess cell surface FLT3, cells were stained with 1 μg of a CD135-PE 
antibody or 2.5 μg of an isotype control mouse IgG2a-PE antibody for 20 min 
before being washed once with PBS. Pellets were re-suspended in PBS and 
cells analysed by flow cytometry. Total FLT3 levels (cell surface and 
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internalized receptor) were measured by first permeabilizing and fixing cells 
with Cytofix/Cytoperm buffer (BD Biosciences) for 30 minutes prior to staining. 
 
2.7 Molecular Biology Techniques 
2.7.1 Plasmids 
All plasmid backbones were originally purchased from Addgene (Boston, MA). 
Modifications to LentiCRISPR to generate LentiCRISPR SFFV mod gRNA and 
pLeGO with multiple cloning sites were performed by Dr. Nicholas Harper 
(University of Liverpool, UK). 
 
2.7.2 Preparation of Competent cells 
Competent NEB “Stable” E.coli (New England Biolabs) were generated using 
the Mix and Go E.coli transformation buffers (Zymo Research, Cambridge 
Bioscience, Cambridge). 5 ml of SOB culture medium (10% Tryptone, 5% 
Yeast Extract, 1 mM MgCl2, 1 mM MgSO4 and 0.5 mM KCl) was inoculated 
and incubated overnight. Next day this was used to inoculate a 50 ml culture 
(1/400 dilution) in a 500 ml flask. E.coli were then grown at 24°C until an OD 
600nm between 0.4-0.6 was reached. Bacteria were then rapidly chilled and 
diluted in the Zymo buffers according to the manufacturer’s instructions. 
Competent cells were then aliquoted and stored at -80°C. 
 
2.7.3 Transformation of E.coli 
DNA was added to a tube containing 50 µl of competent E.coli, the tube was 
then briefly vortexed followed by incubation on ice for 20 min. E.coli were then 
heat-shocked (42°C, 45 sec) and recovered on ice. SOC medium (SOB 
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including 1% glucose) was added and tubes incubated at 37°C with shaking 
for 1 hour. For plasmid transformation 50 µl of this culture was then plated on 
Luria Broth (LB)-Agar plates containing the required antibiotic or for ligation 
transformations, bacteria were pelleted (5000 rpm, 5 min) resuspended in a 
small volume of LB medium and the whole culture then plated. Plates were 
then incubated overnight at 37°C. 
 
2.7.4 Plasmid DNA isolation 
Plasmid isolation was carried out using kits according to the manufacturer’s 
instructions. Mini-preps were carried out using the Qia-Quick Mini-Prep kit 
(Qiagen). 4 ml of an overnight culture was routinely used. Briefly the pellets 
were resuspended in 250 µl of Buffer P1 then lysed with an equal volume of 
P2, protein and genomic DNA was then precipitated with 350 µl of Buffer N3. 
This precipitate was removed by centrifugation (13,000 rpm, 10 min) and the 
resulting supernatant added to the spin columns. Plasmid DNA was bound 
following centrifugation and after several sequential wash steps with Buffers 
PB and PE was eluted by the addition of DNA/RNase-free water. 
 
Where larger amounts of DNA were required MAXI-preps were performed 
using the PureLink HiPure Plasmid Filter Maxiprep Kit (Invitrogen, 
ThermoFisher Scientific). A 5 ml starter culture was inoculated and grown for 
6-8 h at 37°C, this was then used to inoculate 200 - 400 ml cultures of LB 
medium (depending on plasmid copy number). The larger cultures were then 
grown overnight and pelleted the following day. Plasmid DNA was then 
isolated according to the manufacturer’s instructions with modifications. 
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Briefly, pellets were resuspended in Buffer R3, followed by lysis with Buffer L7 
and neutralization/precipitation with Buffer N3. The resulting precipitate was 
removed by filtration through glass wool and applied to the provided Maxi-prep 
columns (which had been previously equilibrated). When the lysate had been 
applied, columns were washed successively with Buffer W8 and bound DNA 
eluted with Buffer E4. DNA was then precipitated with an equal volume of 
isopropanol overnight at -20°C. The following day DNA was pelleted by 
centrifugation at 4000 rpm for 1h. DNA pellets were transferred to 1.5 ml 
Eppendorfs and washed with 70% Ethanol before being resuspended in 
DNA/RNase-free water. Isolated DNA was quantified using a Nanodrop 
(Thermo). 
 
2.7.5 DNA Electrophoresis 
Agarose gel electrophoresis was performed to analyse PCR reactions and 
purify DNA. Agarose was dissolved in TAE buffer (40 mM TRIS, 20 mM acetic 
acid and 1 mM EDTA) using a microwave. The percentage of agarose was 
dependent on the size of the DNA to be analysed (for a typical PCR this would 
be 1.5 % (w/v). Ethidium bromide (EtBr) was then added before pouring the 
gel. DNA samples and an appropriate DNA “ladder” were mixed with a 6x 
loading dye (NEB) and gel ran at 135 V until sufficient separation was seen. 
Gels were then visualized on a ChemiDoc imager (Bio-Rad). 
 
2.7.6 Polymerase chain reaction (PCR) 
PCR was performed to analyse genomic DNA, colony PCR to check correct 
insertion of guide oligonucleotides or cassettes into plasmids and to amplify 
85 
 
guide cassettes for cloning. For routine PCR on genomic DNA or colony PCR 
on bacteria we used the OneTaq PCR master mix (NEB). For cloning of guide 
cassettes, we used the high fidelity Q5 polymerase (NEB). Typical PCR 
reactions are shown in Table 2.8. Reactions were cycled according to the 
manufacturer’s instructions. 
 
          Table 2.8 – Typical PCR reactions 
 One-Taq Q5 
PCR Buffer 5 µl (2x buffer) 10 µl (5x buffer) 
DNA/RNase free water 2 µl 31 µl 
dNTPs (10 M) n/a 1 µl 
Forward primer (5 M) 1 µl 2.5 µl 
Reverse primer (5 M) 1 µl 2.5 µl 
Template n/a 1 µl 
Q5 enzyme n/a 1 µl 
 
 
2.7.7 Restriction Digestion of Plasmid DNA 
Plasmid DNA or PCR amplified DNA (insert) were digested with restriction 
enzymes. Typically, 5 µg of plasmid was digested with the appropriate enzyme 
(NEB). Undigested and single enzyme controls were used for all multiple 
enzyme reactions to ensure enzyme activity. Digests were incubated for up to 
4h (depending on the enzyme) at 37°C, before being analysed by agarose 
electrophoresis and gel extracted or, for the inserts, just directly using the 
Wizard SV Gel and PCR Clean-up system (Promega).  
 
2.7.8 Ligation of digested DNA fragments 
Ligation of plasmid and PCR product or oligonucleotides was performed using 
a T4 DNA ligase (NEB). Table 2.9 shows a typical ligation reaction which 
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varies the ratio of plasmid to insert. Reactions were incubated at 4°C overnight 
before transformation.  
 
Table 2.9 – Typical ligation reaction (V – vector, plasmid DNA. I – insert) 
 V+L V:I ratio (1:2) V:I ratio (1:4) 
Digested plasmid 25 ng 25 ng 25 ng 
Insert n/a 100 ng 200 ng 
T4 ligase 0.5 µl 0.5 µl 0.5 l 
2x ligase buffer 5µl 5 µl 5 µl 
DNA/RNase-free water to 10µl to 10 µl to 10 µl 
 
 
2.7.9 Colony PCR 
Colony PCR was performed on bacterial colonies obtained following ligation 
transformations to ensure presence and correct orientation of cloned inserts. 
A One-Taq master mix containing the appropriate primers was aliquoted into 
PCR tubes and bacterial colonies picked and added to each tube. Plates which 
had colonies picked were placed back in the incubator to allow colony 
regrowth. PCR was then performed, and results analysed by agarose gel 
electrophoresis. Positive colonies were marked before being picked for further 
processing. 
 
2.7.10 Transfection of DNA into Mammalian Cells 
Plasmid DNA was transfected into adherent cells (HEK293Ts) using 
Polyethylenimine (PEI) (Sigma). 4 ×105 cells were plated into 6-well plates 16h 
before transfection. The following day 100 µl of 150 mM NaCl was mixed with 
4 µl PEI (1 mg/ml in DNA/RNase-free water). In another tube 100 µl of NaCl 
was mixed with the plasmid 1-2 µg of plasmid DNA. The PEI mix was then 
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added to the plasmid DNA mix and vortexed vigorously. After 20 minutes at 
room temperature the DNA/PEI complexes were added to the cells dropwise 
and the plates returned to the incubator. An EGFP-expressing plasmid was 
routinely used to ensure transfection was working as cells could be visualized 
by fluorescence microscopy. 
 
2.7.11 Isolation of Genomic DNA 
Transfected cells were scraped in medium in the 6-well plates and transferred 
to a 1.5 ml Eppendorf tube. Cells were then pelleted and washed once with 
PBS. Cell pellets were then lysed in 300 µl of “tail” buffer (50 mM Tris/HCL (pH 
7.5), 150 mM NaCl, 1 mM EDTA and 0.2% SDS) supplemented with 20 mg/ml 
proteinase-K and 50 mg/ml RNaseA. Digestion was performed overnight at 
55°C. Proteinase K was inactivated at 95 °C for 10 min then lysates left to cool 
on ice before the addition of glycogen (1 µl of a 100 mg/ml stock) and 400 µl 
of isopropanol to precipitate the DNA. Tubes were incubated on ice for up to 
1 h (or left at -20 °C overnight) before DNA recovered by centrifugation at 
20,000 x g for 1h. The DNA pellet was then washed in 70% ethanol before 
being resuspended in DNase/RNase-free water. Samples could be incubated 
at 55°C to aid resuspension. DNA was then quantified by nanodrop and 
normalized to 500 µg/ml 
 
2.7.12 Gene Editing 
Guide RNA design and cloning 
Guide RNAs were designed to target Exon 1 and the intergenic region 
upstream of the ATG of the STAT5A gene using the CRISPOR tool 
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(http://crispor.tefor.net/). Guide oligonucleotides were obtained from IDT 
(Leuven, Belgium). 
 
Table 2.10 – 5’- 3’ Guide oligonucleotide sequences 














Oligonucleotides were designed such that when annealed they would contain 
“sticky” ends compatible with the LentiCRISPR plasmid and therefore didn’t 
require digestion for cloning. Oligonucleotides were reconstituted at 100 µM in 
DNA/RNase-free water and phosphorylated using a T4 polynucleotide kinase 
(PNK) for 30 minutes at 37°C (Table 2.11). 
            Table 2.11 – Phosphorylation of guide oligonucleotides 
Forward oligo (100 µM) 1 µl 
Reverse oligo (100 µM) 1 µl 
2x Ligase buffer 5 µl 
ATP (1 µM) 0.5 µl 
PNK 0.5 µl 
DNA/RNase-free water 2 µl 
 
Oligos were then denatured and PNK inactivated by incubating tubes at 95°C 
for 10 minutes in a heat-block. The heat-block was then removed and allowed 
to cool to room temperature to anneal the oligonucleotides. Annealed 
oligonucleotides were then diluted 1:25 prior to ligation. Annealed 
oligonucleotides were ligated into a modified LentiCRISPR plasmid that had 
previously been digested with BsmBI and alkaline phosphatase. Resulting 
clones were screened by colony PCR using a U6 forward primer (5’ 
89 
 
GAGGGCCTATTTCCCATGATTCC 3’) and the respective reverse guide oligo 
(Table 2.10). Plasmids were sequenced prior to use. 
 
2.7.13 Genotyping  
Primers recognising ~500 bp spanning Exon 1 of STAT5A were designed and 
synthesised (IDT) Table 2.12. PCR was performed on genomic DNA from 
transfected cells as described in 2.7.9. 
 
Table 2.12 – STAT5A Exon 1 genotyping primers 
STAT5A Exon 1 For #1  5’ TCTTTCAGTTTCTGGCCGTCC 3’ 
STAT5A Exon 1 For #2  5’ TCCACTCCTCACCATCTCTGTTC 3’ 
STAT5A Exon 1 Rev #1  5’ CCAGCAGCTCCACAGACATCC 3’ 
STAT5A Exon 1 Rev #2  5’ CCACCATGAGTAAAACTAGAGGCC 3’ 
  
 
2.7.14 Single cell clone Isolation  
Single cell clones were isolated by growing cells in methylcellulose. 2.4 g of 
sterilised methylcellulose 4000 cP dry powder was added to 50 mL of sterile 
water and gently simmered for several hours with constant stirring. The 
solution was then cooled to 50°C and diluted 1:1 with 2 x RPMI medium. To 
allow the methylcellulose to fully solubilise the solution was stirred overnight 
at 4°C. The following day the solution was transferred to a 50 mL conical tube 
and centrifuged at 920 x g for 60 min to clear any particles that had not 
solubilised. The methylcellulose solution was stored at -20°C in 10 mL aliquots 




50 μL of non-essential amino acids (NEAA), 50 μL of 10 U/mL 
Penicillin/Streptomycin and 1.5 mL FBS were added to 1.5 mL of media 
containing (6000 cells/ml). 3 mL of Methylcellulose / RPMI was added to the 
cells and mixed with a 5 mL syringe and 12-gauge needle. This was then left 
to stand for the bubbles to disperse before the cells were seeded in 12 well 
plate (1 mL/well) (1500 cells/well). Plates were left for 10-14 days after which 
colonies were picked under a microscope using a 10 μL pipette and transferred 
to a 96 well plate for expansion. Images were acquired using an EVOS FLOID 
system (Bio-Rad). Scale bar 100 µM. 
 
2.8. Lentivirus 
2.8.1 Virus production in HEK-293T cells 
The plasmids necessary for virus production are packaging plasmid psPAX2, 
an envelope plasmid encoding VSV-G (pMD2.G) and a lentiviral transfer 
plasmid, pCW Cas9-blast plasmid. 3.5 x 106 HEK-293T cells were seeded in 
10 cm3 dishes and allowed to adhere overnight. Culture medium was changed 
4h prior to transient transfection. Transfection mixture was prepared by 
combining 150 μL of 150 mM NaCl with 20 μL of 1 mg/mL Polyethylenimine 
(PEI) in one tube and 150 μL of 150 mM NaCl with 4 μg of transfer plasmid 
and 2 μg of each of the packaging and envelope plasmids in a second tube. 
The NaCl/PEI mix was added to the NaCl/plasmid mix, vortexed and left for 
20 min at room temperature before it was added dropwise to the HEK-293T 
cells. Medium was changed the next morning and 72 hours post-transfection, 
the media (containing the viral particles) was removed, cleared using a 0.45 
μm filter and concentrated on the day of harvesting by Ultracentrifugation at 
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4°C for 1.5 h at 25000 rpm using an SW41Ti rotor in a Beckman 
Ultracentrifuge. The supernatant was then removed and the pellet air dried 
then resuspended in 200 μl OptiMEM (ThermoFisher Scientific) and stored at 
-80°C. 
 
2.8.8 Transduction with Lentivirus  
Medium of target cells was changed 24 h before transduction. Six-well plates 
were set up with target cells. Polybrene (1 μg/ml), sodium butyrate (4mM)  ,and 
20 μl of concentrated virus was added to each well and the cells were 
transduced via spinoculation for one hour at 400 x g, then incubated at 37°C. 
24 h after the transduction, medium was replaced and cells incubated for a 
further 48 h and cells were pooled and transferred into a T25 tissue culture 
flask for selection/expansion or used immediately for experiments.  
 
2.9 Real-time PCR  
2.9.1 RNA extraction  
RNA extraction was carried out using the RNeasy Mini Kit (Qiagen). We 
followed the manufacturer protocol but essentially cells were pelleted in 1.5 ml 
microcentrifuge tubes and washed in PBS. Cells were lysed in RLT buffer 
using the included QiaShredder columns. 70% ethanol was added to the lysate 
which was then applied to an RNeasy Spin Column. The column was washed 
with the buffers RW1 and RPE. After which the empty spin column was 
centrifuged to remove any traces of ethanol before being eluted using 30 µl 
DNase/RNase-free water. The concentration of the extracted RNA was 
determined by nanodrop. 
92 
 
2.9.2 Reverse Transcription  
RNA was converted to cDNA using the Qiagen Quantitect Reverse 
Transcription Kit (Qiagen) according to the manufacturer’s instructions. Briefly 
the purified RNA sample is incubated in gDNA Wipeout Buffer at 42⁰C for 5 
minutes to remove any genomic DNA contamination (Table 2.13). 
 
Table 2.13 – Genomic DNA (gDNA) elimination reaction  
Component Volume/reaction Final concentration 
gDNA Wipeout Buffer, 
7x 
2 µl 1x 
RNA 1 µg  
RNase-free water Variable  
 DNA/RNase-free water to 14 µl - 
 
After genomic DNA elimination, cDNA was prepared using the Quantiscript 
Reverse Transcriptase (Table 2.14). 
Table 2.14 – Reverse-transcription reaction components 






Quantiscript RT Buffer, 5x 
 



















genomic DNA elimination 
reaction 
14 µl  




Reactions were incubated at 42⁰C for 20 minutes (required for cDNA 
synthesis) followed by 95⁰C for 5 minutes (to inactivate the reverse 
transcriptase). 
 
2.9.3 Quantitative real time-PCR (qPCR) 
qPCR was used to quantify gene expression in cells. cDNA was diluted 1:4 to 
make up the working solution. A typical qPCR reaction is shown below (Table 
2.15). Reactions were plated into white-walled 96-well plates (Roche). Plates 
were then sealed with PCR sealing foil (Roche) and briefly centrifuged. The 
qPCR reaction was performed on a Stratagene Mx3005P qPCR machine 
(Thermo Fisher) for 45 amplification cycles. Results were normalized to 
GAPDH expression and quantified using the following formula = 2 – (ΔCT 
gene of interest ΔCT GADPH).  
 
Table 2.15 – Example of a typical 20µl qPCR reaction using 5x EvaGreen 
buffer 
Component Amount 
5x EvaGreen® qPCR buffer 4 µl 
Forward primers (10 µM) 1 µl 
Reverse primers (10 µM) 1 µl 
DNase/RNase-free water 12 µl 
cDNA 2 µl 
 
All primers were designed and purchased from Integrated DNA Technologies 
(www.idtdna.com) and subjected to BLAST (NCBI) analysis 




Table 2.16 – 5’- 3’ Primer sequences used for qPCR 
Gene Forward Primer Reverse Primer 
GADPH GAPDH was purchased from Qiagen 
STAT5A CAGTGGTTTGACGGGGTGAT GTCGTGGGCCTGTTGCTTAT 
STAT5B CAGAACACGTATGACCGCTG CTGGAGAGCTACCATTGTTGG 
   
 
2.10 Statistics  
The data in this thesis were analysed by using GraphPad Prism 8 and ImageJ 






















































Effect of quizartinib and FLT3-
ligand on the regulation of FLT3 












 Approximately one-third of acute myeloid leukemia (AML) patients carry an 
“activating” mutation in the FMS-related tyrosine kinase 3 (FLT3) gene, most 
commonly an internal tandem duplication (ITD) (Smith et al., 2012b, Yokota et 
al., 1997). FLT3-ITD mutated AML is associated with an unfavorable 
prognosis, characterized by shorter overall survival and high risk of relapse 
making it difficult to treat effectively (Kottaridis et al., 2001). Despite extensive 
research, no single agent, specific, FLT3 inhibitor has been approved for 
patients harbouring ITD mutations.  
 
On a cellular level, the ITD mutation causes constitutive activation of FLT3. 
This results in activation of a number of signalling pathways including 
extracellular signal-regulated kinase (ERK), PI3K/Akt kinases, and the signal 
transducer and activator of transcription 5 (STAT5), which in turn can promote 
proliferation of hematopoietic stem and myeloid progenitor cells (Meshinchi 
and Appelbaum, 2009, Choudhary et al., 2005). ITD mutations lead to 
conformational changes in the receptor, resulting in impaired maturation of the 
protein and intracellular accumulation of incompletely glycosylated FLT3-ITD 
protein (Gilliland and Griffin, 2002a). For these reasons, development of FLT3-
ITD targeted therapies is being actively pursued either as a single-agent or an 
adjuvant to conventional chemotherapy. 
 
Many small molecule inhibitors targeting FLT3-ITD have been evaluated in 
clinical trials (Knapper, 2007). However, a substantial number of patients 
develop resistance due to the failure to completely eradicate all ITD-mutated 
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cells (Small, 2006). Quizartinib (AC220) is the first FLT3-ITD inhibitor to 
demonstrate potency, selectivity and pharmacokinetic properties in clinical 
trials (Zarrinkar et al., 2009b, Chao et al., 2009). Despite this the clinical 
response to monotherapy remains limited due to a high risk of relapse that can 
occur within months. To overcome this resistance, it is crucial to improve the 
understanding of how ITD mutations affect FLT3 signalling and how cells 
harbouring these mutations respond to these targeted drugs. 
 
Aberrant ITD signalling appears to be dependent on subcellular localization. 
For example, THP-1 cells express wild-type FLT3 which localises primarily to 
the cell surface (Takahashi, 2019). In these cells FLT3 ligand (FLT3L) is 
required to activate ERK, and PI3K/Akt.  In contrast, MV4-11 cells have a 
homozygous ITD mutation resulting in constitutively active FLT3 which 
localises almost exclusively to the endoplasmic reticulum (ER). As well as ERK 
and PI3K/Akt, this mutation also causes activation of STAT5 pathway 
(Spiekermann et al., 2003a). The effect of FLT3 inhibition by quizartinib and 
activation by FLT3L on signalling and subcellular localisation of the receptor 
and its ITD mutants has not yet been examined systematically.  
 
3.1.1 Aims 
This chapter will focus on the effects of quizartinib and FLT3L on the 
expression, localisation and downstream targets of FLT3 and its ITD mutants 




3.2 Results  
3.2.1 Characterization of FLT3 mutations in common AML cell lines 
Four AML cell lines that differ in FAB classification and FLT3 mutational status 
were used (Table 3.1) (Quentmeier et al., 2003). The ITD mutation in the MV4-
11 cell line is well described and comprises a 30 bp duplication in Exon 14 but 
the mutation in the MOLM-13 cell line is more obscure (Quentmeier et al., 
2003). To characterise the mutational status of FLT3 in each of the AML cell 
lines prior to use, genomic DNA was extracted and Exon 14 amplified by PCR 
and resulting products analysed, first by DNA-PAGE.  
 
The MV4-11 cells clearly showed a single PCR product larger than the 
corresponding bands in the wild-type-expressing THP-1 and U937 cell lines 
(Fig 3.1A). This agrees with these cells being homozygous for a 30 bp ITD 
mutation. The MOLM-13 cells exhibited two bands, one corresponding to the 
wild-type product and an additional band, larger than wild-type but smaller than 
that obtained in the MV4-11s. This would agree with these cells harbouring a 
heterozygous ITD mutation that differed from the one found in the MV4-11 
cells. 
 
To further characterize these bands the PCR products were excised from 
Agarose gels and sequenced. The MOLM-13 products could not be 
successfully, separated on Agarose gels and therefore they were cloned into 
pBluescript prior to sequencing. Sequences obtained from both THP-1 and 
U937 cells as expected corresponded to wild-type sequence with no mutations 
in Exon 14 (Fig 3.1B).  
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The MV4-11 sequence had a 30 bp insertion in Exon 14 which has previously 
been described. This sequence is homozygous as determined by the single 
product following PCR and the single trace obtained with sequencing. Several 
pBluescript plasmids were sequenced following cloning of the PCR products 
from the MOLM-13 cell line and two sequences were obtained. The first was 
wild-type but the second had a 21 bp insertion in Exon 14 (Fig 3.1B). In 
conclusion the genotyping shows that two of the lines (U937 and THP-1) have 
wild-type FLT3 (FLT3ITD-/-), MV4-11 cells have a homozygous 30 bp ITD 
(FLT3ITD+/+), and the MOLM-13s have both a wild-type and an ITD allele 
(FLT3ITD-/+) which differs from that found in the MV4-11s. 
A) 










Figure 3.1: Identification of FLT3-ITD mutations in common AML cell 
lines – A) Exon 14 of FLT3 was amplified from genomic DNA isolated from 
AML cell lines and products separated by Agarose gel electrophoresis (upper 
panel) and DNA-PAGE (lower panel). The doublet observed in the MOLM-13’s 
indicates a heterozygous mutation. B) Sanger sequencing of PCR products. 
MOLM-13 products were first cloned into pBluescript prior to sequencing 
several clones. 
 
3.2.2 Quizartinib induces apoptosis only in ITD-expressing AML cell lines 
Having characterized FLT3 mutations in the AML cell lines (Fig 3.1) their 
response following treatment with the FLT3 inhibitor quizartinib was assessed 
using Annexin-V/PI. The effect of quizartinib was analysed with increasing 
concentrations (0.01–10 µM) over a four-day period. Treatment with 
quizartinib induced apoptosis and decreased cell viability in the ITD 
expressing MV4-11 and MOLM-13 cell lines in a time and concentration-
dependent manner. In contrast, the wild-type FLT3 expressing, THP-1 and 
U937, cells were not sensitive (Fig 3.2A). The IC50 values of quizartinib after 
72h are summarized in Table 3.1. The pan-tyrosine kinase inhibitor, 
midostaurin, was also tested, and all AML lines appeared to exhibit some 
sensitivity following treatment (Fig 3.2B).  These data suggest that the Type II 
TKI quizartinib is selective for ITD-expressing AML cells whereas the type I 
TKI midostaurin effectively induce apoptosis in all AML cell lines irrespective 





Table 3.1 – IC50 of quizartinib on AML  
Cell lines FAB FLT3 status IC50 (72h) 
MV4-11 M5a FLT3ITD+/+ 31 nM 
MOLM-13 M5a FLT3ITD-/+ 6 nM 
THP-1 M5 FLT3ITD-/- N/A 



























Figure 3.2: Quizartinib selectively induces apoptosis in FLT3-ITD 
expressing cells – MV4-11, MOLM-13, THP-1, and U937 cells were 
incubated with increasing concentrations of A) quizartinib or B) midostaurin. 
Apoptosis was measured at indicated times using Annexin-V/PI staining. 
Results represent the mean +/- SEM for 5 independent experiments. Scatter 
plots are representative of cells at 72h with quizartinib or midostaurin.  
 
3.2.3 Quizartinib inhibits FLT3 signalling in ITD-expressing Cells  
As the AML cell lines displayed a differential sensitivity to quizartinib but not 
midostaurin, we looked at the effect of quizartinib on FLT3 signalling pathways 
in ITD, compared to WT cells. Again, cells were incubated with increasing 
concentrations of quizartinib (0.01–10 µM) and the phosphorylation status of 
known FLT3 signalling intermediates analysed by Western blotting. Both 
ERK1/2 and AKT were constitutively phosphorylated in MV4-11 and MOLM-
13 cells and this was inhibited by quizartinib indicating these pathways were 
downstream of FLT3. Cells displayed constitutive phosphorylation of STAT5, 
and this was also inhibited by quizartinib, again indicating this was dependent 
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on ITD signalling in these cells (Fig 3.3A). ERK1/2 and AKT were also 
constitutively phosphorylated in the WT-FLT3 expressing THP-1 and U937 
cells, and this was unaffected by quizartinib (Fig 3.3B).  
 
To confirm the inhibition in signalling observed is a result of ITD inhibition and 
not a secondary effect due to cell death, we examined the effect of quizartinib 
on FLT3 signalling at earlier time points (Fig 3.3C). Consistent with the 
previous results, quizartinib inhibited constitutive phosphorylation of STAT5, 
ERK1/2, and AKT in MV4-11. Inhibition was observed as early as 30 minutes 
after treatment with 1µM quizartinib but 0.1 µM and even 0.01 µM was effective 
with later time points.  
 
Western blotting results examining FLT3 inhibition by quizartinib for all AML 
cell lines correlated well with the Annexin-V/PI data. Taken together, these 
results show that inhibition of FLT3-ITD by quizartinib is accompanied by 
potent inhibition of FLT3 signalling pathways within 30 minutes of TKI 


























Figure 3.3: Quizartinib inhibits FLT3 signalling in ITD expressing cells – 
A) MV4-11, MOLM-13 and B) THP-1, and U937 cells were treated with 
quizartinib for 24h for indicated concentrations. C) Effect of quizartinib on MV4-
11 cells at shorter time periods. Total cellular protein extracts were separated 
by 10% SDS-PAGE and subjected to immunoblot analysis with antibodies 
against known FLT3 signalling intermediates; phospho-STAT5, -AKT, -
ERK1/2 and their unphosphorylated forms. β-actin was used as a loading 
control. Results are representative of 3 independent experiments.  
 
 
3.2.4 Effect of quizartinib on cell cycle progression and proliferation of 
AML cell lines 
To further confirm the selectivity of quizartinib in ITD expressing cells, we 
looked at its effect on cell cycle progression and proliferation using flow 
cytometry. In MV4-11 and MOLM-13 cells, incubation with quizartinib for 24h 
resulted in an increased in the population of G1 phase cells, and for 72h a 
higher percentage of cells in (sub-G1) than untreated cells were observed. 
This was accompanied by a decrease in proportion of cells in S and G2/M 
phases (Fig 3.4A). By contrast, quizartinib appeared to have no effect of on 
cell cycle status in THP-1 or U937 cells.  
 
This was further confirmed using a CFSE-based cell proliferation assay. The 
mean fluorescence intensity (MFI) of viable CFSE‐stained cells was obtained 
for untreated and treated cells. CFSE staining decreases following cell 
division, as it is diluted within the daughter cells. Thus inhibition of cellular 
division results in higher MFI levels of the CFSE in cells. As with the previous 
data, quizartinib only affected proliferation in the ITD-expressing cells but not 
THP1 or U937s (Fig 3.4B). Of the two ITD lines effects were more pronounced 
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in the MOLM-13s. These results demonstrate that quizartinib induces cell 
cycle arrest and has an anti-proliferative effect in ITD but not WT-FLT3 cells, 
which is in agreement with the apoptosis and inhibition of FLT3 signalling 















Figure 3.4: Quizartinib induces cell cycle arrest and displays anti-
proliferative activity only in FLT3-ITD expressing cells – A)  MV4-11, 
MOLM-13, THP-1, and U937 cells were treated with quizartinib (Q) (0.1 µM) 
for 24h-72h and cell cycle analysis was performed on fixed cells using PI 
staining followed by flow cytometry. B) Proliferation was measured by CFSE 
staining after treatment for 24 and 72h. Results represent the mean +/- SEM 
for 3 independent experiments and are expressed as mean fluorescence 
intensity (MFI). 
 
3.2.5 FLT3 localisation in AML cell lines  
It has been reported that FLT3 mutational status affects it subcellular 
localisation as well as its signalling. To further investigate this, AML cells were 
stained with a FLT3 (CD135) antibody and cell surface receptor localisation 
evaluated by flow cytometry. MOLM-13 (FLT3ITD-/+) and THP-1 (FLT3ITD-/-) 
cells exhibited significantly higher cell surface expression of FLT3 (MFI 3.6 
and 4.3) than that observed with MV4-11 cells (FLT3ITD+/+) (MFI 1.7). No cell 
surface staining of FLT3 was detected in U937 cells (Fig 3.5 A-B).  
 
To compare total FLT3 expression to cell surface localisation, cells were 
permeabilized prior to staining. Permeabilization resulted in an increase in 
FLT3 staining in the ITD expressing MV4-11 and MOLM-13 cells indicating a 
significant proportion of the FLT3 in these cells is intracellular (Fig 3.5 C-D). In 
the THP-1 cells, permeabilization did not increase staining above that seen in 
intact cells indicating the majority of the FLT3 in these cells is on the cell 
surface. In the U937 cells, permeabilization did not increase the FLT3 staining 
and, given that there is also no FLT3 on their cell surface strongly suggests 
these cells do not express FLT3 protein. These results indicate that in 
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homozygous ITD-expressing cells the majority of FLT3 is intracellular, 
suggesting these mutations may impair trafficking of the receptor to the cell 
membrane. 
 
Furthermore, mRNA from each of the cell lines was analysed using NanoString 
nCounterTM gene expression system. In agreement with the flow cytometry 
data no mRNA was detected in the U937 cells again indicating these cells 
don’t express FLT3. Of the other cells, the FLT3 mRNA transcript level was 
higher in the ITD expressing MOLM-13 and MV4-11 cells compared to the 
THP-1 cells (Fig 3.5E). Despite only expressing a single ITD allele, mRNA 
levels were considerably higher in MOLM-13 cells compared to the THP-1s. 
 
Western blot analysis on whole cell lysates showed that the AML cell lines 
expressed the different glycosylated forms of FLT3 (Fig 3.5F). THP-1 
(FLT3ITD-/-) presented as two species; partially glycosylated (130 kDa), 
corresponding to the intracellular form and fully glycosylated (160 kDa) that 
is present at the cell surface (Choudhary et al., 2009b). In MV4-11 cells 
(FLT3ITD+/+) only the partially glycosylated (130 kDa) form was present 
agreeing with the flow-cytometry data demonstrating receptor is 
predominantly intracellular in these cells.  FLT3 in MOLM-13s presents as a 
doublet which includes the partially glycosylated 130 kDa form and another 
closely related species. Genotyping suggests this cell line could potentially 
express 2 species and these bands could possibly be the WT and ITD (21 
bp insertion corresponding to approximately a 3 kDa difference) forms. 
Although there was no clearly defined 160 kDa species a smear of 
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immunoreactivity is clearly visible above the two major bands which may 
represent the cell surface form. As expected, given the flow cytometry 
results, FLT3 protein was undetectable in the U937 cells again indicating 










































































































Figure 3.5: Localisation of FLT3 in AML lines depends on ITD status – A-
B) U937, THP-1, MV4-11, and MOLM-13 cells were stained with anti-CD135-
PE antibody and cell surface FLT3 assessed using flow cytometry. IgG-PE was 
used as an isotype control and results presented as MFI ratio compared to 
control. Significance testing was done by two-tailed unpaired t-test (n=3), **p 
≤  0.01 and ***p ≤  0.001. C-D) cells were first permeabilized with BD 
Cytofix/Cytoperm buffer prior to staining to assess total (cell surface + 
intracellular) FLT3. Significance testing was done by two-tailed paired t-test 
(n=3),*P ≤ 0.05, **P ≤ 0.01, ns, not significant. Results represent the mean +/- 
SEM for 3 independent experiments E) Nanostring analysis of FLT3 mRNA in 
AML cell lines. mRNA level was normalized against several internal reference 
genes. Results represent the mean +/- SEM for 2 independent experiments. 
F) Total cellular protein (20 µg) from the AML cell lines was separated by SDS-
PAGE and subjected to immunoblot analysis with a FLT3 antibody. β-actin was 
used as a loading control. 
 
 
3.2.6 Role of FLT3 activation and inhibition on receptor localisation and 
signalling in AML cell lines. 
3.2.6.1 FLT3L and FLT3 antibody binding experiment 
As we wished to use the FLT3 (CD135) antibody to detect FLT3 localisation 
following FLT3L treatment we needed to ensure whether FLT3L would 
interfere with binding of the CD135 antibody. For this purpose, we used the 
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THP-1 cells as they express WT-FLT3, which almost exclusively resides on 
the cell surface in unstimulated cells (Fig 3.5C). THP-1 cells were incubated 
on ice for 30 minutes before being treated with FLT3L for a further 30 minutes, 
this allows the ligand to bind the receptor in the absence of activation or 
internalization. The cells are washed in ice-cold PBS and subsequently 
stained with the CD135 antibody. As we have seen previously, THP-1 cells 
bound the CD135 antibody demonstrating they express FLT3 on their cell 
membrane. Staining was unaffected by preincubation of the cells with FLT3L 






Figure 3.6: The FLT3L does not compete with the anti-FLT3 (CD135) 
antibody – THP-1 cells were treated with FLT3L for 30 minutes on ice (to 
block receptor internalization) before washed with PBS and stained with anti-
CD135-PE and IgG-PE antibodies to detect FLT3. Cells were analysed for cell 
surface FLT3 expression by flow cytometry and mean fluorescence intensity 
plotted. Results represent the mean +/- SEM for 2 independent experiments. 
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3.2.7 Activation of FLT3 receptor in AML cells by exogenous FLT3L 
As the FLT3-WT and ITD appeared to be differently localised in the 
unstimulated AML cells, the effect of FLT3L on cell surface expression was 
determined by flow cytometry. Treatment with FLT3L decreased cell surface 
expression of FLT3 in THP-1 and MOLM-13, but not MV4-11 cells. This agrees 
with results obtained with related receptors such as c-kit which is rapidly 
internalized following engagement with ligand (Yee et al., 1994). In MV4-11s 
the FLT3 would have no access to the exogenous FLT3L as it’s primarily 
intracellular, and therefore its subcellular localisation would be expected to 
remain unchanged. U937 cells showed no staining with or without ligand (Fig 
3.7A-B). 
 
We next investigated the effect exogenous FLT3L had on activation of FLT3 
signalling by examining phosphorylation of ERK1/2, AKT, and STAT5.  As 
seen before, many of these pathways were constitutively active in all the AML 
lines in the absence of ligand. Enhanced phosphorylation of ERK1/2 and AKT 
by FLT3L was observed in the THP-1 cells however, no STAT5 
phosphorylation was apparent (Fig 3.8A). No effect of exogenous ligand was 
observed in U937s as these cells don’t express FLT3. In MV4-11 and MOLM-
13 cells, the ITD causes ligand-independent activation of FLT3 and this likely 
results in the constitutive phosphorylation of ERK1/2 and AKT, and STAT5 in 
these cells. Despite this, we observed that the FLT3L could further activate the 
ITD cells leading to increased phosphorylation of ERK1/2 and AKT but not 
STAT5 (Fig 3.8B). This data suggests that the addition of FLT3L activates WT-
FLT3 and can augment the activation of ITD-FLT3 receptors resulting in 
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additional activation of ERK1/2 and AKT. The data also confirmed that only 












Figure 3.7: FLT3L reduces cell surface levels of FLT3 – A-B) U937, THP-
1, MV4-11, and MOLM-13 cells were stimulated with FLT3L for indicated 
times. Cell surface FLT3 expression was measured by staining with anti-
CD135-PE or isotype control (IgG-PE) antibodies and analysing stained cells 
by flow cytometry. Results are presented as the mean fluorescence intensity 
(MFI) and represent the mean +/- SEM of 3 independent experiments. 
Significance testing was done by one-way ANOVA with Dunnette’s multiple 
comparison test (n=3), **P ≤0.01, ***P ≤0.001, ns, not significant. 
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Figure 3.8: Activation of FLT3 signalling in AML cells by FLT3 Ligand – 
A) U937, THP-1 and B) MV4-11 and MOLM-13 cells were stimulated with 
recombinant human FLT3L (100 ng/ml) and incubated for indicated times. 
Total cellular protein extracts were separated by 10% SDS-PAGE and 
subjected to immunoblot analysis with antibodies against known FLT3 
signalling intermediates; phospho-STAT5, -AKT, -ERK1/2 and their 
unphosphorylated forms. β-actin was included as a loading control. C) 
Densitometric levels of phosphorylated protein band intensity was normalized 
with its total protein then each value was calculated in relative to untreated 
cells. Significance testing was done by one-way ANOVA with Dunnette’s 
multiple comparison test (n=3), *P ≤0.05 and **P ≤0.01. Results represent the 
mean +/- SEM for 3 independent experiments. 
 
3.2.8 Inhibition of ITD signalling affects subcellular localisation of FLT3 
We next examined the effect of ITD inhibition with quizartinib on FLT3 
localisation. Cells were first cultured in the presence of the quizartinib, and 
surface FLT3 expression measured by flow cytometry. In ITD-expressing cells, 
FLT3 surface expression altered significantly following inhibition with 
quizartinib.  
 
In MV4-11 cells, the FLT3-ITD protein appears entirely intracellular. 
Quizartinib treatment resulted in redistribution of FLT3 with significantly higher 
levels of cell surface expression compared to untreated cells (Fig 3.9A). 
MOLM-13s already display some cell surface FLT3 expression in untreated 
cells presumably due to the presence of inactive, WT-FLT3. In these cells 
surface levels were increased by quizartinib likely through inhibition and 
redistribution of the ITD variant to the cell surface (Fig 3.9B). The increase in 
surface FLT3 was larger in MV4-11 compared to the MOLM-13 cells. THP-1 
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cells did not response to quizartinib, and the surface level remained 
unchanged (Fig 3.9C), suggesting redistribution of FLT3 following quizartinib 
occurred only in ITD expressing cells.  
 
When cells were treated with the pan-tyrosine kinase inhibitor (midostaurin), 
FLT3 surface expression levels remained essentially unaltered even in the 
ITD-expressing cell lines which suggests that this inhibitor does not specifically 

































Figure 3.9: Quizartinib alters FLT3-ITD localisation – A) MV4-11, B) 
MOLM-13 and C) THP-1 cells were treated with increasing concentrations of 
quizartinib for indicated times. Cell surface FLT3 expression was measured by 
staining with anti-CD135-PE or isotype control (IgG-PE) antibodies and 
analysing stained cells by flow cytometry. Results are presented as the mean 
fluorescence intensity (MFI) and represent the mean +/- SEM of 3 independent 
experiments. Significance testing was done by one-way ANOVA with 
Dunnette’s multiple comparison test (n=3), *P ≤0.05 and ***P ≤0.001 shows 











































Figure 3.10: The pan-tyrosine kinase inhibitor Midostaurin does not 
change FLT3 localisation – A) MV4-11, B) MOLM-13 and C) THP-1 cells 
were treated with increasing concentrations of midostaurin for indicated times. 
Cell surface FLT3 expression was measured by staining with anti-CD135-PE 
or isotype control (IgG-PE) antibodies and analysing stained cells by flow 
cytometry. Results are presented as the mean fluorescence intensity (MFI) 
and represent the mean +/- SEM of 3 independent experiments. Significance 
testing was done by one-way ANOVA with Dunnette’s multiple comparison 
test (n=3), *P ≤0.05 and ***P ≤0.001 shows statistical higher significant 
difference versus untreated cells.   
 
3.2.9 The role of FLT3 activation and inhibition on signalling in wild-type 
and ITD-expressing AML cells 
We have previously shown that quizartinib alters the cell surface expression 
of FLT3-ITD but fails to affect levels in WT-expressing cells. We next wished 
to relate the changes seen in subcellular localisation to FLT3 signalling in the 
presence of quizartinib or following activation with FLT3L. 
 
As shown before, results indicate that THP-1s display high surface expression 
of FLT3 and as expected, these were unaffected following treatment with 
quizartinib (Fig 3.11A-B). Activation with FLT3L resulted in a decrease in cell 
surface staining which was unaffected by quizartinib pre-treatment. FLT3L 
activation was accompanied by a reduction in the 160 kDa membrane-
localised glycosylated form. An increase in phosphorylation of both ERK1/2 
and AKT indicated the receptor was available for activation with exogenous 




Inhibition of ITD-FLT3 in MV4-11 cells resulted in an increase in cell surface 
FLT3 (Fig 3.11A-B). Adding FLT3L to the quizartinib pre-treated MV4-11 lead 
to a slightly decrease in the surface localized ITD receptor when compared to 
quizartinib only treated condition. Western blot analysis indicated a 
corresponding increase in the fully glycosylated (160 kDa), mature form 
together with a decrease in the partially glycosylated form, likely as a 
consequence of relocalisation of the receptor from an intracellular 
compartment to the cell surface (Fig 3.11C). Inhibition was also accompanied 
by a reduction in phosphorylated ERK1/2, AKT and STAT5. This indicate that 
the FLT3L can cause internalization of homozygous FL3-ITD, however, for the 
time point we used for FLT3L stimulation (2 min), this was not enough to 
rescue ERK1/2 and AKT dephosphorylation that caused by quizartinib pre-
treatment.  
 
The MOLM-13s already have high levels of cell surface FLT3 expression and 
there was only a small increase following quizartinib treatment (Fig 3.11A-B). 
As with the MV4-11s quizartinib resulted in inhibition of basal phosphorylation 
of ERK, AKT and STAT5 indicating these were due to ITD signalling. Addition 
of FLT3L caused an increase in activation of these pathways which is 
presumably due to the presence of WT-FLT3 in these cells. This enhanced 
activation was unaffected by quizartinib reinforcing the fact that quizartinib can 
only affect ITD but not WT-FLT3 signalling (Fig 3.11C).  
 
The fully glycosylated mature (160 kDa) form was reduced in MOLM-13 upon 
FLT3L stimulation; however, no changes in MV4-11 were detected due to an 
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undetectable amount of cell surface FLT3. Interestingly as shown in Fig 3.11B, 
when FLT3L was added to quizartinib pre-treated MV4-11 cells, the surface 
localisation of FLT3 reduced compared to cells treated with quizartinib alone 
and this reduction matched the level of untreated cells. Unlike in the MOLM-
13s, the co-treatment in MV4-11 was not accompanied by an increase in FLT3 
signalling independent of that inhibited by quizartinib. The rapid activation by 
exogenous FLT3L must there be causing ligand-dependent internalization of 
the receptor, but this is not accompanied by an increase in signalling in the 













Figure 3.11: FLT3L alters cell surface localisation and signalling of FLT3-
ITD – A-B) THP-1, MV4-11, and MOLM-13 cells were treated with quizartinib 
(10 nM) for 24h before being stimulated with FLT3L (100 ng/ml) for 2 minutes. 
Cells were stained with anti-CD135-PE to detect FLT3 and IgG-PE as an 
isotype control. Cell surface FLT3 expression was measured by FACS 
analysis, and the mean fluorescence intensity plotted. C) THP-1, MV4-11, and 
MOLM-13 cells were treated with quizartinib (10 nM) for 24h. The following 
day cells were stimulated with FLT3L (100 ng/ml) for 2 minutes. Total cellular 
protein extracts (20 µg) were separated by 10% SDS-PAGE and subjected to 
immunoblot analysis with phospho- STAT5, -AKT, -ERK1/2, and their 
unphosphorylated forms. β-actin was included as a loading control. Results 
represent the mean +/- SEM for 3 independent experiments. Significance 
testing was done by one-way ANOVA with Dunnette’s multiple comparison 
test (n=3), *P ≤0.05, **P ≤0.01 and ***P ≤0.001 shows statistical significant 




3.2.10 Short term FLT3L treatment cannot rescue quizartinib inhibition 
of homozygous FLT3-ITD  
In the previous result, FLT3L (2 minutes) stimulation of MV4-11 pre-treated 
with quizartinib caused the decrease in cell surface ITD-FLT3 but did not 
rescue signalling as was observed in the MOLM-13s. MV4-11 cells have 
constitutive, basal activation of FLT3 and quizartinib appears to inhibit 
signalling, in part, by increasing the surface localisation of fully glycosylated 
ITD-FLT3. To further study this, MV4-11s were treated with quizartinib (10 nM, 
24 h) a concentration that has been previously shown in to increase the 
surface localised ITD-FLT3 (Fig 3.10) followed by a “wash-out” to remove 
unbound drug. Results showed that re-localisation of ITD-FLT3 induced by 
quizartinib remained unchanged and only STAT5 phosphorylation was 
partially restored. This is indicative that the binding of quizartinib to ITD is 
irreversible. We then wished to see whether FLT3L (2-10 minutes stimulation) 
could restore signalling following “wash-out”, as these cells would have cell 
surface ITD-FLT3 available for ligand binding. This treatment failed to restore 
signalling indicating that the surface re-localisation and kinase activity 
inhibition is not affected by FLT3L after quizartinib “wash out”. However, 
restoration of STAT5 activation following quizartinib “wash out” could be the 
de novo synthesis. This suggests a mechanism by which STAT5 inhibition is 
a result of a shift in ITD-FLT3 localisation from an intracellular space to the 
plasma membrane (Fig 3.12). The concentration of TKIs and the number of 
washing steps could affect the accumulation of TKIs inside the cell as 
described by (Lipka et al., 2016). Therefore, this experiment can done 

































































































           
Figure 3.12: FLT3L cannot restore FLT3 inactivation by quizartinib – A) 
MV4-11 cells were treated with 10 nM quizartinib for 24h. The following day, 
the cells were washed and incubated in fresh media for 3h followed by 
treatment with FLT3L (100 ng/ml) for indicated times. Total cellular protein 
extracts were separated by 10% SDS-PAGE and subjected to immunoblot 
analysis with antibodies against known FLT3 signalling intermediates; 
phospho-STAT5, -AKT, -ERK1/2. β-actin was included as a loading control. 
B) MV4-11 cells were treated with 10 nM of quizartinib for 24h and then cells 
were washed and left untreated for the indicated times followed by treatment 
with FLT3L for 2 and 10 minutes. Cells were stained with anti-CD-135-PE and 
an isotype control IgG-PE and analysed for cell surface FLT3 expression by 
FACS analysis. The mean fluorescence intensity (MFI) was plotted and results 
represent the mean +/- SEM of 2 independent experiments. 
  
3.2.11 Quizartinib cannot restore FLT3L-mediated reduction in surface 
localisation of FLT3 in THP-1 cells 
Quizartinib leads to a redistribution and increase in cell surface localisation of 
FLT3 both in MV4-11 and MOLM-13 but not THP-1 cells whose FLT3 is almost 
exclusively at the cell surface (Fig 3.5D). Unlike the ITD-expressing cells, THP-
1 cells lack any FLT3 mutations and therefore require exogenous ligand to 
activate the receptor. We next wanted to examine if quizartinib had any effect 
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on WT-FLT3 localisation in the THP-1 cells. As expected, treatment with 
quizartinib for 24h did not affect surface localisation of FLT3. To induce FLT3 
internalization, THP-1 cells were treated with FLT3L for 10 minutes, this 
resulted in a large decrease in cell surface FLT3 staining (Fig 3.13). 
Pretreatment of cells for 10 minutes with FLT3L prior to quizartinib treatment 
for 24h failed to restore surface FLT3 localisation indicating that quizartinib 
can only affect FLT3-ITD localisation and not FLT3L internalized WT-FLT3. 
 
 
Figure 3.13: Quizartinib cannot restore FLT3 surface localisation in THP-
1 cells following FLT3L – THP-1 cells were treated with quizartinib (10 nM) 
for 24h or FLT3L for 10 minutes. Cells also treated with FLT3L for 10 minutes 
followed by quizartinib treatment for 24h. The cells also stimulated with FLT3L 
for 10 minutes and washed by PBS prior to re-suspending in fresh growth 
medium and left untreated or treated with quizartinib for 24h. Cells were 
stained with anti-CD-135-PE and IgG-PE antibodies to detect FLT3 and 
isotype control, respectively. Cells were analysed for cell surface FLT3 
expression by FACS analysis, and the mean fluorescence intensity (MFI) was 












































































The FLT3 receptor has been reported to be mutated in around 30% of AML 
patients (Kiyoi et al., 1998b). The most common FLT3 mutations are internal 
tandem duplications, which result in a constitutive activation of the receptor 
and are associated with an adverse impact on disease progression and overall 
survival (Kottaridis et al., 2001). For this reason, targeting FLT3 is one of the 
most recent strategies to treat AML. In order to compare the impact of different 
FLT3 genotypes on the therapeutic response to FLT3 kinase inhibitors, we 
investigated the functional aspects of targeting multiple FLT3 mutational 
genotypes; wild-type, homozygous, heterozygous, and FLT3-negative in AML 
cell lines. As this project was focused on the signalling of FLT3 and its mutant 
form ITD, We wished to characterize our cells model as it’s important for all 
further work in this thesis. 
 
We first genotyped four common AML cell lines and confirmed ITD mutations 
in two of them by Sanger sequencing. Mutations in the MV4-11 and MOLM-13 
cells were both in Exon 14 in the juxtamembrane region but were not 
equivalent, one being a homozygous 30bp insertion (MV4-11), the other a 
21bp heterozygous insertion (MOLM-13s). We next confirmed FLT3 
localisation, expression, and mRNA level in our model lines; U937 (FLT3-
negative), THP-1 (WT-FLT3), MV4-11 and MOLM-13 (ITD-FLT3). FLT3 
mRNA was detected in the cell lines but transcript expression was much higher 
in the ITD expressing cells (MV4-11 and MOLM-13) than the wild-type THP-1 
cells. The U937 cells did not express any FLT3 protein or mRNA and therefore 
acted as a FLT3-negative control line. 
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Midostaurin (PKC412) and quizartinib (AC220) are examples of first and 
second generations FLT3 inhibitors, respectively. We analysed their activity 
using flow cytometry protocol involves the use of fluorescein isothiocyanate 
(FITC)-conjugated Annexin V and PI staining, a gold standard technique for 
apoptosis measurements and more accurate than MTT or cell count 
techniques (Schutte et al., 1998). Midostaurin is a pan-kinase inhibitor and has 
been approved to treat newly diagnosed, FLT3-mutated AML patients, in 
combination with standard chemotherapy (Stone et al., 2005). As midostaurin 
is not selective for just FLT3, all AML cells were highly sensitive. Quizartinib is 
currently in phase III clinical trials to treat relapsed/refractory patients 
expressing FLT3-ITD. Only the MV4-11 and MOLM-13 cells with ITD were 
sensitive to quizartinib and unlike midostaurin, the drug did not induce 
cytotoxicity in the FLT3-negative U937 or the WT-FLT3 THP-1 cell lines. 
Quizartinib induced cell cycle arrest in ITD-expressing cells and inhibited 
proliferation. We were able to track proliferation even when cells have only 
20% viability. This was done by gating on the viable cell population using 
CFSE staining, which originally developed to track lymphocyte migration 
studies (Weston and Parish, 1990) then start to be used in Vitro and in Vivo 
studies (Marchesi et al., 2004, Jetani et al., 2018). The proliferation of 
quizartinib treated cells at 72h was markedly decreased compared to 
untreated cells, however, this still has implications for the cell’s response to 
FLT3L and the resistance seen in AML patients. Even though the cell cycle 
analysis using PI was an indicative of cell cycle arrest, the interpretation would 




In the model we used sensitive to TKI treatment and this may be related to 
various factors including; the length and location of ITD insertion (21bp vs 
30bp in MV4-11),  the different genetic background with gene fusions MLL-
MLLT3; MLL-AF9 vs MLL-AFF1; ALL-1/AF4 in MV4-11 We also know that 
MOLM-13 has both ITD and WT alleles and so there is the possibility that 
heterogeneity in receptor composition (WT/WT, ITD/ITD or ITD/WT) may also 
influence signalling and sensitivity of the cells to the inhibitors. As a result, it 
would be expected to see variation in response to treatment among AML cell 
lines due to individual cell-specific factors and this would be interesting to 
address in future studies. 
 
The results also confirmed that quizartinib is highly selective against FLT3-
ITD–mutated AML cells as all downstream signalling was inhibited following 
treatment. Given the selectivity of quizartinib, this confirms that the basal 
activation of ERK1/2, AKT and STAT5 observed is through the constitutively 
active ITD-FLT3expressed in these cells. This is further reinforced with 
observations in the THP-1 (inactive WT-FLT3 and U937s (FLT3-expression-
negative) which were resistant to quizartinib. Although these cells have high 
basal activation levels of AKT and ERK1/2 (two pathways activated by FLT3) 
they must be activated by additional factors in these cells. It has been reported 
that quizartinib inhibits KIT and PDGFR, and this activity explains its effects 
on cell lines with genetic alterations of KIT and PDGFR such as the FLT3-WT 
cell lines Kasumi-1 (Heterozygous for KIT) and EOL-1 (Gene fusion FIP1L1-
PDGFRA) (Kampa-Schittenhelm et al., 2013). As THP-1 and U937 cells don’t 
carry KIT or PDGFR mutations, but PTEN, TP53 and NRAS genetic 
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alterations, it would be of interest to study in future the effect of FLT3L and 
quizartinib in FLT3-WT cell lines with KIT and PDGFR genetic alteration and 
compare that to our model in this project. 
 
An additional aspect of FLT3 expression regulation is glycosylation status and 
subcellular localisation which we looked at using Western blotting and FACS 
analysis. It was crucial for us to determine the different localisation of wild-type 
FLT3 and FLT3 ITD in human AML cell lines. This has been reported 
previously using murine myeloid progenitor cell line, 32D and homozygous ITD 
(Choudhary et al., 2009a). We took this further by using wild-type FLT3 and 
heterozygous FLT3 mutation cells along with other cells and also looked into 
mRNA, surface and total FLT3 expression and how this could affect the 
responsiveness of cells to kinase inhibition with or without FLT3L stimulation 
which may improve our understanding of FLT3 signalling. Different maturation 
status of FLT3 has been previously reported, partially glycosylated FLT3 
species at 130 kDa and the fully glycosylated mature form at 160 kDa 
(Schmidt-Arras et al., 2005). This is particularly important concept when study 
any receptor tyrosine kinases (RTKs). The constitutively active RTKs including 
FLT3, Stem-cell factor receptor (c-Kit), fibroblast growth factor receptor 3 
(FGFR3) and others are recognized as an active in a ligand-independent 
manner, and impaired in the normal processing of RTKs N-glycosylation lead 
to mislocalised subcellular localisation and subsequent aberrant signalling 
(Lievens et al., 2006, Tabone-Eglinger et al., 2008).  In our cells model, two 
glycosylated forms were detected in THP-1 and MOLM-13, while MV4-11 
expressed only the partially glycosylated form. We noted that a strong signal 
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for 130 kDa-sized FLT3 protein that could be detected in FLT3-ITD expressing 
cells (MV4-11 and MOLM-13) compared to WT-FLT3 cells (THP-1).  We also 
employed the flow cytometry to evaluate the cell surface localisation of FLT3 
using CD135 antibody conjugated to phycoerythrin (PE), and WT-FLT3 and 
FLT3-ITD expressing cells exhibited different cell surface expression levels 
with the WT cells being higher than those containing ITD mutations. Therefore, 
the lower surface level of FLT3 in MV4-11 is a consequence of different cellular 
distribution rather than transcript or protein expression differences. Indeed, 
MV4-11 has more mRNA level than THP-1 and upon permeabilization the 
surface FLT3 level was increased dramatically. This may has an implication in 
drug resistance as the ITD receptor can be traffic to the cell surface as a result 
of kinase inhibition.  
 
Physiologically, FLT3 is normally expressed at low levels in hematopoietic 
progenitor cells (Rosnet et al., 1996b). In AML patients, in addition to being 
mutated, the leukemic cells frequently overexpress FLT3 with 90% of the 
patients found to have overexpressed the FLT3 receptor (Carow et al., 1996, 
Rosnet et al., 1996b). FLT3 activity depends on the binding of FLT3L, which 
is not exclusively expressed in hematopoietic cells, rather it is expressed in a 
variety of tissues (Brasel et al., 1995, Meierhoff et al., 1995). Together, these 
observations suggest that the expression level and localisation of mutated or 
wild-type FLT3, and the FLT3L can influence the development of AML. We 
showed that the capacity for further stimulation of ITD-FLT3 by FLT3L was 
directly proportional to the presence of cell surface FLT3. In fact, a study 
suggests that FLT3 mutations result in differential subcellular localisation of 
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the receptor as explained by (Köthe et al., 2013), in which K-Ras and N-Ras 
are equally activated by ligand stimulation of WT-FLT3 and ITD can mediate 
Ras activation at the surface level but not the mislocalised intracellular pool of 
ITD and this ultimately lead to cell transformation. We were interested to 
investigate the possible variation of signalling network in response to FLT3L. 
WT-FLT3 (THP-1) was mainly located on the cell surface and showed a strong 
response to FLT3L. By contrast, FLT3 in ITD expressing cells (MV4-11 and 
MOLM-13) was mainly retained intracellularly and this resulted in a weaker 
response to FLT3L. As has been reported before constitutive activation of 
STAT5 by FLT3-ITD in MV4-11 and MOLM-13 cells occurred is independent 
of FLT3L. Many studies have provided insights into intracellular signalling 
pathways mediated by the FLT3, but only few studies pay attention to the 
differential response of differing FLT3 genotypes to FLT3L (Rosnet et al., 
1996a, Steelman et al., 2008). Additionally, FLT3 signalling in ITD-expressing 
cells have been reported in the literature mainly looking at signalling in a ligand 
independent manner (Choudhary et al., 2005). As FLT3 mutations appear 
exclusively in intracellular domains it is conceivable that the extracellular 
domain remains available for FLT3L binding or sequestration. One group has 
shown that the mutated FLT3 can be further activated by treatment with FLT3L 
which led to a slight increase in phosphorylation of STAT5 and AKT but not 
MAPK in MV4-11s, whereas, in BaF3/ITD cells only MAPK was affected 
(Zheng et al., 2011). This work has shed a light in the possibility of activation 
of FLT3-ITD by exogenous ligand. We explored this idea further using a time 
course of ligand treatment as well as different cells expressing different FLT3 
genotypes. Following stimulation with FLT3L, we observed that AKT and 
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ERK1/2 are signalling pathways of the membrane-bound WT-FLT3 (THP-1). 
We also found that the surface-bound FLT3-ITD is required for the full 
activation of AKT and ERK1/2 but not STAT5 in FLT3-ITD mutant cell lines. 
However, this was not the case with ITD in all experiments we have done as 
for example in Fig 3.11C we didn’t observe activation of ERK1/2 upon ligand 
stimulation but in Fig 3.8B it does.  The basal level of ERK1/2 or AKT 
phosphorylation in MV4-11 cells (ITD) could affect the final activation of these 
kinases by ligand stimulation. We observed that in case if the cells presented 
with high basal level of ERK1/2 or AKT phosphorylation, the cells most likely 
won’t response to 2-10 minutes FLT3L stimulation. On the other hand, THP-1 
and MOLM-13 cells were always sensitive to FLT3L and further activation of 
ERK1/2 or AKT were presented in all experiments. Our result was in 
agreement with what it has been reported previously that STAT5 activation 
occurs with the ITD variant but not ligand stimulated WT receptor and in an 
intracellular compartment, as STAT5 was exclusively activated by ITD, in 
which the majority of receptor is localized intracellularly (Zhang and 
Broxmeyer, 2000, Choudhary et al., 2007, Choudhary et al., 2005). This 
particularly has been studied in AML patient’s samples as the work done by 
Seedhouse and Cao et al groups. (Seedhouse et al., 2009, Cao et al., 2019), 
or in 32D and BaF3 with FLT3-ITD construct and has been linked to the 
transforming potential of leukemogenesis (Mizuki et al., 2000, Spiekermann et 
al., 2003b). In the model we used, STAT5 was only phosphorylated in ITD 
expressing cells but not in FLT3-WT like THP-1 cells even though the cells 
has high level of total STAT5. One possible explanation of this was explained 
by Rocnik et al as STAT5 activation is a consequence of ITD mutation. The 
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finding suggest that disruption of juxtamembrane structure by ITD lead to 
expose of two candidate STAT5 SH2 docking phosphorylation sites (Y589 and 
Y591) and allowed activation of STAT5 (Rocnik et al., 2006). Our work also 
indicated that STAT5 does not response to stimulation by FLT3L at detectable 
levels by immunoblotting in both wild-type and ITD receptor, at least in the cell 
lines we used, and that STAT5 may not be regulated by surface localised 
FLT3.  
 
The wide range of signalling responses to FLT3 ligand in MV4-11 versus the 
consistent response in THP-1 or MOLM-13 observed in this chapter 
highlighted the crucial concept of AML molecular heterogeneity and how this 
underlie the various response to FLT3 stimulation and ultimately management 
and clinical outcome of AML patients. The different observations between our 
work and Zheng et al group could explain the importance of studying ITD 
response to FLT3L and how this might change the sensitivity of AML cells to 
kinase inhibition. One of the limitation of signalling results in this chapter is that 
we used a semi-quantitative approach (immunoblotting), and given the 
important of the signalling in a diseases like AML it’s crucial to employ more 
sensitive proteomic platforms to analyse the biologic complexity of FLT3 
signalling in response to FLT3L. 
 
The exact mechanism by which inefficient glycosylation of FLT3 occurred is 
yet unknown. However, a work led by Schmidt-Arras and his group indicate 
that the inefficient maturation of FLT-3 ITD and as a result it’s low surface 
localisation caused by the constitutive kinase activity of the receptor itself 
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(Schmidt-Arras et al., 2005). The next logical question is that what happen if 
the receptor exposed to kinase inhibition, is that going to change the 
localisation from intracellular compartments to cell surface?. This was 
presented as an observation during several previous studies (Yee et al., 2002, 
Scheijen et al., 2004), but not until a recent work ,published while we are 
investigating the effect of kinase inhibition, showed that tyrosine kinase 
inhibition increases the cell surface localization of FLT3-ITD and taking the 
advantage of this phenomenon by employing FLT3-directed immunotherapy 
as a result of upregulation of the FLT3 target antigen caused by TKIs (Reiter 
et al., 2018).  
 
We next looked into this as if we re-localised FLT3-ITD or WT-FLT3 by TKIs 
or FLT3L using different FLT3 genotypes, what are the possible 
consequences of FLT3L stimulation on surface FLT3 level and also on the 
downstream cascades. We were interested on how the different pools of FLT3 
(both the intracellular and the plasma membrane forms) will react to the kinase 
inhibition and subsequently FLT3L stimulation. That’s to our knowledge has 
not been studied before. The change in cell surface localisation of FLT3 in 
non-permeabilized cells after treatment with quizartinib was tested at several 
time points. MV4-11 and MOLM-13 showed an increased cell surface 
localisation following FLT3 inhibition. This increase may be due to an increase 
in FLT3 expression or possibly the binding of quizartinib to the cytosolic portion 
of FLT3-ITD facilitates glycosylation resulting in increased trafficking to the 
plasma membrane. This effect was not seen with the Type I inhibitor, 
midostaurin, which did not affect FLT3 surface localisation in any of the cells 
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but could block signalling. This data suggest a mechanism by which quizartinib 
induces cytotoxicity through FLT3-ITD by promoting cell surface localisation 
of FLT3 in the MV4-11 and MOLM-13 cells and accompanied by inhibition of 
FLT3 signalling. The regulation of signal transduction relies on the receptor 
localisation and expression. It is well documented that FLT3-ITD is largely 
retained in the ER and causes constitutive activation and phosphorylation of 
the receptor (Schmidt-Arras et al., 2009a). Because quizartinib facilitates full 
glycosylation of FLT3 and trafficking to the plasma membrane, we investigated 
the consequences of changes in FLT3-ITD localisation in the MV4-11 and 
MOLM-13 cells induced by quizartinib but also in the presence of ligand. We 
also studied the effect of FLT3L and quizartinib in the activation of ERK1/2, 
AKT and STAT5, the main representative proteins of FLT3 signalling cascade.   
 
In THP-1 and MOLM-13s, the cell surface localisation is reduced following 
treatment with FLT3L, which is indicative of ligand-induced receptor 
internalization and recycling as seen with other RTKs such as c-KIT (Blume‐
Jensen et al., 1991).  However, there was no changes in MV4-11s, presumably 
as these cells have a homozygous ITD mutation leading to the receptor 
residing almost exclusively inside the cells. In THP-1 and MOLM-13 which 
express WT-FLT3, ERK1/2 and AKT were activated upon stimulation with 
FLT3L; however, this effect was hardly observed in MV4-11s which exhibited 
constitutive ERK1/2 and AKT activation. Since quizartinib has no effect on 
THP-1 cells, ERK1/2 and AKT activation were sustained by FLT3L. Short term 
FLT3L stimulation (2 minutes) to quizartinib pre-treated MOLM-13s and MV4-
11s lead to decrease in the surface localised FLT3 when compared to 
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quizartinib only treated condition, yet restoration of ERK1/2 and AKT activation 
only observed in MOLM-13s but not MV4-11s. MOLM-13 cell harbours a 
heterozygous ITD mutation and therefore still expresses WT-FLT3 which can 
be activated by the ligand. This data and in consistent with published data 
suggests that the phosphorylation of ERK1/2 and AKT is driven mainly from 
the activation of WT-FLT3 expressed on the cell surface and not the 
intracellular ITD form. It also shows the disparity between the homozygous 
and heterozygous ITD mutations. It is also tell us that FLT3L is able to induce 
both surface bound-ITD and WT-FLT3 internalization, even though the 
internalization of FLT3 was more efficient with WT form. Several studies 
described that only the ER localised FLT3-ITD can activate STAT5 (Yoshimoto 
et al., 2009). As expected, STAT5 in ITD cells does not respond to FLT3L, and 
its phosphorylation was inhibited by quizartinib treatment. 
  
Of note, most studies examining FLT3-ITD in cell lines, have introduced the 
FLT3 mutations into BaF3 or 32D cells (Mizuki et al., 2000, Tse et al., 2000). 
These models do have the benefit of expressing ITD mutations on the same 
cellular background, making delineation of signalling events attributed to FLT3 
and ITD signalling much easier. They also have their drawbacks as they are 
based on overexpressed receptors and even when stably expressed, 
depending on the promoter of the plasmid, used they will have much higher 
expression than endogenous. This may lead to a different data interpretation 
when compare to AML cell lines as in Zheng et al work that discussed above.  
They are also of murine origin, may contain murine FLT3 and this could 
potentially heterodimerise with the human receptor or bind the human ligand 
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this is in addition to containing their own unique genetic background of 
mutations that could similarly affect FLT3 signalling. Although the human and 
murine FLT3 is highly conserved, some studies have indicated that there are 
potentially biologic differences in downstream signalling pathways for instance 
(Zhang and Broxmeyer, 2000, Beslu et al., 1996). Both are IL-3 dependent, 
which amongst other pathways strongly activates STAT5 and therefore they 
require starvation prior to experimentation. IL-3 withdrawal induces apoptosis 
in both lines so getting the balance between starvation to reduce signalling, 
but not initiate early apoptosis, whose cleavage events can start hours before 
any common markers (Annexin V staining) are seen, can make interpretation 
difficult. ITD expression is also sufficient to transform these cells which is 
different to the action of FLT3 in AML in humans as additional mutations are 
required (Mizuki et al., 2000). This may be due to expression levels as 
mentioned above. On the other hand, the genetic background is more 
complicated in human AML cell lines and the ITD mutation usually occurs with 
other molecular abnormalities. In the context of our project, the expression of 
human FLT3 in a murine cellular context may not represent the molecular 
biology of FLT3 in a human leukemic cell. We therefore believed that using 
human AML cell lines that have naturally occurring FLT3-ITD mutations for 
signalling study could represent the significant of AML heterogeneity status as 
appeared in patients. Accordingly, using cell models of chronic myelogenous 
leukaemia (CML) have been essential for better understanding the biology of 
the diseases and led to advancement in therapeutic approaches like imatinib, 




Collectively, changes in the subcellular localisation of FLT3 induced by 
quizartinib and FLT3L impacts the function of FLT3 and downstream 
signalling. We showed that FLT3L can promote ITD activation of its signalling 
(ERK1/2 and AKT), and also that the ligand can bind to and internalize the 
replenished cell surface receptor pool following TKI treatment In the MOLM-
13s, ERK1/2 and AKT signalling was restored meaning the WT receptor must 
be available for signalling and as quizartinib has no effect on this form, FLT3L 
would act to promote proliferation in quizartinib-treated patients with 
heterozygous ITD/WT mutations. This can be utilized more to further clarify 
the different biological response of FLT3 mutants and WT forms and suggests 
new avenues for therapeutic approaches to treat ITD-mutated AML. The 
second-generation inhibitor, quizartinib had a greater effect on cell surface re-
localisation than multi-kinase inhibitors such as midostaurin. In this context, 
second generation ITD inhibitors may show reduced efficacy in ITD mutation 
(homozygous or heterozygous) positive patients when these patients also 
present with high serum levels of FLT3L. The disparities in response to TKIs 
and FLT3L reinforce the importance of assessing the modulation of 
intracellular signalling and also to characterize the biology of individual AML 
patents in the context of genetic alterations for the best prognostic outcome. 
Overall, these data suggest that FLT3L is able to act on both WT- and ITD-
FLT3, possibly contributing to drug resistance in AML. In next chapter we will 
be looking to possible resistance mechanisms induced by FLT3L in both 




















Investigating the mechanism of 
resistance to quizartinib mediated 












FMS-like Tyrosine Receptor 3 (FLT3) plays a critical role in the differentiation 
and survival of hematopoietic stem cells in bone marrow. An internal tandem 
duplication (ITD) in the juxtamembrane domain of FLT3 is an important driver 
mutation in AML and has been reported in approximately 25-30% of patients. 
The prognosis for AML patients with this mutation, particularly those who have 
lost the wild-type (WT) allele, is far worse than patients possessing only the 
WT receptor (Whitman et al., 2001).  
 
FLT3L exists as a transmembrane homodimer consisting of two short chain α-
helical bundles. FLT3L is constitutively made by fibroblasts and endothelial 
cells, and is abundantly expressed in most human tissues, including the bone 
marrow and peripheral blood. As FLT3 expression is mainly restricted to early 
progenitor cells and FLT3L expression is relatively ubiquitous, FLT3 signalling 
is dictated more by the presence of FLT3 rather than FLT3L (Matthews et al., 
1991).  
 
FLT3 resides in an inactive state at the cell membrane as a result of the 
autoinhibitory conformation of the JM domain. Binding of FLT3L to inactive 
FLT3 induces receptor homodimerization to produce the active dimer form and 
stabilizing the receptor in an open conformation (Turner et al., 1996). This then 




ITD mutations disrupt the autoinhibitory activity of the JM domain and stabilize 
the receptor in the ‘open,’ ATP-binding conformation resulting in ligand-
independent, constitutive dimerization and activation of the FLT3 signal 
transduction cascade (Kiyoi et al., 2002). Whereas, normal FLT3 activation 
requires binding of FLT3L, and the ITD mutants are constitutively active 
despite this exogenous FLT3L can also further activate both homozygous and 
heterozygous ITD to different extents as we previously showed. 
 
The biological and clinical significance of mutated FLT3 in leukaemia makes it 
a promising avenue for the treatment of patients with FLT3 mutations. For this 
reason, several selective FLT3 inhibitors have been developed; including the 
first-generation multi-targeted kinase inhibitors, such as midostaurin, sunitinib 
and lestaurtinib, and more selective second-generation kinase inhibitors, such 
as quizartinib, gilteritinib and crenolanib (Larrosa-Garcia and Baer, 2017, 
Garcia and Stone, 2017). Despite promising responses in preclinical models, 
most of the clinical trials using FLT3 inhibitors as single agents or in 
combination with conventional cytotoxic chemotherapies have not been 
completely successful (Weisberg et al., 2010).  
 
Several mechanisms of resistance have been identified which negatively 
impact inhibitor efficacy compromising FLT3-targeted therapeutic strategies. 
One such mechanism in refractory AML patients is treatment-induced 
elevation of plasma levels of FLT3L that appear to antagonise the efficacy of 






It has been reported that following chemotherapy or FLT3 inhibitor treatment 
many AML patients are found to express increasing serum levels of FLT3L 
(Sato et al., 2011, Levis et al., 2011). Given most FLT3-ITD mutations are 
heterozygous many cells are likely to express one wild-type copy of the FLT3 
gene that would respond to FLT3L. FLT3L-FLT3 responses are known to have 
a proliferative effect on cells, however the effect of FLT3L on the inhibitory 
action of quizartinib is unclear. 
 
The aim of this chapter is to discover the mechanism by which FLT3L may 
cause resistance to FLT3 inhibitors.  We will also uncover how the FLT3 
genotype might play a role in the observed resistance to FLT3 inhibition. 
Resulting future strategies to overcome the effect of FLT3L on FLT3 inhibition 















4.2 Results  
4.2.1 Effect of FLT3-ligand on quizartinib-induced apoptosis in FLT3-ITD 
AML cells 
FLT3L is constitutively expressed in the bone marrow, whether a cell is 
affected depends on its FLT3 expression. FLT3L-FLT3 interactions are known 
to have a proliferative effect on early hematopoietic progenitor cells, dendritic 
cells and NK cells (McKenna et al., 2000). Pathologically, an increase in FLT3L 
as a cellular response to chemotherapy, FLT3 inhibitors or BH3 mimetics has 
been reported as a cause of resistance to FLT3-targeted therapy (Zhou et al., 
2009, Stölzel et al., 2010). We first tested the effect of FLT3L on quizartinib 
treatment in different FLT3-ITD–mutated cells (homozygous and 
heterozygous ITD). MV4-11 and MOLM-13 were used as we have previously 
shown that these cells are sensitive to FLT3-ITD inhibition. 
 
Cells were treated with quizartinib (0.1 µM) in the presence or absence of 
FLT3L (100 ng/ml) for 48h and the effect on cell death measured using 
Annexin V staining. Quizartinib alone induced about 32% and 49% apoptosis 
in MV4-11 and MOLM-13 cells respectively. Co-treatment with both quizartinib 
and FLT3L resulted in a significant reduction in apoptosis by 30% in MOLM-
13 compare to 11% in MV4-11 cells (Fig 4.1A).  
 
Treatment with increasing concentrations of quizartinib (0.01-10 µM) resulted 
in an increase in the cell death that was reduced in the presence of FLT3L (Fig 
4.1B). The IC50 of quizartinib against homozygous ITD MV4-11 cells was 31 
nM compared with 97 nM in the presence of exogenous FLT3L.  
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In heterozygous ITD-expressing MOLM-13 cells the protective effect of FLT3L 
was more pronounced as the IC50 increased from 6 nM to 49 nM (Table 4.1). 
 
Table 4.1 – IC50 of quizartinib on ITD expressing cells 
Cell line and Cytogenetics compound IC50 (72h) 
MV4-11(FLT3-ITD+/+) 
 
Quizartinib 31 nM 
Quizartinib + FLT3L 97 nM 
MOLM-13 (FLT3-ITD-/+) 
 
Quizartinib 6 nM 
Quizartinib + FLT3L 49 nM 
 
 
To determine whether the concentration of FLT3L used was important, cells 
were treated with a fixed concentration of quizartinib (0.1 µM) in the presence 
of increasing concentrations of FLT3L. Reduction of quizartinib-induced 
cytotoxicity by FLT3L did not vary significantly between FLT3L doses ranging 
from 5-100 ng/ml. The largest inhibition was observed at 100 ng/ml and 
therefore this was used for subsequent experiments (Fig 4.1C). Time course 
analysis indicated that co-treatment of 0.1 µM quizartinib and 100 ng/ml FLT3L 
resulted in a significant reduction in cell death when compared with quizartinib 
treated cells. This effect was more pronounced in the MOLM-13s compare to 
MV4-11s which is likely due to the association of exogenous FLT3L with the 




Next, we wanted to assess whether FLT3L can have a similar inhibitory effect 
on the multi-kinase inhibitors, (which can inhibit WT-FLT3 in addition to ITD-
FLT3). To explore this further, MV4-11, MOLM-13 and THP-1 cells were 
treated with different FLT3 inhibitors including midostaurin, gilteritinib, and 
sorafenib. Midostaurin and sorafenib are classified as first-generation 
inhibitors, whereas gilteritinib is a second-generation FLT3 inhibitor like 
quizartinib.  
 
We have previously shown that quizartinib is selective for ITD-FLT3 and 
consequently has no effect on cells expressing WT-FLT3 alone or on FLT3L 
signalling in these cells. Midostaurin, however, has similar potency against WT 
and ITD (Figs 3.2). To test the response of FLT3 mutational status to sorafenib 
and gilteritinib, we first measured apoptosis induction by these inhibitors in the 
absence of ligand (Appendix Fig A1). Results show that sorafenib has more 
selectivity towards ITD-FLT3 as in THP-1s, no significant apoptosis was 
observed with up to 10 µM sorafenib. Gilteritinib inhibit both ITD and WT with 
more selectivity against ITD. 
 
Unlike with quizartinib (Appendix Fig A2), the addition of FLT3L was unable to 
rescue midostaurin and gilteritinib treated cells, however, the FLT3L reduces 
the cytotoxicity of sorafenib (Fig 4.1E). The IC50 of all four inhibitors in the 




















Quizartinib     -      +      -      +
FLT3L             -       -      +      +
MV4-11
       -      +      -      +























































































































































































































Midostaurin     -    +     -   +
FLT3L               -    -     +   +
MV4-11 MOLM-13 THP-1
 -    +    -    +
 -    -     +   +
 -    +    -    +





















Gilteritinib    -    +     -   +
FLT3L           -    -     +   +
MV4-11 MOLM-13 THP-1
 -    +    -    +
 -    -     +   +
 -    +    -    +





















Sorafenib    -    +     -   +
FLT3L          -    -     +   +
MV4-11 MOLM-13 THP-1
 -    +    -    +
 -    -     +   +
 -    +    -    +





















Figure 4.1: Effect of FLT3L on apoptosis induction by FLT3 inhibitors in  
FLT3-ITD expressing cells – A) MV4-11 and MOLM-13 cells were treated 
with quizartinib (0.1 µM) in the presence of FLT3L (100 ng/ml) for 48h following 
which apoptosis was assessed by Annexin V/PI staining. B) Cells were 
exposed for 48h to the indicated concentrations of quizartinib in combination 
with FLT3L (100 ng/ml) and cell death measured by flow cytometry.  C) Cells 
were treated with increasing concentrations of FLT3L in combination with 
quizartinib (0.1 µM) for 48h after which apoptosis measured using Annexin 
V/PI staining. Results represent the mean +/- SEM for 3 independent 
experiments. Significance testing was done by one-way ANOVA with 
Dunnette’s multiple comparison test (n=3), *P ≤0.05, **P ≤0.01 and ***P 
≤0.001. D) Cells were treated with quizartinib (0.1 µM) and/or FLT3L (100 
ng/ml) for indicated times and assessed by AV/PI. Scatter plots are 
representative of cells after 48h treatment). E) MV4-11, MOLM-13, and THP-
1 were treated with midostaurin (0.1 µM), gilteritinib (0.1 µM), sorafenib (1 µM) 
in the presence of FLT3L (100 ng/ml) for 72h. Apoptosis was measured at 
indicated times using Annexin V/PI. Significance testing was done by two-
tailed paired t-test (n=5),*P ≤ 0.05, **P ≤ 0.01, ***p ≤ 0.001 and ns, not 
significant. Results represent the mean +/- SEM for 5 independent 
experiments. F) IC50 of FLT3 inhibitors against AML cells in the presence 




























4.2.2 Effect of FLT3-ligand on proliferation of quizartinib treated ITD 
expressing cells 
To further investigate the mechanism by which FLT3L can impair the efficacy 
of ITD inhibition, we treated MV4-11 and MOLM-13 cells with quizartinib and 
analysed cell survival and proliferation following quizartinib treatment in the 
presence of FLT3L. Survival assays performed by counting viable cell 
numbers demonstrated that exogenous FLT3L promoted the survival of 
quizartinib treated cells.  MOLM-13s, in particular, exhibited significant 
protection when cultured in the presence of FLT3L. These data are consistent 
with previous results suggesting that FLT3L can contribute to resistance to 
FLT3 inhibition by prolonging the survival of cells expressing ITD-FLT3 in the 
presence of quizartinib (Fig 4.2A). 
 
Proliferation is a critical process for the maintenance and progression of 
cancer. We measured the effect of quizartinib combined with FLT3L on 
proliferation of the AML cells using a CFSE dilution assay monitored by flow 
cytometry. In untreated cells the fluorescence intensity of CFSE was reduced 
in both cell lines in a time-dependent manner. This indicated the cells were 
proliferating normally as the concentration of the dye, and hence the 
fluorescence, reduces with each division. 
 
In the presence of quizartinib, the loss of fluorescence was markedly slowed 
indicating that proliferation was reduced in these cells. Co-treatment with 
quizartinib and FLT3L did not appear to alter proliferation compared to 
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quizartinib treatment alone indicating that FLT3L did not reverse the decrease 















Figure 4.2: Effect of FLT3-ligand on proliferation of FLT3-ITD expressing 
cells – MV4-11 and MOLM-13 cells were treated with quizartinib (0.1 µM) in 
the presence of FLT3L (100 ng/ml) for indicated times. A) Cell numbers were 
assessed by trypan blue exclusion assay. B) Proliferation was measured using 
CFSE staining. CFSE results are expressed as mean fluorescence intensity 
(MFI). Results represent the mean +/- SEM of 3 independent experiments. 
 
4.2.3 Effect of FLT3-ligand and quizartinib on cell cycle progression in 
FLT3-ITD expressing cells 
We next looked at the effects quizartinib and FLT3L had on cell cycle 
progression in the ITD-expressing AML cells. Cell cycle analysis was 
performed on treated and fixed cells using propidium iodide staining followed 
by flow cytometry. MV4-11 and MOLM-13 cells were treated with quizartinib 
(0.1 µM) or FLT3L (100 ng/ml) or a combination of both for 48-72h following 
which cell cycle distribution was analysed (Fig 4.3). 
 
As the result shown in previous chapter, 24h treatment with quizartinib alone 
resulted in G0/G1 cell cycle arrest. Here we presented the result of 48-72h as 
we started to see the effect of FLT3L on quizartinib. In both cell lines the 
increase in the sub-G1 population likely representing cells undergoing 
apoptosis. As was observed previously the MOLM-13 cells appeared more 
sensitive. Co-treatment of the cells with FLT3L and quizartinib for 72h 
decreased the sub-G1 population. This protective effect was much more 
pronounced in the MOLM-13s as the sub-G1 peak decreased (from 75 to 16 
%) compared to the MV4-11s (from 33 to 26 %) again likely due to the fact that 
these cells expressing WT as well as ITD-FLT3. These data support previous 
findings that suggest the role of FLT3L in drug resistance and suggests that 
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FLT3L expression could be responsible for quizartinib resistance in ITD-
expressing cells. FLT3L alone did not affect cell cycle progression in either cell 
line for all time points used 24 to 72h. Taken together, these data support the 
previous findings suggesting a role for FLT3L in quizartinib resistance which 





Figure 4.3: FLT3L decreases quizartinib-induced cell cycle arrest in 
FLT3-ITD-/+ cells – MV4-11 and MOLM-13 cells were treated with quizartinib 
(0.1 µM) in the presence of FLT3L (100 ng/ml) for indicated times. Cell cycle 
analysis was performed on fixed cells using PI staining followed by flow 
cytometry. Results represent the mean +/- SEM of 3 independent experiments. 
 
4.2.4 Role FLT3 localisation plays in quizartinib resistance in FLT3-ITD 
expressing cells 
It is known that FLT3 is partially glycosylated in the ER before being 
transported to the Golgi complex where further modification takes place 
(Schmidt-Arras et al., 2005). Only the fully glycosylated form is trafficked to the 
cell surface.  We have previously shown that FLT3 is present in the AML cells 
161 
 
in a partially glycosylated form (130 kDa) which represents that residing in an 
intracellular compartment or as a fully glycosylated form (160 KDa) 
representing that expressed at the cell surface. We next investigated whether 
the localisation of these different FLT3 species plays a role in the differential 
sensitivity observed with quizartinib and the protective effect of FLT3L. 
 
FLT3L can activate WT and ITD-FLT3 at the plasma membrane level, however 
only the ITD form is potentially active before reaching the cell surface. To 
investigate if FLT3 cell surface localisation can alter the effect of FLT3L-
mediated resistance, cells were treated with either the glycosylation inhibitors, 
Tunicamycin or Brefeldin A (BFA) which blocks ER to Golgi transport prior to 
FLT3 inhibition (Helenius and Aebi, 2004).  
 
Tunicamycin inhibits glycosylation at the ER so will impair production of both 
130 and 160 kDa forms of the receptor. BFA will inhibit maturation of the 
receptor from the 130 kDa to the 160 kDa forms in the Golgi. First, we checked 
the effectiveness of glycosylation inhibition to modulate FLT3 surface 
localisation and its signalling in our AML cell model. MV4-11 (ITD) and THP-
1(WT) cells were treated with BFA or Tunicamycin and the FLT3 signalling 
analysed by immunoblotting. Both inhibitors resulted in the loss of 130 kDa or 
160 kDa FLT3 forms in ITD and WT cells as indicated in total FLT3 blot in 
Figure 4.4, which indicate the loss of surface localisation of FLT3 as confirmed 
by FACS in next section Fig 4.5B. However, phosphorylation of ERK1/2 and 
AKT was inhibited. Notably, in ITD-expressing cells Tunicamycin or BFA 





Figure 4.4: Tunicamycin and BFA alter glycosylation state and modulate 
FLT3 signalling – MV4-11 and THP-1 cells were treated with indicated 
concentrations of Tunicamycin or BFA for 24h. Total cellular protein extracts 
were separated by 10% SDS-PAGE and subjected to immunoblot analysis 
with antibodies against known FLT3 signalling intermediates; phospho-
STAT5, -AKT, -ERK1/2, and their unphosphorylated forms. β-actin was used 
as a loading control. n=1. 
 
Treatment with Tunicamycin or BFA results in ER stress through the 
accumulation of unfolded proteins in the ER. Therefore, we tested the 
cytotoxicity of these inhibitors in MV4-11 and MOLM-13 cells and observed a 
dose and time-dependent induction of cell death with increasing 
concentrations of both drugs over three-day period (Fig 4.5A). 
 
Flow cytometry results showed that starting from 0.1 µM concentration,  
brefeldin A and tunicamycin treatment caused a reduction in cell surface FLT3 
(CD135) expression, and this was more pronounced in the MOLM-13 cells as 
we have previously shown that MV4-11 cells have low levels of FLT3 on the 
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cell surface in untreated cells (Fig 4.5B). Western blot analysis of total FLT3 
indicated that tunicamycin lead to the complete inhibition of FLT3 glycosylation 
and resulted in accumulation of the unglycosylated form (110-120 kDa) (Fig 
4.5C). As expected BFA treatment only resulted in inhibition of the fully 
glycosylated form. 
 
To check whether the inhibition of FLT3 glycosylation and cell surface 
localisation would prevent the FLT3L induced ERK1/2 and AKT activation, we 
treat MOLM-13 cells with 0.1 µM BFA in the presence of quizartinib for 24h 
following by FLT3L stimulation for 2 minutes.  Activation of ERK1/2 and AKT 
by FLT3L was blocked in the presence of BFA (Fig 4.5D). Annexin V/PI 
staining showed that the reduction in quizartinib-induced apoptosis by FLT3L 
was also attenuated following BFA or tunicamycin treatment (Fig 4.5E-F).  
These results indicate that cell surface localisation of FLT3 is crucial for FLT3L 
to cause resistance to quizartinib. Inhibition of FLT3 trafficking to the cell 
















































Figure 4.5: Tunicamycin and BFA abrogates FLT3L protective effect on 
FLT3 inhibition by quizartinib – A) MV4-11 and MOLM-13 cells were 
incubated for indicated times with increasing concentrations of Tunicamycin or 
BFA Following which apoptosis was measured using Annexin V/PI staining. B) 
Cells were treated with increasing concentrations of Tunicamycin or BFA for 
12h followed by staining with CD-135-PE (anti-FLT3) or IgG-PE (control) 
antibodies. Cells were then analysed for cell surface FLT3 expression by flow 
cytometry, n=2. C) MOLM-13 cells were treated with tunicamycin and BFA for 
12h and total protein (20 µg) was subjected to immunoblot analysis with a 
FLT3 antibody. β-actin was used as a loading control. D) MOLM-13 cells were 
treated with BFA (0.1 µM) and quizartinib (0.1 µM) for 24h. Next day, the cells 
were stimulated with FLT3L (100 ng/ml) for 2 minutes. Total protein extracts 
were separated by 10% SDS-PAGE and subjected to immunoblot analysis 
with indicated antibodies. E-F) Cells were incubated for 24 and 48h with of 
Tunicamycin (0.1 µM), BFA (0.1 µM), and quizartinib (0.1 µM) with or without 
FLT3L as indicated.  Apoptosis was measured at indicated times using 
Annexin V/PI. Significance testing was done by two-tailed paired t-test (n=3), 
**P ≤ 0.01 and ***p ≤ 0.001. Results represent the mean +/- SEM for 3 
independent experiments. 
 
4.2.5 Role of the Bcl-2 protein family in cell death induced by quizartinib 
in ITD cells   
In many cancer types, the balance between pro- and antiapoptotic Bcl-2 family 
members is disrupted leading to chemoresistance. To examine the potential 
role Bcl-2 proteins play in both the cytotoxicity-induced by quizartinib and the 
protective effect of FLT3L we first looked at their expression in the ITD-
expressing cells.  
 
Both cell lines expressed a number of anti-apoptotic proteins including Bcl-2, 
Bcl-XL and Mcl-1 as well as the pro-apoptotic effector proteins Bak and Bax 
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(Fig 4.6A-B). Basal levels of Bim, a pro-apoptotic BH3-only protein, were very 
low in untreated cells. Treatment with quizartinib caused a decrease in Mcl-1 
expression in both cell lines but this was more pronounced in the MOLM-13s. 
Downregulation of Mcl-1 was accompanied by a marked increase in the 
expression of Bim. No significant change was observed in the other Bcl-2 
family proteins following treatment. FLT3L increased Mcl-1 expression in both 
lines but again levels of the other Bcl-2 proteins remained unchanged. Co-
incubation of FLT3L with quizartinib did not affect the MV4-11 cells as Mcl-1 
levels were still reduced and Bim levels increased similar to treatment with 
quizartinib alone. In FLT3L treated MOLM-13s ,however, Mcl-1 levels were 
slightly higher than in those treated with quizartinib and the increase in Bim 






                    
B)  
 
Figure 4.6: Mcl-1 and Bim levels are modulated by FLT3 inhibition and 
activation – A) MV4-11 and MOLM-13 cell lines were treated with quizartinib 
(0.1 µM) and/or FLT3L (100 ng/ml) for 24 and 72h, followed by immunoblotting 
with indicated antibodies. β-actin was used as a loading control. Apoptosis 
was measured at indicated times using Annexin V/PI. Significance testing was 
done by two-tailed paired t-test (n=3), **P ≤ 0.01 and and ns, not significant. 
B) Densitometric levels of protein bands intensity in (A) was normalized to β-
actin then each value was calculated in relative to untreated cells. Results 







Quizartinib   -      +      -      +
FLT3L           -       -      +      +
MV4-11 (72h)
       -      +      -      +







































































































4.2.6 Role of Mcl-1 in ITD-expressing AML 
Down regulation of Mcl-1 with a concomitant upregulation of Bim could 
potentially be one mechanism through which quizartinib induces apoptosis in 
ITD-expressing cells.  This would mean that FLT3 potentially regulates both 
Mcl-1 and Bim.  
 
To investigate whether Mcl-1 can be regulated by FLT3 we first analysed its 
expression in THP-1s and the ITD-expressing AML cell lines. The results 
indicated that FLT3-ITD cells (MV4-11 and MOLM-13) express high basal 
levels of Mcl-1 compared to WT-FLT3 cells such as the THP-1s (Fig 4.7A). 
However, when FLT3 was activated in the THP-1s with FLT3L, we observed 
a significant upregulation of Mcl-1. This effect was specific to Mcl-1 as no 
change was observed in Bcl-2 following FLT3L treatment. This indicates that 
FLT3L can regulate Mcl-1 expression through WT-FLT3 and suggests that the 
high basal level of expression seen in the MV4-11 and MOLM-13 cells is likely 
due to the constitutively active ITD-FLT3. 
 
We have previously seen downregulation of Mcl-1 in both ITD-expressing cell 
lines following ITD inhibition and this could provide a potential mechanism for 
quizartinib-induced cell death. Upregulation of Mcl-1 could also explain the 
pronounced protective effect of FLT3L seen in the WT-FLT3-expressing 
MOLM-13 cells (Fig 4.6). To confirm ITD-regulation of Mcl-1 we used FLT3 
siRNA in the MV4-11 and MOLM-13 cell lines. FLT3 siRNA effectively knocked 
down FLT3 in both cell lines as judged by Western blotting (Fig 4.7B). This 




Mcl-1, as well as being an antiapoptotic protein is also a caspase substrate 
during induction of apoptosis, and therefore the possibility exists that the 
downregulation seen following ITD inhibition or FLT3 siRNA was a 
consequence of cell death rather than direct downregulation through FLT3 
signalling pathways.   
 
To investigate this, ITD cells were treated with quizartinib together with the 
broad-spectrum caspase inhibitor, z-VAD-FMK (Fig 4.7C).  Inhibition of FLT3-
ITD was confirmed by a reduction in STAT5 phosphorylation. As expected, 
quizartinib induced Mcl-1 downregulation, Bim upregulation, and procaspase 
3 cleavage in both cell lines with both Mcl-1 and Bim levels modified within 
24h of ITD inhibition. z-VAD-FMK abrogated procaspase 3 processing but also 
rescued Mcl-1 suggesting this may be linked to caspase activation. 
Interestingly, Bim was upregulated even in the presence of z-VAD-FMK 
demonstrating this was independent of cell death. AV/PI results showed that 
Z-VAD-FMK attenuated the apoptosis induced by quizartinib. Taken together, 
these findings suggest that down regulation of Mcl-1 by quizartinib may be 
through the caspase cleavage. This would make the down regulation of Mcl-1 
a consequence of quizartinib-induced cell death rather than a causative event. 
This would still cause an imbalance between Bim and Mcl-1 potentially 
controlling the ITD cells sensitivity to apoptosis following inhibition.  
 
To confirm a role further for Mcl-1 in FLT3L signalling we used siRNA to 
specifically knockdown the expression of Mcl-1 in the ITD cells and then tested 
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their sensitivity toward quizartinib and potential rescue by FLT3L. Transfection 
of MV4-11 and MOLM-13 cells with Mcl-1 specific siRNA but not with control 
siRNA significantly reduced Mcl-1 protein whereas Bcl-2 levels were 
unaffected (Fig 4.7D).  Mcl-1 knockdown alone induce significant cell death 
with about 30% apoptosis in both cell lines prior to quizartinib treatment. 
Consequently, upon treatment with quizartinib, there was an increase in 
apoptosis of both cells with Mcl-1-targeting siRNA compared to control siRNA 
(Fig 4.7E). To test if reduction in Mcl-1 inhibits the protective effect of FLT3L, 
we also treated siRNA transfected cells with quizartinib and FLT3L. FLT3L had 
no protective effect on Mcl-1 siRNA transfected cells compare to control siRNA 
or non-transfected cells. Both experiments showed that Mcl-1 knockdown 
renders FLT3-ITD cells more sensitive to the FLT3 inhibitor quizartinib and 
prevent the protective effect by FLT3 ligand. 
 
To further establish the role of Mcl-1 in ITD-expressing AML cells we used an 
Mcl-1 inhibitor, S63845 (Kotschy et al., 2016). Induction of cell death following 
treatment with quizartinib or Mcl-1 inhibition was assessed using Annexin V/PI. 
Cells were treated for 24 and 48h with increasing concentrations of S63845 
(10 – 200 nM) or quizartinib (100 nM) or the two drugs in combination. A dose-
dependent induction of apoptosis was seen in MV4-11 and MOLM-13 cells 
following treatment with S63845. In MOLM-13s, treatment with S63845 in 
combination with quizartinib appeared to have an additive effect compared to 
the compounds as single agents. This additive effect was not observed in 




Upregulation of Mcl-1 in both cell lines could potentially provide an explanation 
for the protection observed with FLT3L. We therefore hypothesized that Mcl-1 
inhibition would prevent the FLT3L-induced resistance in ITD cells treated with 
quizartinib. We chose the lowest concentration of S63845 (10 nM) and treated 
the cells with quizartinib and FLT3L for 24 and 72h. As before, FLT3L reduced 
quizartinib-induced apoptosis in both cell lines (Fig 4.6G). Apoptosis induced 
by combination of quizartinib and S63845 was not reduced with FLT3L 
suggesting that Mcl-1 could be important for the protective effect. 
 
This was further confirmed by analysis of PARP and procaspase-3 cleavage. 
Quizartinib caused processing of PARP and procaspase-3 that was abrogated 
when co-treated with FLT3L (Fig 4.6H). Processing was also observed in both 
cell lines in combination of quizartinib with S63845 as this was not rescued 
with FLT3L. Collectively, these data support the importance of Mcl-1 for 
survival of the ITD cells and give a rational for targeting Mcl-1 in AML including 
the patient who represents with high FLT3L plasma level after starting the 
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Figure 4.7: Role of Mcl-1 in quizartinib-mediated cell death and FLT3L-
mediated resistance – A) Mcl-1 expression in ITD-expressing cells and THP-
1 cells treated with FLT3L (100 ng/ml, 6h) was analysed by immunoblotting. 
Whole cell lysates were analysed for Mcl-1 and Bcl-1 expression. β-actin was 
used as a loading control. B) ITD-expressing cell lines were transfected with 
FLT3 siRNA (10 nM) for 72h before cells were harvested and analysed by 
Western blotting. C) Cell lines were treated with quizartinib (0.1 µM) and zVAD 
(20 µM) for indicated times after which lysates were analysed by Western 
blotting and apoptosis was measured using Annexin V/PI staining.  D) MV4-
11 and MOLM-13 were transfected with Mcl-1 specific or control siRNAs (10 
nM). Whole cell lysates were analysed for Mcl-1 protein expression. β-actin 
was used as a loading control. E) Cells were transfected with Ctrl or Mcl-1 
siRNA for 72h. For quizartinib/FLT3L experiments cells were treated, 24h after 
transfection with quizartinib (0.1 µM) with or without FLT3L for a further 48h. 
Apoptosis was measured using Annexin V/PI staining. F) Apoptosis following 
quizartinib (0.1 µM) and S63845 (10-200 nM) or combination treatment was 
assessed by Annexin V/PI staining. G) Cell lines were incubated for 24 – 72h 
with quizartinib (0.1 µM), S63845 (10 nM) and/or FLT3L (100 ng/ml) and 
apoptosis measured using Annexin V/PI staining. H) Caspase-3 activation and 
PARP cleavage following quizartinib and S63846 treatment. Results represent 
the mean +/- SEM for 3 independent experiments. Significance testing was 
done by two-tailed paired t-test (n=3), *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001 and 




4.2.7 Role of Bim in quizartinib-induced apoptosis 
Despite our efforts to implicate Mcl-1 in FLT3L-mediated resistance to 
quizartinib its role is still somewhat obscure since inhibition or knockdown is 
cytotoxic even before quizartinib treatment. For this reason, it remains unclear 
whether the downregulation seen following inhibition of FLT3 is simply a result 
of Mcl-1 cleavage during apoptosis rather than a mechanism of quizartinib 
inducing cell death or protection afforded by FLT3L. We also observed that the 
proapoptotic BH3-only protein Bim is significantly upregulated following FLT3 
inhibition, this was independent of cell death as it was unaffected by z-VAD. 
To further understand any potential role for Bim in quizartinib-mediated cell 
death we used Bim siRNA to assess its role in apoptosis following FLT3 
inhibition.   
 
MV4-11 cells were transfected with Bim siRNA for 48h followed by quizartinib 
for 24h. As we had observed previously Bim expression was very low in 
untreated cells but was significantly increased following quizartinib treatment. 
This upregulation was blocked by the Bim-specific siRNA indicating it was 
successfully targeting Bim (Fig 4.8A).  siRNA transfected cells were then 
treated with quizartinib to assess the effects of Bim knock-down on ITD-
inhibition. As we have seen before quizartinib induced apoptosis in cells 
treated with a control siRNA but this was blocked in cells treated with the Bim 
siRNA (Fig 4.8B). Taken together, these results suggest that upregulation of 





A)                                                      B) 
  
 
Figure 4.8: siRNA-mediated knockdown of Bim inhibits quizartinib-
induced apoptosis – MV4-11 cells were transfected with Bim specific or 
control siRNAs (10 nM) for 48h before treatment with quizartinib (100 nM) for 
24h. A) Transfected cells were analysed by Western blotting to validate Bim 
knockdown. B) Apoptosis measured by Annexin V/PI staining. Results 
represent the mean +/- SEM for 3 independent experiments. Significance 
testing was done by two-tailed paired t-test (n=3), *P ≤ 0.05. 
 
 
4.2.8 Activation of FLT3 signalling pathways by FLT3L following 
quizartinib treatment in FLT3-ITD cells 
Based on our earlier results, phosphorylation of ERK1/2, AKT and STAT5 
were decreased in ITD-expressing cells treated with quizartinib. We next 
investigated potential survival signalling pathways activated in these cells by 
FLT3L following ITD inhibition. 
 
MV4-11 and MOLM-13 cells were treated with quizartinib or FLT3L or a 
combination for 24h following which the phosphorylation status of downstream 
signalling proteins was assessed by Western blot. FLT3 is active in both cells 
























ERK/12, AKT, and STAT5. Treatment with quizartinib blocked all these 
pathways in both cells (Fig 4.9A). In MOLM-13 cells, ERK1/2 and AKT 
phosphorylation could still be induced by FLT3L even in the presence of 
quizartinib. By contract, ERK1/2 and AKT phosphorylation status were not 
changed by FLT3L in the MV4-11s.  
 
As we have observed before, In MV4-11 cells there appeared to be a delay in 
protection afforded by FLT3L which only started to reduce quizartinib-
mediated apoptosis after 48h (Fig 4.1D). We therefore treated MV4-11s with 
quizartinib and FLT3L simultaneously for 48h before downstream signalling 
activation was assessed. Under these conditions, ERK1/2 phosphorylation 
was restored but not AKT or STAT5 phosphorylation (Fig 4.9B). This indicates 
that FLT3L reactivates ERK1/2 and to lesser extent AKT through WT-FLT3 in 
MOLM-13, and only ERK1/2 in MV4-11 resulting in reduced sensitivity to 
quizartinib. These observations implicate ERK1/2 and AKT pathways as being 
responsible for the protective effect of FLT3L.  
 
We next investigated whether ERK1/2 or AKT inhibition by selective inhibitors 
could abrogate this resistance and restore quizartinib cytotoxicity in the FLT3-
ITD cells. We used U0126, a MEK1/2 inhibitor to inhibit ERK1/2 and IPI-145, 
a PI3-Kinase inhibitor for the AKT pathway (KERR et al., 2003, Pillinger et al., 
2016). MOLM-13 cells were treated with quizartinib and FLT3L in the presence 
of either U0126 or IPI-145 before pathway analysis by Western blotting and 
cell death analysis. The selectivity of MEK1/2 and AKT inhibitors was 
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confirmed as U0126 inhibited only ERK1/2 phosphorylation, whereas, IPI-145 
inhibits only AKT (Fig 4.9C).  
 
FLT3L can activate ERK1/2 even in the presence of quizartinib however, in 
cells treated with a U0126, FLT3L could not restore ERK1/2 phosphorylation 
(Fig 4.9C). However, Inhibition of AKT with IPI-145 only partially attenuated 
the protective effect of FLT3L. Annexin V/PI results showed that treatment of 
the cells with U0126 alone only caused slight cytotoxicity on its own, however 
it reversed the protective effect of FLT3L. This indicates that inactivation of 
ERK1/2 is sufficient to counteract the protective effect of FLT3L. This effect 
was also observed with U0126 in MV4-11 treated for 48h (Fig 4.9D). This data 
suggests that the protective effect of FLT3L appears to be predominately 
through the ERK1/2 pathway. 
 
As we described earlier, only the type II inhibitors (sorafenib and quizartinib) 
but not type I inhibitors (midostaurin and gilteritinib) could be affected by 
FLT3L (Fig 4.1).  We therefore further tested FLT3 signalling in MOLM-13 cells 
treated with FLT3 inhibitors in combination with FLT3L. We also investigated 
the effect of combining type II inhibitors sorafenib and quizartinib with the MEK 
inhibitor, trametinib which is used to treat metastatic melanoma (Thota et al., 
2015).  
 
All inhibitors blocked constitutive activation of ERK1/2 and AKT (Fig 4.9E). 
FLT3L was able to restore ERK1/2 phosphorylation only following sorafenib or 
quizartinib but not gilteritinib. Co-treatment of sorafenib or quizartinib with 
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trametinib inhibited FLT3L-induced ERK1/2 activation, and interestingly also 
protect the cells from FLT3L-induced Mcl-1 overexpression. The cell death 
results were consistent with those obtained with U0126 and demonstrated that 
FLT3L inhibition of apoptosis induction by type II inhibitors can be restored by 
adding the MEK inhibitor, trametinib (Fig 4.9F). Furthermore, ERK1/2 inhibition 
increased the sensitivity of cells to FLT3 inhibitors-induced apoptosis 
induction.  This was not observed with gilteritinib (Appendix Fig A4).  Inhibition 
of ERK1/2 phosphorylation was observed at trametinib concentration used in 
the experiment without affecting cell viability (Appendix Fig A5). These results 
confirmed that inhibition of MEK/ERK1/2 inhibits the protective effect of FLT3L 
and provides a rationale for overcoming FLT3L-mediated resistance in ITD 
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Figure 4.9: ERK1/2 is crucial for FLT3L to render the FLT3-ITD inhibition 
–  A-B) MV4-11, and MOLM-13 cells were treated with quizartinib (0.1 µM) 
and FLT3L (100 ng/ml) for up to 48h. Total cellular extracts were separated by 
10% SDS-PAGE and subjected to immunoblot analysis with phospho- STAT5, 
-AKT, -ERK1/2, and their unphosphorylated forms. β-actin was used as a 
loading control. C) MOLM-13 cells were treated with indicated treatment for 48 
h, followed by immunoblotting with the indicated antibodies, apoptosis 
assessed by Annexin V staining. D) MV4-11 cells were treated with indicated 
treatment for 48h, followed by immunoblotting with the indicated antibodies, 
apoptosis was assessed by Annexin V.  E) MOLM-13 cells were treated with 
quizartinib (0.1 µM), sorafenib (1 µM), gilteritinib (0.1 µM), trametinib (0.05 µM) 


























indicated antibodies. F) Apoptosis was assessed by Annexin V staining. 
Results represent the mean +/- SEM for 3 independent experiments. 
Significance testing was done by two-tailed paired t-test (n=3), *P ≤ 0.05, **P 
≤ 0.01, and and ns, not significant. 
 
4.2.9 Mcl-1 Expression Is Up-Regulated by the MAPK/ERK Pathway 
We have demonstrated that Mcl-1 is the main anti-apoptotic protein 
downregulated upon FLT3 inhibition by quizartinib, and FLT3L reduces the 
cytotoxicity of FLT3 inhibitors through Mcl-1 upregulation. Also, we showed 
that ERK1/2 and to a lesser extent AKT pathways play an essential role for 
modulation of FLT3 inhibition in the presence of FLT3L. The involvement of 
main FLT3 signalling in Mcl-1 upregulation was examined.  
 
Our previous result indicated that STAT5 remains inhibited either with 
quizartinib treatment or quizartinib plus FLT3L (Fig 4.9A-B), so it’s not act as 
a modulator for FLT3L to induce drug resistance in ITD cells and may not be 
essentially involved in the regulation of Mcl-1. Indeed, we have shown that 
WT-FLT3 does not activate STAT5 even after stimulation with FLT3L and this 
suggest that Mcl-1 upregulation in THP-1 cells stimulated with FLT3L as 
shown in (Fig 4.7A) is linked to other pathways. In contrast to WT, ITD cause 
a constitutive activation of STAT5 and further activation of ITD by FLT3L has 
no effect on p-STAT5 status. To test whether or not STAT5 is necessary in 
ITD to induce Mcl-1 expression we knocked down STAT5 in MV4-11. STAT5 
silencing lead to Mcl-1 downregulation at protein level, however, this could be 
related to cell death observed as a result of the knockdown rather than direct 
regulation of Mcl-1 by STAT5 (Appendix Fig A6). We were not able to use 
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selective STAT5 inhibitor (Ruxolitinib) as the cells maintained STAT5 
phosphorylation throughout experiments. Taken together, STAT5 appears to 
not play an essential role in Mcl-1 upregulation mediated by FLT3 signalling.  
  
As the Mcl-1 downregulation by quizartinib is not a functional effect rather than 
a cell death consequence, we were interested to study if Mcl-1 is regulated by 
MAPK/ERK pathway. First, we checked the apoptosis induction by U0126 
(MEK inhibitor) and IPI-145 (AKT inhibitor) for different time points in MOLM-
13 cells. For both inhibitors, induction of apoptosis has started after 24h 
treatment (Fig 4.10A). To examine which pathway is more implicated in the 
regulation of Mcl-1, we treat MOLM-13 with these two inhibitors for 12h, a time 
point prior to the induction of apoptosis, and Mcl-1 expression was checked 
by immunoblotting. As expected, U0126 treatment inhibits only ERK1/2, and 
IPI-145 inhibits only AKT. Treatment with MEK inhibitor but not AKT inhibitor 
leads to a decrease in the expression of Mcl-1 (Fig 4.10B). 
 
To confirm further the reduction of Mcl-1 protein by ERK inhibition is not a 
consequence of cell death, cells were pre-treated with the pan-caspase 
inhibitor Z-VAD-FMK and MEK inhibitor for 48h. The MEK inhibitor U0126 
reduced the Mcl-1 protein level despite the presence of the caspase inhibitor. 
Together, these results suggest that the Mcl-1 reduction by MEK inhibitor is 
not a result of cell death; however, the MAPK/ERK pathway seems to play a 





 Among the anti-apoptotic Bcl-2 family protein, Mcl-1 is known to have a much 
shorter half-life (Brunelle et al., 2009). Down-regulation of Mcl-1 is thought to 
be regulated by protein degradation through the ubiquitination pathway (Wu et 
al., 2020). MOLM-13 cells treated with the proteasome inhibitor MG132 for up 
to 6h lead to the increase and stabilization of Mcl-1 protein level (Fig 4.10C).  
 
To study if the downregulation of Mcl-1 by ERK1/2 inhibition is mediated 
through the proteasome pathway by enhancing Mcl-1 turnover, cells were 
treated with the MG132 (proteasome inhibitor) for 2h before added MEK 
inhibitor U0126 for 4h. U0126 reduced Mcl-1 protein level even in the 
proteasomal inhibition condition (Fig 4.10C). This result suggests that ERK1/2 
pathway regulates the Mcl-1 protein level in different mechanisms to protein 













































Figure 4.10: MAPK/ERK pathway regulate Mcl-1 expression in FLT3-ITD 
– A) MOLM-13 cells were treated with U0126 or IPI-145 for indicated times 
following which apoptosis was assessed by Annexin V/PI staining. 
Significance testing was done by one-way ANOVA with Dunnette’s multiple 
comparison test (n=3), ***P ≤0.001, ns, not significant. B) MOLM-13 cell were 
treated with U0126 (10 µM) or IPI-145 (1 µM) for 12h, followed by 
immunoblotting with the indicated antibodies. Cells were also treated with 
U0126 with or zVAD (20 µM) for 48h followed by immunoblotting analysis. C) 
Cells were treated with MG132 for up to 6h, or pretreated with MG132 for 2h 
and then treated with U0126 for 4h followed by immunoblotting analysis. β-





4.3 Discussion:  
Over the last decade, FLT3 has been considered a potential molecular target 
in a subset of AML cases. The therapeutic effects of several FLT3 inhibitors 
possessing different characteristics have been reported in AML patients 
harbouring FLT3 mutations (Assi and Ravandi, 2018). With the early 
generation of FLT3 inhibitors, the peripheral AML blasts percentages were 
reduced transiently with limited effect on the percentages of bone marrow AML 
blast (Smith et al., 2004). Lacking the specificity of these multi-targeted TKIs 
for FLT3-ITD may explain their transient anti-leukemic activity, especially 
when used as monotherapy (Fischer et al., 2010). Therefore, next-
generation FLT3 inhibitors with greater specificity for FLT3 have been 
developed and shown promising single-agent anti-leukemic activity in clinical 
trials (Perl et al., 2017, Cortes et al., 2018a). Despite the higher response rate 
of selective ITD inhibitors, one of the major obstacles with the use of newest 
FLT3 inhibitors in AML is drug-resistance which has been observed even with 
more recent inhibitors such as quizartinib (Dumas et al., 2019, Smith et al., 
2017, Moore et al., 2020, Alvarado et al., 2014). Although several mechanisms 
of resistance have been identified such as secondary mutations (Smith et al., 
2012a), elevated levels of FLT3L appears to be particularly problematic 
especially as most FLT3 mutations are heterozygous meaning a WT allele is 
still present (Sato et al., 2011). Therefore, further elucidating the resistance 





Human AML stem cells residing in the endosteal niche of the bone marrow are 
relatively chemoresistant (Ishikawa et al., 2007). Indeed, bone marrow 
microenvironment confers a protection to leukaemia cells as a result of 
different survival cues, either through cytokines/growth factors such as 
(PDGF, IL-3, SCF, and FLT3L) or through cell-cell surface contact such as 
SDF1 and CXCR4 (Sison and Brown, 2011, Lane et al., 2009). It has been 
reported that the FLT3-ITD AML blasts circulating in the peripheral circulation 
are sensitive to FLT3 inhibitors, however, FLT3-ITD AML blasts that residing 
within BM exhibit some degree of resistance to FLT3 inhibitors (Smith et al., 
2004). Moreover, studies also suggest that FLT3-ITD leukaemia stem cells but 
not FLT3-WT leukaemia cells can be protected by stromal niche cells and 
reduce the efficacy of first-generation FLT3 tyrosine kinase inhibitor SU5614 
(Parmar et al., 2011). However, the overexpression of FLT3 receptor in AML 
patients, the different allelic ration of ITD/WT, and the releasing of FLT3L may 
have changed the responsiveness of AML cells to all types of FLT3 inhibitors.  
All of these studies suggest that leukaemia niches can provide a protective 
effect on the FLT3-ITD AML blasts from being eradicated by the FLT3 
inhibitors. Sato et al has demonstrated that FLT3-ITD AML cells are still 
responsive to exogenous FLT3 ligand, and also that the FLT3 ligand that is 
expressed in the marrow microenvironment increases the resistance of FLT3-
ITD AML cells to the FLT3 inhibitors (Sato et al., 2011). They also showed that 
the FLT3L levels are routinely elevated in AML patients undergoing therapy 
which also can be a major obstacle when combined with the protective stromal 
effects and so promote resistance to FLT3 inhibitors. Another cytokines, 
Fibroblast growth factor 2 (FGF2), also found to protects FLT3-ITD AML cells 
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from quizartinib treatment through binding to FGFR1 receptor, and the MAPK 
signalling pathway was consistently restored in all FGF2 dependent resistant 
cultures (Traer et al., 2016). Additionally, the FLT3 inhibitor MLN518 lost its 
kinase inhibition activity significantly in the presence of FLT3L in heterozygous 
ITD cells, MOLM-13 and MOLM-14 but not against FLT3-ITD homozygous 
MV4-11 cells (Wang et al., 2016a). The inhibitory effects of MLN518 were 
decreased for FLT3 phosphorylation and/or c-MYC expression and increased 
for pS6K phosphorylation upon FLT3 ligand stimulation, and using dual 
inhibitor of AKT/FLT3-ITD, A674563, was able to overcome FLT3 ligand 
induced drug resistance in vitro and in xenograft models. This subsequently 
led to development of novel FLT3 kinase inhibitor such as G-749 which could 
the next generation of FLT3 inhibitor with an ability to overcome other drug 
resistances conferred by patient plasma, FLT3 ligand, and stromal cells (Lee 
et al., 2014). All of the these studies indicate that the effect of FLT3L is depend 
on the type of AML cells genotype, the cells model, as well as the type of FLT3 
inhibitors being used as there was different mechanism has been proposed 
for the FLT3L mediated-resistance. Given that FLT3-ITD cells have different 
protection and sensitivity towards FLT3 tyrosine kinase inhibitors, it was crucial 
to understand how the cytokines and growth factor like FLT3L could interfere 
in this process and how they can derive resistance to FLT3 inhibitors. 
Therefore, to address these discrepancies in the role of FLT3L, we 
investigated the effect of exogenous FLT3L on the efficacy of different types 
of FLT3 inhibitors using AML cell lines model of WT-FLT3, homozygous and 
heterozygous ITD mutations and provide a novel strategy to overcome this 
emerging resistance mechanism. Although four different FLT3 inhibitors were 
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initially evaluated, we mainly focussed on quizartinib to delineate the 
resistance mechanism mediated by FLT3L.  In the previous chapter, we 
demonstrated that quizartinib cause cell cycle arrest, inhibit cell proliferation 
and induces apoptosis. To explore the mechanism by which FLT3L reduce the 
cytotoxicity effect of quizartinib, we investigated the effects of FLT3L on cell 
cycle, cell proliferation and apoptosis. The FLT3L has no effect on G1 cell 
cycle arrest induced by quizartinib but it decease the sub-G1 population 
starting from day 2 of cell cycle analysis. FLT3L also has no effect on the cell 
proliferation inhibition induce by quizartinib. This indicate that FLT3L mainly 
working against quizartinib through apoptosis pathway. This was confirmed by 
Annexin V/PI and by the previous observation of reducing sub-G1 population.  
 
We demonstrated that FLT3L can attenuate the inhibitory effect of type II FLT3 
inhibitors such as quizartinib and sorafenib in both homozygous and 
heterozygous ITD-expressing cells. By contrast, no such effect was seen with 
the type I inhibitors gilteritinib or midostaurin. Type I inhibitors exhibit a similar 
potency against both WT and ITD-FLT3 and this is likely the reason why 
FLT3L has less effect in a homozygous ITD mutation background (Daver et 
al., 2019). Quizartinib and sorafenib tend to be more selective for ITD-FLT3 
therefore FLT3L-mediated attenuation of quizartinib and sorafenib is a result 
of their weaker inhibitory effect on WT-FLT3 (Levis, 2014, Antar et al., 2017). 
This was clearly seen in the MOLM-13s as the effect of FLT3L on type II FLT3 
inhibitors was more pronounced than that in the MV4-11s. Our result was 
similar to Sato et al work in terms of the effect of FLT3L on FLT3 inhibitors, 
however, by employing AV/PI technique we also showed that only type II but 
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not type I inhibitors can be affected by the presence of FLT3L. This was shown 
as all FLT3 inhibitors can be modulated by FLT3L using MTT assay in Sato et 
al work. We also found that cytotoxicity of type II inhibitors not only reduced 
by FLT3L in heterozygous cells like MOLM-13 or MOLM-14, but also in 
homozygous ITD mutated cells, MV4-11. These results suggest the 
mechanism by which FLT3L decreases the efficacy of FLT3 inhibitors is likely 
due to FLT3L dependent activation of WT-FLT3 as well as with long exposure 
to FLT3L this also can affect to less extent FLT3-ITD receptor. This effect is 
only seen against ITD-selective FLT3 inhibitors such as quizartinib and 
sorafenib. Given that most of AML patients present with heterozygous ITD 
mutations, non-selective FLT3 inhibitors such as midostaurin may be of more 
therapeutic benefit as they can also overcome any protective effect afforded 
by endogenous FLT3L. Therefore, tyrosine kinase genotyping and selection 
of FLT3 inhibitors types may become a prerequisite for optimal clinical use of 
this agent in patients with ITD mutation. 
 
The glycosylation changes in the post translated protein FLT3 has pronounced 
effect on its kinase activity and downstream signalling cascades (Choudhary 
et al., 2009a). Mass spectrometry analysis revealed nine potential N-
glycosylation sites in the extracellular domain of FLT3 indicating the critical 
roles of glycosylation in folding, stability, and functions of FLT3 (Verstraete et 
al., 2011, Pinho and Reis, 2015). Different glycosylation of FLT3 resulted in 
different patterns of FLT3 on Western blots. It is known that there are two forms 
of human FLT3. One appears around 150-160 kDa, and it’s thought to be the 
mature form of the receptor which reside on the cell surface. The other one is 
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an immature form which appears around 130 kDa and mainly localised in the 
ER (Schmidt-Arras et al., 2005). To confirm the heterogeneous pattern of FLT3 
on Western blots, we checked cell lysates of FLT3-WT (THP-1) and ITD-FLT3 
(MV4-11) for total FLT3 expression. The mutant FLT3 presented with one 
band at 130 kDa, and WT-FLT3 presented with two bands at 130 and 160 kDa. 
A lower third band was observed in untreated THP-1s which may be a non-
specific band or could represent the immature unglycosylated form that would 
appear around 110-120 kDa. Cells were treated with two glycosylation 
inhibitors; tunicamycin and BFA and analysed for FLT3 expression pattern and 
activation status of STAT5, AKT, and ERK1/2, which are important pathways 
for FLT3 WT and mutant downstream signalling. In THP-1 (FLT3-WT), 
treatment with both inhibitors lead to decrease in 130-160 kDa forms and this 
suggest that the receptor tend to be retained intracellularly. This was 
accompanied by ERK1/2 and AKT inhibition indicating that surface localisation 
of FLT3 is required for activation of ERK1/2 and AKT which may be a 
problematic when surface FLT3 exposed to FLT3L. In MV4-11 cells with 
homozygous ITD we interestingly found that BFA, which only prevent the 
maturation form of FLT3 (160 kDa), lead to decrease in surface localised 
FLT3. From FACS experiment, we know that there is a minimal level of FLT3 
on the surface of MV4-11 cells and this pool was not detectable by Western 
blotting. The ERK1/2 was more inhibited than AKT by treatment with 
glycosylation inhibitors suggesting that surface localised FLT3-ITD is mainly 
required for ERK1/2 activation. This result suggests that glycosylation is an 
important for FLT3 trafficking to the cell surface, and the surface localisation 
of FLT3 is important for activation of ERK1/2 and AKT in WT as well as ITD 
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FLT3. It also confirmed that STAT5 is mainly activated by intracellularly 
retained ITD not WT receptor, and support the finding of (Schmidt-Arras et al., 
2009b) in which the intracellularly retained FLT3-ITD reduces ERK1/2 and 
AKT activation and further activate STAT5.  
 
We next wanted to investigate the role of surface localised WT or ITD on the 
FLT3L-mediated resistance in our cell lines model taking the advantage of 
several published works suggested targeting proteins such as FLT3 on 
glycosylation process. This basically might be a tool to study the glycosylation 
inhibition rather than a therapeutic molecules as these inhibitors can affect any 
protein folding not just FLT3. Tunicamycin inhibits the transfer of active sugars 
to dolichol phosphate, which is an important step in the N-glycosylation of 
proteins at endoplasmic reticulum, and found to induced a cytotoxic effects 
and enhanced the susceptibility of several cancer cell lines such as head and 
neck carcinoma and lung cancer via glycosylation inhibition (Ahsan et al., 
2010). Furthermore, a recent work showed that interference in FLT3-ITD 
glycoprotein maturation using tunicamycin has an anti-proliferative and pro-
apoptotic effects on FLT3ITD-expressing human cells, and the combination of 
tunicamycin with FLT3-ITD kinase inhibitors caused synergistic cell death 
especially in ITD-expressing cells (Tsitsipatis et al., 2017). Fluvastatin and 2-
deoxy-D-glucose are another examples of drugs that have been used to target 
FLT3 glycosylation and now being evaluated in clinical trial phase I (Williams 
et al., 2012, Larrue et al., 2015). We are aware that these inhibitors can induce 
cytotoxicity through ER stress. Therefore, we realised that further work need 
to be done in order to study the ER stress that can be caused by theses 
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inhibitors and looking for several UPR adaptive activation readouts such as, 
phosphorylation of  PERK or IRE1, XBP1 splicing or processing of ATF6 
(Oslowski and Urano, 2011). The question was if we manipulate the surface 
localisation of ITD and WT using low dose of BFA and tunicamycin ,which 
apparently attenuating FLT3ITD-driven AKT and ERK signalling, can lead to 
abrogate the FLT3L-mediated resistance to quizartinib. To determine the 
lowest concentration which can prevent surface localisation of FLT3 but at the 
same time does not induce significant apoptosis, we tested different 
concentrations varying from 0.01 µM to 10 µM for several time points. The 
dose response curve of tunicamycin and BFA indicate that these inhibitors 
caused cell death in both cell lines (MV4-11 and MOLM-13) to different extent. 
For this reason we checked the dose that required to inhibit the surface 
localisation of FLT3, and FACS results showed that 0.1 µM but not 0.01 µM 
can decrease surface localised FLT3. The 0.1 µM of BFA and tunicamycin 
induce ~10-20% cell death after 24h treatment. Therefore, we picked this 
concentration for MOLM-13 immunoblotting experiment and treat the cells with 
quizartinib plus BFA for 24h, a time we can start observe the effect of FLT3L 
on quizartinib, following by 2 minutes activation by FLT3L in order to study the 
possible rescued downstream cascades. The FLT3L was not able to restore 
ERK1/2 or AKT in the presence of BFA. This give an indication that the low 
dose of BFA prevent signalling rescued and could inhibit the resistance 
mediated by FLT3L. We observed that with BFA treatment in the presence of 
quizartinib and FLT3L, total FLT3 levels decreased. Quizartinib has been 
shown to increase the 160 kDa surface localised FLT3 species, and that BFA 
can prevent maturation of the 130 kDa form into 160 kDa form. We also know 
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that FLT3L will bind to any trace of surface localised FLT3 that is not prevented 
by BFA, and all of these factors could have an implication in the decreasing 
level of total FLT3 we observed in the plot. In order to study if the ERK/12 and 
AKT rescued prevention by BFA treatment would have an effect on the cell 
viability induced by FLT3L in the presence of quizartinib, we treat the cells with 
quizartinib, BFA or tunicamycin with or without FLT3L for 24h-48h. Similarly, 
we used a concentrations (0.1 µM) that has shown the ability to prevent the 
majority of surface localised FLT3 in FACS experiment and also induce the 
minimal cytotoxicity to the cells. Linking the effect of glycosylation inhibitors to 
FLT3-ITD is somehow unreliable for the experiments we have done as THP-1 
total FLT3 surface localised respond to these inhibitors. Whether or not the 
THP-1 cells have the same sensitivity towards these inhibitors is need more 
investigation. However, we can clearly suggest that heterozygous cells as 
MOLM-13 cells are sensitive to BFA and tunicamycin.  Generally, results 
showed that preventing FLT3 maturation and as a result trafficking to the cell 
surface using glycosylation inhibitors inhibits the effect of FLT3L on both WT 
and ITD FLT3 and consequently the resistance to quizartinib. We also 
observed that the STAT5, a specific downstream target of ITD activation did 
not change following inhibition of glycosylation indicating that cell surface 
FLT3 and so ERK1/2 and AKT is critical for FLT3L to mediate resistance to 
FLT3 inhibition. Although tunicamycin is currently not a clinically studying 
molecule, it was reported tunicamycin is well-tolerated in mouse models (Hou 
et al., 2013). As a result, the possibility of using tunicamycin in more pre-




The Bcl-2 family members have been studied extensively for its role in 
leukemic pathogenesis and drug resistance. Anti-apoptotic protein BCL2 
found to be highly expressed in AML leukaemia stem cells (LSC) and 
contribute to chemotherapy resistant (Carter et al., 2016). A recent study 
employed BH3 profiling to assessed dependence on anti-apoptotic pathways 
showed that co-inhibition of BCL2 with ABT-199 in addition to tyrosine kinase 
inhibitors enhanced eradication of diverse co-existing mutations AML in 
patient-derived xenograft (PDX) models (Saito et al., 2017). As different cell 
types can be relay on certain anti-apoptotic proteins for their survival, it’s 
crucial to study each AML cells model with certain genetic abnormalities to 
determine which bcl-2 proteins required for cells survival or for drug sensitivity. 
Venetoclax lack the ability to inhibit MCL1, this leads to resistance in 
leukaemia cells that are depend on MCL1 for survival (Lin et al., 2016). Other 
anti-apoptotic member of the BCL2 family proteins is myeloid leukaemia cell 
differentiation protein 1 (MCL1), and it’s commonly upregulated in AML cells, 
especially in relapsed patients (Kaufmann et al., 1998). A recent study provide 
a rationale for initiating a clinical study evaluating the combination of MCL1 
inhibitor S63845 and MEK-inhibitor trametinib, and showed that  
haematological cells with elevated MCL1- and MEK-protein levels were most 
sensitive to the combined treatment (Seipel et al., 2019). While it is clear that 
inhibiting anti-apoptotic proteins is important for the synergistic killing of 
leukaemia cells, the mechanism how FLT3L promotes quizartinib resistance 
in the context of BCL-2 proteins is not clear. Therefore, in order to understand 
how quizartinib induces cytotoxicity and how FLT3L-mediated its resistance, 
we looked at the role of Bcl-2 family members in MV4-11 and MOLM-13 cell 
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lines. We identified the anti-apoptotic protein Mcl-1 as promising target in ITD-
expressing cells, and this was consistent with the data showed that 32D cells 
transfected with ITD mutations induced a dramatic up-regulation of the anti-
apoptotic myeloid cell leukaemia 1 protein (Mcl-1) (Breitenbuecher et al., 
2009b). Another work showed that Mcl-1 is upregulated in FLT3-ITD-positive 
cell lines and primary AML cells and that Mcl-1 is a downstream target of 
FLT3L-stimulated FLT3 signalling (Kasper et al., 2012). In the context of our 
project, looking into BCL-2 apoptotic proteins will help to provide a rational 
approach to improve the therapeutic outcome of quizartinib and also to prevent 
the resistance mechanism that can be emerged by FLT3L. The expression 
level of Mcl-1 in MV4-11 and MOLM-13 was high compared with THP-1s and 
the expression was found to be regulated either through the ITD or WT-FLT3 
stimulated with FLT3L. This observation was confirmed by inhibiting ITD 
signalling with quizartinib or by siRNA-mediated suppression of FLT3. This 
data confirmed what has been shown in the literature that Mcl-1 is regulated 
by FLT3L acting upon WT-FLT3 in non-ITD AML lines, and also that the high 
basal expression in the MV4-11 and MOLM-13 cell lines is likely due to the 
presence of ITD-FLT3. We next showed that quizartinib modulate Mcl-1 and 
Bim, but not other BCL-2 proteins in ITD cells, and FLT3L itself can induce 
Mcl-1 upregulation in WT-FLT3, and as a result this finding may be clinically 
meaningful for patients who develop resistance to type II FLT3 inhibitors like 
quizartinib and present with high FLT3L plasma level. The issue of 
mechanistically implicating Mcl-1 in survival signalling in the AML cells lines is 
that both the Mcl-1 inhibitor and the siRNA induced apoptosis as single agents. 
They both increased the effects of quizartinib but at times this appeared 
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additive rather than a true synergism. So Mcl-1 inhibition alone is clearly a 
therapeutically relevant for treatment of AML. The other Bcl-2 protein we found 
to be regulated by FLT3 is the pro-apoptotic BH3-only Bim. Bim levels were 
significantly increased following treatment with quizartinib suggesting that ITD 
signalling is responsible for suppression of its expression. We subsequently 
found this effect was not limited to ITD signalling as when cells were treated 
with quizartinib in combination with FLT3L upregulation of Bim was inhibited. 
This only occurred in the MOLM-13 cells as these cells also express WT-FLT3 
as well as the ITD allele. Therefore, FLT3 signalling (both WT and ITD) 
appears to regulate negatively Bim expression. What is clear from these data 
is that both quizartinib and FLT3L can modulate Bim and Mcl-1 at protein 
levels. Quizartinib appears to cause an upregulation of Bim with a concomitant 
downregulation of Mcl-1. FLT3L, which has a protective effect following ITD 
inhibition can modulate Mcl-1 in both lines but appears to suppress Bim in the 
MOLM-13s. Given these cells also express WT-FLT3, which cannot be 
inhibited by quizartinib, it is likely that the upregulation of Bim, following ITD 
inhibition, was being reversed by FLT3L through WT- FLT3. This suggests that 
the imbalance between Mcl-1 and Bim expression may play a major role in 
ITD inhibition and in the resistance induced by FLT3L. These findings provide 
a rationale for a combination strategy targeting both FLT3-ITD and Mcl-1 to 
overcome drug resistance induced by FLT3L.  
 
Downstream pathways activated by FLT3 play an important role in modulating 
the efficacy of FLT3 inhibitors. Major pathways activated are PI3K, MAPK and, 
at least in ITD-expressing cells, the STAT5 pathway. In the previous chapter, 
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we showed that short term FLT3L stimulation (2 -10 minutes) does not prevent 
quizartinib inhibition of FLT3 signalling in MV4-11 even though there was an 
internalization of ITD receptor, however, it rescued ERK1/2 and AKT in MOLM-
13 cells. This variation in the quick response to FLT3L can rely on several 
factors including; the initial localised cell surface FLT3, the extent of re-
localisation of FLT3 upon quizartinib treatment and the time point used for 
FLT3L stimulation. Sato it all shows that FLT3L maintains p-FLT3 levels in 
MOLM-14 cells upon several TKIs treatment. Even though we were not able 
to detect p-FLT3 level using several antibodies and therefore we did not 
interpret the phosphorylation status of FLT3, our results were in consistent 
with Sato it all in which the FLT3L restored ERK1/2 and AKT in MOLM-13 cell 
(similar to MOLM-14 cells) assuming this was as a result of FLT3 
phosphorylation and activation. Interestingly, we showed that MV4-11 cells are 
response to long exposure of FLT3L in the presence of quizartinib and start to 
restore ERK1/2 but not AKT within 48h of co-treatment. This observation has 
not been shown by Sato et al as only p-FLT3 was studied but not it’s 
downstream signalling ERK1/2, AKT and STAT5.  
 
It has been well established that the PI3K/AKT signalling pathway plays an 
important role in FLT3 oncogenic signalling, however, we observed a different 
AKT response to FLT3L in AML cells treated with various FLT3 inhibitors. This 
was not consistent with the inhibition of apoptosis induced by FLT3 inhibitors.  
Using PI3K/AKT inhibitor dose not rescue the effect of FLT3L on quizartinib 
treated cells to the same extent as MEK inhibitor does. This suggest that AKT 
has less effect on the mechanism of resistance caused by FLT3L. The MAPK 
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pathway does appear to be important for both WT- and ITD-FLT3 signalling in 
the AML cells.  Using MEK and PI3K/AKT inhibitors, we showed that the 
expression of Mcl-1 by the ITD is regulated by the MAPKs suggesting a role 
for this pathway in cell survival. These results are consistent with the fact that 
FLT3L mediates its resistance through the MAPK pathway. The mechanisms 
by which the MAPKs regulate the expression of Mcl-1 are still under 
investigation. We have shown that inhibition of the MAPKs decreases the Mcl-
1 protein level, however, further experiments need to be done to study the 
transcriptional level of Mcl-1 following MAPKs inhibition. One protein which is 
well known to be regulated by the MAPK pathway is Bim (Ley et al., 2003, 
Balmanno and Cook, 2009).  This appears to be a key mediator of ITD-induced 
apoptosis as siRNA blocked cell death by quizartinib. We demonstrated that 
activation of MAPK/ERK pathway by FLT3L is responsible for the inhibition of 
cell apoptosis induced by quizartinib. Therefore, a strategy for targeting both 
FLT3 and MEK/ERK could enhance the apoptotic effect of FLT3 inhibitors 
even in the presence of FLT3L. Indeed, we observed targeting FLT3 with 
quizartinib or sorafenib in combination with MEK inhibitors such as U0126 or 
trametinib restored cell death induced by FLT3 inhibitors overcoming FLT3L-
mediated resistance. The fact that this was not observed with gilteritinib further 
confirmed the role of WT-FLT3 in this resistance.  
 
Unfortunately, due to the absence of commercial STAT5 inhibitors we were 
unable to fully examine the role of this pathway. However, several pieces of 
information would suggest that its role in apoptosis suppression through ITD 
signalling is less important than other pathways. It also cannot be involved in 
204 
 
FLT3L-medited resistance as it cannot be activated by WT-FLT3 
(Spiekermann et al., 2003b). Also, STAT5 phosphorylation did not restore as 
a result of ligand stimulation in both cell lines, and this is in agreement with 
Choudhary et al findings, in which STAT5 is activated by the intracellular pool 
of ITD receptor and therefore cannot response to exogenous ligand 
(Choudhary et al., 2009a). While, silencing STAT5 has been shown to regulate 
Mcl-1 and Bcl-2 expression at least in ALL, our data suggests the MAPK 
pathway is much more important to mediate FLT3L resistance mechanism 
(Minieri et al., 2018). This observation is likely a result of WT-FLT3 expression 
in the MOLM-13s which is available on the surface for ligand binding and 
activation by FLT3L and is unaffected by quizartinib. This is further supported 
by the fact that quizartinib abolished STAT5 phosphorylation and this could 
not be restored by FLT3L. STAT5 phosphorylation is specifically activated by 
ITD-FLT3 not FLT3L acting on the WT receptor. 
 
In summary, we demonstrate that elevated FLT3L levels may correlate with 
resistance to FLT3 inhibition. FLT3L reduces the inhibitory effects of 
quizartinib by activation of surface localised wild-type FLT3 receptor through 
the MAPK/ERK pathway and subsequently Mcl-1 overexpression. This also 
can be observed with prolong activation of ITD-FLT3. We also indicate that 
inhibition of upregulated Mcl-1 in the ITD model might be a promising 
therapeutic approach to sensitize cells to targeted therapy and to overcome 
the resistance induced by FLT3L. Given most patients present with a 
heterozygous mutation and elevated plasma FLT3L levels following 
chemotherapy, midostaurin and gilteritinib should be favoured over quizartinib. 
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These multi-kinase type I inhibitors dephosphorylate ERK1/2 even in the 
presence of FLT3L. On the other side, using multi-kinase inhibitor as 
midostaurin have a risk for inducing adverse effects as a result of its off-target 
effects. Finally, the combination of FLT3-ITD selective drugs such as 
quizartinib with MAPK/ERK inhibitors, glycosylation inhibitors, or Mcl-1 






























































Validation of STAT5 knock-out 













Over recent years, genome-editing using programmable nucleases has 
become a significant technological breakthrough in the field of molecular 
biology that enables targeted gene disruption both in vitro and in vivo. Custom 
nucleases such as Zinc fingers (ZFNs), transcription activator like effectors 
(TALENs), and the “clustered regularly interspaced short palindromic repeats” 
(CRISPR)/“CRISPR-associated genes 9” (Cas9) have all been used for 
genetic modification. The CRISPR/Cas9 system has become the most popular 
technique due to the fact it is easy to use and readily re-taskable with simple 
cloning protocols. Indeed, the 2020 Nobel Prize in Chemistry was awarded to 
Emmanuelle Charpentier and Jennifer Doudna for their discovery of the 
CRISPR-Cas9 system.  CRISPR-Cas9 is also less sensitive to epigenetic 
modifications and can be incorporated into viral vectors or delivered as a 
ribonucleoprotein complex (Lino et al., 2018).  As discussed in Section 1.5, 
Genome editing technologies have advanced significantly over the past few 
years allowing us to manipulate precisely specific loci within the genome. 
These approaches using programmable nucleases can potentially correct or 
delete single genes responsible for disease (Capecchi, 1989, Capecchi, 
2005).  
 
Several CRISPR/Cas systems have been developed and characterised from 
different bacteria with each of them having their own application-specific 
advantages. The most commonly used Cas nuclease, is SpCas9 derived from 
Streptococcus pyogenes (Jinek et al., 2013). One advantage of SpCas9 is that 
its required Protospacer adjacent motif (PAM) for DNA binding, 3’ NGG, 
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occurs frequently in most genomes, resulting in many available target sites 
(Cong et al., 2013). This protein has been subjected to a large number of 
mutagenesis studies which have sought to widen its PAM recognition and also 
enhance its activity resulting in a number of new variants hfCas9, eSpCas9 
and xCas9 (Hu et al., 2018). The large size of the Cas9 endonuclease is a 
major disadvantage, restricting some delivery methods. There has therefore 
been a great interest in identifying smaller orthologues, and these include 
SaCas9 from Staphylococus, LsCas9 from Leptotrichia and CjCas9 from 
Campylobacter (Ran et al., 2015). The disadvantage of all of these 
orthologues is that they use more restrictive PAM sequences meaning more 
limited genomic targeting (Cebrian-Serrano and Davies, 2017).  Gene-editing 
has difficulties in application terms in leukaemia research.  This is down to in 
vitro selection protocols, which are exclusively on suspension cell types.  
Similar difficulties are observed with gene editing in other leukaemia models 
and species utilised. A recent work revealed the importance of CRISPR-cas9 
as a tool for studying a key regulators of AML stem cells. In this work, 
an in vivo pooled CRISPR-Cas9 screen that targeted selected cell surface 
genes has been performed in order to identify the top regulator of leukaemia-
initiating cells. Using CRISPR single guide RNA (sgRNA) library that targeting 
96 cell surface genes, scientists were able to identify the critical role of CXCR4 
in AML cell growth and survival in vivo (Ramakrishnan et al., 2020). 
 
The aim of this chapter is to establish a CRISPR-Cas9 strategy to use in the 
MV4-11 cells to establish further the role STAT5 plays in ITD signalling. The 
tools developed could allow the FLT3-ITD pathway, which is pathologically 
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implicated in acute myeloid leukaemia (AML), to be further interrogated in the 
hope of finding novel therapeutic targets.   
 
STAT5 plays a critical role in a variety of developmental processes such as 
proliferation and differentiation, and it is also constitutively phosphorylated in 
a number of haematological disorders (Yamada et al., 2017). Several reports 
have described STAT5 as protein activated by FLT3-ITD which promotes an 
aggressive form of acute myeloid leukaemia (AML) (Choudhary et al., 2007). 
High STAT5 phosphorylation have been associated with tyrosine kinase 
inhibitor (TKI)-resistance (Warsch et al., 2011). In our cells model, we were 
unable to directly inhibit STAT5 as we have done with ERK1/2 or AKT, as a 
result suggesting STAT5 possible role in FLT3L resistance or Mcl-1 regulation 
has been challenging in FLT3-ITD cells. How STAT5 activated in FLT3-ITD 
signalling remains controversial. It has been suggested that STAT5 is 
activated in ITD by Jak1/2 kinases, Src family kinases (SFK) or directly by RTK 
receptor such as mutated FLT3 (Choudhary et al., 2007). As STAT5 has two 
isoforms (STAT5A and STAT5B) with a high degree of similarity (Ambrosio et 
al., 2002), we were interested to knock-out the most relevant isoform in ITD 
cells and study the role (canonical and non-canonical function) of this isoform 
in the pathogenesis of AML and drug resistance. To date, STAT5 has not been 
targeted using the CRISPR/Cas system in AML cells. The CRISPR/Cas 
system was chosen as the preferred method over other genome editing 
technologies due to its simplicity and efficiency. Comparing CRISPR/Cas with 
RNA interference to disrupt gene expression, CRISPR/Cas is more consistent 
allowing complete knockout thereby eliminating low-level protein expression 
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- Design a gene-editing strategy to investigate the role of STAT5A in FLT3 
signalling. This will be used as a basis for further gene-editing studies to 
investigate clinically-relevant mutations in vitro. 
- Establish tools and cell lines that could be used to further study the role of 













5.2.1 mRNA and protein levels of STAT5A and STAT5B in AML cell lines 
STAT5A, and the closely related protein, STAT5B were first reported in 1995 
by 3 different groups (Azam et al., 1995, LIu et al., 1995, Mui et al., 1995). 
Although they share 96% homology, they exhibit different expression patterns. 
In most AML studies, the effect of p-STAT5 has been extensively investigated, 
however, non-phosphorylated STAT5 is mostly evaluated without 
distinguishing between STAT5A and STAT5B. 
 
We first compared STAT5A and STAT5B mRNA levels in the AML cell lines. 
The mRNA levels expression of both STAT5A and B were higher in WT-FLT3 
expressing cells (THP-1s) compared to FLT3-ITD cells. STAT5A mRNA levels 
appeared higher than STAT5B in all cells (Fig 5.1A). 
 
To analyse the expression and phosphorylation status in the different AML 
cells, proteins were extracted and subjected to immunoblotting. All cells 
expressed both forms of STAT5 and expression appeared to be higher in the 
ITD-expressing cells (Fig 5.1B). As expected, phosphorylation of STAT5 was 
only seen in the ITD-expressing cells (MV4-11 and MOLM-13). To test whether 
STAT5 could be phosphorylated in WT-FLT3, THP-1s cells were treated for 
30 minutes with GM-CSF, a potent activator of STAT5. STAT5 was inactive in 




These results suggest that STAT5A and B are differentially expressed among 
the AML cell lines and appears higher in the ITD cells despite these cells 











Figure 5.1: STAT5A/B expression in AML cells – A) mRNA expression of 
STAT5A/B genes was analysed by RT-qPCR. Data were normalized to 
GAPDH. Results represent the mean +/- SEM for 2 independent experiments. 
B) Total cellular protein (30 µg) from the AML cell lines was separated by SDS-
PAGE and subjected to immunoblot analysis with indicated antibodies. THP-
1 cells were treated with GM-CSF for 30 minutes and β-actin was used as a 
loading control. 
 
5.2.2 Functional Effects of STAT5A/B knockdown in MV4-11 cells 
It has been reported that STAT5A is more important than STAT5B for FLT3 
signalling (Zhang et al., 2000). Our results show that AML cells appear to 
express more STAT5A mRNA than STAT5B and levels of both are higher in 
WT than ITD-expressing cells (Fig 5.1A). At the protein level, STAT5A but not 
STAT5B was more highly expressed in ITD-expressing cells (Fig 5.1B). The 
variation in protein and mRNA levels could be related to the activity of STAT5A 
in ITD cells.  
 
To further analyze the role of STAT5A/B in FLT3 signalling, we knocked down 
STAT5A/B in MV4-11 cells using siRNA. Firstly, validation of knockdown was 
evaluated at the protein level by immunoblotting (Fig 5.2). Both siRNA 
appeared to cause significant STAT5 knockdown in the MV4-11s, although the 
knockdown of STAT5A appeared more complete. 
 
Knockdown of STAT5A or STAT5B caused an increase in cell death compared 
to untreated cells. This increase was more pronounced with the STAT5A 
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siRNA. We also found that siRNA targeting STAT5A led to an increase in 
sensitivity of MV4-11s to quizartinib although this effect appeared at most 
additive (Fig 5.2). This effect was not seen with the STAT5B siRNA.  
 
 
                          
 
Figure 5.2: Apoptosis in MV4-11 cells following STAT5 knockdown – 
MV4-11 cells were transfected with STAT5A or STAT5B siRNA (10 nM) for 
72h before cells were harvested and analysed by Western blotting. siRNA 
transfected cells were transfected for 24h before being treated with quizartinib 
(100 nM) for 48h. Apoptosis was measured using Annexin V/PI staining. 
Results represent the mean +/- SEM for 3 independent experiments. 
Significance testing was done by two-tailed paired t-test (n=3),*P≤0.05, **P 

















































5.2.3 Design of STAT5A CRISPR 
Our results appeared to show a potential role for STAT5A in ITD-expressing 
cell survival (Fig 5.2). Given the limitations of siRNA in the AML lines we 
wanted to explore a CRISPR-based system to further study the role of 
STAT5A in the AML cell lines. These reagents could subsequently be adapted 
to generate Mcl-1 and Bim-null cell lines to validate their role in FLT3 signalling 
and quizartinib cytotoxicity.  
 
The STAT5A gene is located on the human chromosome 17 and consists of 
20 exons (794 amino acids). To knockout STAT5A we designed three different 
guides targeting exon 1.  A double-guide system was employed in which 2 
guides are chosen which span the region of interest. Work in our laboratory 
has shown that this results in the deletion of a fragment of DNA between each 
Cas9 cleavage site. This makes identification of edited cells much easier than 
when using single guides as it is unnecessary to use DNA mismatch assays, 
such as SurveyorTM, to identify edited clones. Genomic PCR across the edited 
region is sufficient to distinguish heterozygous and homozygous edits. 
Additionally, evidence suggests that paired guides are more efficient at editing 
than when used singly (Nicholas Harper personal communication). The cDNA 
sequence for STAT5A was obtained from the NCBI Unigene database 
(https://www.ncbi.nlm.nih.gov/unigene).Guide RNAs targeting the STAT5A 
gene were designed using CRISPoR (http://crispor.tefor.net/). A region 
spanning the ATG site was used. Guide sequences and their binding location 
can be found in (Fig 5.3). All guides are immediately 5’ to the Streptococcus 
pyogenes Cas9 (SpCas9) PAM sequence 5’ NGG 3’ (highlighted in red). The 
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PAM sequence serves as a Cas9 binding site and the double-strand break 
(DSB) will occur 3 nucleotides 5’ to the PAM site. Guide #1 was chosen to be 





Figure 5.3: STAT5A guide selection – Cartoon of partial Exon 1 and region 
upstream of ATG in STAT5A gene showing binding of guide RNAs and Cas9 
cleavage sites. 5’ PAM sequences are depicted in red and ATG is in green. 
 
STAT5A and STAT5B are highly related (96% similar at the amino acid level) 
and to efficiently target only the STAT5A gene, guides were chosen to be 
unable to bind STAT5B (Fig 5.4). Whilst there was no homology in the 
intergenic region of both genes (so guide #1 can only bind the STAT5A gene) 
the coding region of Exon 1 has similarity so guides were designed at position 
where their binding to STAT5B would be disrupted while still exhibiting low off-





Figure 5.4: STAT5A and STAT5B Exon 1 alignments and guide binding – 
Alignment of Exon 1 of STAT5A and B. Guides were chosen such that they 
failed to target STAT5B. There is no similarity between STAT5A and B in the 
region upstream of the ATG therefore guide 1 cannot be shown.  
 
5.2.4 Cloning of guide RNA plasmids 
To generate the guide RNA plasmids, we used LentiCRISPR (Addgene - 
#52961) as a backbone. This plasmid contains a human U6 promoter and 
spCas9 together with a puromycin selection marker. The original EF-1α core 
promoter was replaced with a spleen focus-forming virus (SFFV) promoter as 
this has previously been shown to work well in haematopoietic cells lines.  
 
For guide cloning the CRISPoR-designed oligos were phosphorylated with T4 
Polynucleotide Kinase and annealed. The plasmid was digested with BsmB1 
to remove the stuffer leaving 3’ and 5’ overhangs. Guide oligos were also 
designed with overhangs already present when annealed. Following ligation, 
transformation, and screening (as described in Materials and Methods) 
plasmids were sequenced to ensure correct guide incorporation. The plasmid 






Figure 5.5: Cloning STAT5A guides into modified LentiCRISPR plasmid 
– A) Schematic of modified LentiCRISPR plasmid used for guide cloning. 
Digestion with BsmB1 results in removal of stuffer region and exposure of 
compatible overhangs. B) Ligation of annealed guide oligonucleotides 









5.2.5 STAT5A Exon 1 genotyping 
Before testing the guide plasmids, we needed to design and optimise primers 
to detect the genomic regions being targeting (Exon 1 in STAT5A). We 
designed several primers spanning the targeted region ensuring the guide 
sequences and PAM sites were within the amplified region. A schematic of the 
primers and their location with respect to the guide sequences is shown in (Fig 
5.6A). All primers sets were checked using the NCBI BLAST algorithm 
(https://blast.ncbi.nlm.nih.gov/Blast.cgi) to ensure specificity. 
 
All combination of primer sets were tested on genomic DNA extracted from 
HEK-293T cells. Multiple PCR products were detected in the genotyping PCR 
for STAT5A Exon 1. No difference was observed between the predicted 
product size and that found when carrying out the PCR, indicating all tested 











Figure 5.6: STAT5A Exon 1 genotyping PCR – A) Schematic of genotyping 
primer pair combinations for screening Exon 1 of STAT5A gene. B) Predicted 
products using SnapgeneTM and PCR on HEK-293T genomic DNA using 




5.2.6 Validation of CRISPR plasmids 
Guide plasmids were validated by transfection in pairs. Our lab has previously 
noted that when two guide plasmids are transfected a fragment of DNA 
between both guide cleavage sites is released. If guides are chosen 
sufficiently far apart this can simplify screening for knock-out alleles.  
 
A schematic of the guide sequences and adjacent PAM sites can be seen for 
STAT5A Exon 1 (Fig 5.7A). Guide #1 in the intergenic region 5’ to the ATG is 
paired with either guide #2 or #3 in Exon 1. This would be predicted to produce 
deleted fragments of sizes 104 and 153bp respectively (Fig 5.7A). HEK-293T 
cells were used for guide validation as they are easy to transfect. Two clones 
of each plasmid (A and B) were chosen for each guide to ensure no artefacts 
had been introduced when cloning and cells harvested for genotyping 72h 
after transfection. Figure 5.7B shows the predicted agarose gel of PCR 
products expected from transfected cells. Figure 5.7C shows the results in 
untransfected (ut) and transfected HEK-293T cells. As predicted the exon-
spanning primer set 2 gives a 521 bp product in all cells acting as a control for 
the genotyping PCR. The lower bands only occur in transfected cells and 
directly correlate with the sizes of the predicted deletion fragments. The two 
guides would produce site-specific DSBs at the two loci and thus remove the 
section of DNA between the two guides. The bp deletion products between the 
two guides was predicted to be 153 bp and 104 bp which is confirmed by the 
lower bands shown on the gel (Fig 5.7C). Deletion fragments in all transfected 
cells confirmed that all 3 guide sequences were able to target and cut within 




Figure 5.7: Validation of STAT5A guides in HEK293Ts – A) Schematic of 
STAT5A Exon 1 and ATG upstream sequence. Indicated are guides, PAMs 
and Cas9 cleavage sites. 2 different guides result in a “double-cut” and the 
removal of a “chunk” of DNA in between the cleavage sites (pictured in red). 
B) Predicted PCR products obtained from double-guide transfection. C) 
Validation of guides pairs in HEK293Ts. HEK293T cells were transfected with 
indicated guide plasmids for 72h following which genomic DNA was isolated 
and CRISPR cleavage efficiency validated by PCR. 
 
To further confirm the exact deleted region the 3 bands obtained from 
transfection (untransfected, guide #1/2, guides #1/3) were amplified, extracted 
and Sanger sequenced.  Results confirm that primers are amplifying Exon 1 
of STAT5A (Fig 5.8). Sequencing of guide transfected cells shows that 
fragments are excised from the region surrounding Exon 1 exactly as predicted 
with flanking regions corresponding exactly to the guide RNA and Cas9 



























































































































































5.2.7 CRISPR-Based Lethality Assay 
The LentiCRISPR plasmids we used to validate the guide sequences are an 
example of an all-in-one plasmid as they also contain the Cas9 endonuclease. 
Lentivirus packaging constraints preclude us from adding an additional guide 
cassette therefore validated guide cassettes (U6 promoter, gRNA and tracr 
RNA) needed to be transferred to a smaller plasmid. Our preliminary siRNA 
results indicate that knocking-down (or knock-out) of STAT5A may be lethal in 
ITD-expressing cells in which case we would be unable to derive any 
knockouts. We therefore designed a CRISPR-based lethality assay which 
could be performed in cells that already express Cas9 (see later section 5.2.9) 
under the control of an inducible promoter. We would only need to supply the 
2 guides to edit STAT5A in the cells. The plasmid would require visualization 
(EGFP) and a selection marker (puromycin) and be introduced using an 
integration competent virus (Fig 5.9A). If lethality was not observed, knockouts 
could be made using the same plasmid in an integration deficient virus (IDLV) 
which would still allow us to use the markers for selection, but they would only 
be transiently expressed. 
 
The double guides would be inserted into a custom pLeGO plasmid generated 
in our lab (Addgene # 27341) which had been modified to include an EGFP 
marker fused to a puromycin resistance gene using a viral 2A peptide. Two 
MCS sites for guide cassette cloning had also been inserted flanking the 





Figure 5.9: A CRISPR-based STAT5A Lethality Assay – A) Cartoon of a 
CRISPR-based lethality assay. Tetracycline-dependent Cas9-expressing 
MV4-11 cells are transduced with lentivirus containing STAT5A guides 
together with EGFP and puromycin markers.  Cells are selected with 
puromycin to enrich transduced cells (to ~ 50% of population). Cas9 is then 
induced using Doxycycline. STAT5A will only be edited in the EGFP-positive 
cells and these will be removed from the population if its deletion is lethal. 
Maintenance of EGFP/non-transduced cell ratio means STAT5A is non-lethal. 
B) Custom plasmid for double guide and marker expression for lethality assay. 
The modified pLeGO lentiviral plasmid contains 2 multiple cloning sites for 
cloning guides cassettes (promoter and sgRNA) and EGFP and PAC-1 





5.2.8 Double-guide cloning and validation 
To avoid potential recombination issues due to the presence of 2 similar U6 
promoters we cloned guides #2 and 3 into a LentiCRISPR plasmid containing 
a murine U6 promoter in place of the human variant (gift from Nicholas Harper, 
University of Liverpool). The double guide plasmids were then synthesised first 
by amplifying guide cassette #1 by PCR then cloning this into the first MCS of 
the modified pLeGO plasmid using the Not1 and Nhe1 sites. pLeGO MCS was 
digested with Not1 and Nhe1 and gel extracted. After ligation and PCR 
screening, clones were verified for insertion by Sanger sequencing (Fig 
5.10A).   
 
The second guide containing the mU6 promoter was amplified from 
LentiCRISPR mU6 and inserted into MCS#2 using the Kpn1 and PvuII sites.  
pLeGO MCS STAT5A guide #1 was digested with Kpn1 and PvuII and 
following gel extraction either guide cassette #2 or #3 inserted. Positive clones 

















Figure 5.10: Cloning STAT5A double guides (pLeGO) – A) STAT5A guide 
#1 was inserted into the left-hand MCS of pLeGO MCS EGFP 2A Puro. The 
human U6 (hU6) promoter and guide #1 sgRNA cassette was first amplified 
from LentiCRISPR, purified, and digested together with the plasmid with NotI 
and NheI. Digested vector and insert were ligated and transformed, and clones 
screened for insertion by colony PCR. Clones were sequenced verified before 
use. B) Guides #2 and 3 insertion into right-hand MCS. A guide cassette 
containing a murine U6 promoter (mU6) and either STAT5A guides #2 or 3 
was amplified from LentiCRISPR mU6 then inserted into the previous guide 
#1 plasmid by KpnI and PvuII digestion and ligation. Following colony 
screening several clones were sequence verified before use. 
 
Double-guide plasmids were validated in HEK293T cells. Cells were 
transfected with each plasmid in combination with empty LentiCRISPR (to 
supply the Cas9 enzyme). 72h after transfection cells were imaged to visualise 
the EGFP marker then harvested for genotyping. Again 2 clones of each 
plasmid were verified for activity. As expected, all plasmids resulted in EGFP 
positive cells following transfection (Fig 5.11A). Transfection of these plasmids 
should also lead to the deletion fragments we observed previously. 
Genotyping indicated that both combinations of guides #1/2 and those of #1/3 
resulted in the expected deletion fragments (Fig 5.11B) with the combination 
of guides#1 and 3 being the more efficient pairing. This shows that duplexing 





Figure 5.11: Validation of STAT5A double guide plasmids – Double-guide 
plasmids were transfected into HEKs together with an “empty” LentiCRISPR 
plasmid (to provide spCas9) for 72h. A) Cells were first analysed for EGFP 
expression. B) Cells were harvested, genomic DNA extracted, and deletion 
efficiency assessed by genotyping with primer set #1. 
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5.2.9 Generation of MV4-11 cells expressing inducible Cas9  
The double-guide plasmids we generated to edit the STAT5A gene will require 
the presence of the Cas9 endonuclease for editing in our target cells. It would 
therefore be useful to have MV4-11 cell lines that already expressed Cas9 to 
use with these plasmids and any future editing studies (Bim and Mcl-1 etc).  
Puromycin was chosen for the guide plasmids as it kills quickly in the AML cell 
lines. We therefore needed to utilise a different antibiotic for production of 
stable Cas9-expressing cells. Additionally, it would be better if the Cas9 
protein was under an inducible promoter and not constitutively expressed. As 
mentioned previously the use of an IDLV would ensure the guide and markers 
are not integrated into the host cell genome.  
 
We chose the pCW Cas9 plasmid (Addgene # 50661) which was modified by 
replacing the PAC-1 puromycin resistance gene with a Blasticidin resistance 
marker (Fig 5.12A). Transfection of the original and modified plasmid into 
HEKs followed by Doxycycline treatment showed Cas9 induction with both 
plasmids as detected by Western blot (Fig 5.12B). MV4-11 cells were 
transduced with Lentivirus expressing the Cas9-blast plasmid and selected for 
7-10days with Blasticidin. We wished to generate clonal cells from this 
population so after freezing down an initial pool, selected cells were plated into 
6-well plates in Methylcellulose-containing RPMI. This semi-solid medium 
enables cell clones to form “clumps” within ~10 days after which they are 
picked and expanded, first in 96 well plates then bulked up as required. Clones 
are tested for Cas9 expression following Doxycyline treatment a soon as is 
possible to avoid growing negative or low-expression clones (Fig 5.12C). 
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Positive clones are further expanded for freezing and Cas9 induction re-
checked as before (Fig. 5.12D). As mentioned previously these cells can be 
used for numerous editing studies as they only require transduction with 
different guide-containing plasmids. 
 
 
Figure 5.12: Generation of Cas9-inducible MV4-11 clones – A) Schematic 
of pCW Blast derived from pCW (AddGene #50661). The original pCW 
contains the puromycin resistance gene PAC-1 which has been replaced with 
the Blasticidin S-resistance gene (bsr) in pCW Blast. B) Validation of plasmids 
in HEK293Ts. pCW plasmids were transfected into HEK293T cells, 24h later 
Cas9 expression was induced with Doxycycline (2 µg/ml) for 72h after which 
cells were harvested and lysates subjected to Western blotting for spCas9. C) 
Generation of Cas9-expressing cells. Lentivirus was generated from pCW 
Cas9 and used to transduce low passage MV4-11 cells in the presence of 
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polybrene (1 µg/ml) for 72h, cells were then passaged and subjected to 
selection with Blasticidin (7.5 µg/ml) for 7 days. Clonal isolation of Cas9-
expressing MV4-11 cells was performed by culturing the cells in 
Methycellulose (2.5 %). 7-10 days following plating clones were isolated from 
the semi-solid medium and transferred to 96-well plates for expansion and 
expression analysis by Western blot. D) Western blot verification of inducible 

























Given the role of STAT5 activation in mediating the oncogenic effects of FLT3-
ITD, it is expected that STAT5 gene editing may modulate AML cells survival 
and proliferation. In this chapter, we were interested to establish a strategy to 
knock out STAT5 in MV4-11 cells and study whether its expression is required 
for maintenance of AML cells. Initially, it was an important to explore the 
function of two members of the protein: STAT5A and STAT5B. Experiments 
suggested that STAT5A is more critical for AML mediating leukemogenesis.  
STAT5A mRNA expression was significantly higher in FLT3-ITD cells, which 
express pSTAT5, compared STAT5B. To validate this, we decided to evaluate 
the role of total STAT5A by performing the siRNA knock-out experiments in 
FLT3-ITD cells. The data also suggested that STAT5A knocked down can 
induce apoptosis to a greater extent compare to STAT5B. 
 
Gene editing using site-directed nucleases such CRISPR-Cas9 can be used 
to target specific regions of DNA leading to gene disruption. The discovery of 
the CRISPR/Cas9 system as a gene editing tool is revolutionizing many areas 
of biomedical research including gene therapy, model cell line development, 
disease target identification and genomic screening. Its simplicity and flexibility 
to target nearly any location within the genome explains its popularity and 
widespread use. While other genome editing tools such as ZFNs and TALENs, 
have their own advantages, they lack the versatility of CRISPR and require 




Due to their “programmable” nature theoretically any area of the genome is 
targetable, and we wished to see whether we could use these targeted 
nucleases to disrupt STAT5A in AML cells.  We successfully validated double 
guide RNA constructs targeting Exon 1 of STAT5A in HEK-293T cells. We 
cloned CRISPR guides targeting Exons 1, of STAT5A and observed editing in 
this Exon. Our results show a promising method of using what we describe as 
a double-guide system to validate the ability of guide sequences to target Cas9 
to the correct loci.  
 
In AML, heterozygous rather than homozygous modification of FLT3 alleles is 
more likely to present in patients. The double-guide system also allows us to 
easily screen clones for complete knockout (a single band) as well as 
heterozygosity (would produce a double-band on genomic PCR). It also 
appears to be more efficient than using single guides (Nicholas Harper 
personal communication). 
 
The lethality assay is a novel way of using CRISPR to determine whether 
genes are lethal (prior to making knockouts). These assays would initially be 
performed with a wt Lentivirus first to assess when a gene was lethal and if 
not, the knockout lines would be generated using an integration-deficient 
lentivirus to avoid integration and expression of the EGFP marker.  
 
The Cas9-inducible MV4-11 clones will be of great use in looking at other 
proteins involved both in ITD signalling and in FLT3L-mediated resistance. 
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Haemopoietic cell lines in general have proved difficult to clone out and the 
semi-solid medium strategy used here has been particularly successful. The 
MOLM-13s should be similarly transduced and single clones isolated. 
 
Clearly, these techniques and tools could be used further study the role of Mcl-
1 and Bim in FLT3 inhibition and FLT3L-mediated resistance. It is also possible 
to introduce mutations within endogenous proteins to model different FLT3 




















































6.1 Final Discussion 
6.1.1 The ITD mutation affects FLT3 expression and cell surface 
localisation, resulting in dysregulation of downstream signalling 
cascades 
The identification of mutations in FLT3 and their consequences on its 
expression and signalling offers new opportunities for targeted therapy in AML. 
During the past decade, the biology and function of mutated FLT3 and the WT 
receptor have become clearer. One challenge for AML treatment is the high 
degree of heterogeneity with respect to mutations and changes in FLT3 
expression (Kumar, 2011b). The majority of the mutations involve an ITD, 
which is associated with poor prognosis and an increased incidence of relapse 
(DiNardo and Cortes, 2016). Differences in the downstream signalling 
pathways of ITD- versus WT-FLT3 and how these receptor types respond to 
stimulation (from endogenous FLT3L) or inhibition (with drugs) would present 
a better understanding of the disease and its treatment options. 
 
In the first part of this thesis we characterised FLT3 signalling using cell line 
models with different FLT3 genotypes. ITD-FLT3 exclusively activates STAT5, 
and this was confirmed using the ITD inhibitor (quizartinib) which led to STAT5 
dephosphorylation only in ITD-expressing cells. Other signalling pathways 
such as MAPK and AKT were activated both by ITD and the ligand-activated 
WT receptor. While our data indicated that ITD-FLT3 can respond to FLT3L 
resulting in additional activation of ERK1/2 and AKT, this was relatively modest 
in comparison with its effect on the WT receptor. Notably, STAT5 was not 
activated by FLT3L in both WT and ITD AML cells. As FLT3L binds and 
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activates cell surface localised FLT3, the results suggest that activation of 
ERK1/2, AKT and STAT5 is likely a consequence of differential receptor 
localisation in addition to mutational status (Takahashi, 2020). The differences 
observed in signalling present an attractive target for therapeutic intervention.  
 
This led us to next focus on the localisation of the WT and ITD receptors in 
respond to TKIs or FLT3L and how this influences downstream signalling. 
Despite the clinical importance of FLT3, the role of subcellular receptor 
compartmentalisation needs to be further elucidated. We have demonstrated 
that a particular FLT3 mutation may not only differentially activate downstream 
pathways, but it also affects the subcellular localisation of the receptor. In our 
study, we confirmed intracellular accumulation of ITD-FLT3 in both 
homozygous and heterozygous ITD cells, MV4-11 and MOLM-13 respectively. 
 
When we compared cell surface ITD to WT staining, the latter was mainly 
localised at the cell surface. Our data also suggests that the intracellular ITD-
FLT3 activates STAT5, while ERK1/2 and AKT are activated at the plasma 
membrane. Inhibition of ITD signalling by quizartinib resulted in the rapid 
relocalisation of receptor to the plasma membrane which is consistent with an 
activation-induced internalization model seen in other RTKs such as c-kit (Yee 
et al., 1994). The fact that cells harbouring homozygous ITD mutations 
displayed a greater cell surface redistribution than those with heterozygous 
mutations following quizartinib treatment supports this. By contrast 
midostaurin (a type I inhibitor) has less effect on redistribution irrespective of 
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FLT3 genotype which is consistent with it being a poor ITD selective inhibitor. 
Taken together this data suggests the response to quizartinib depends on a 
cell’s FLT3 genotype. Increased cell surface localisation in FLT3-ITD cells is a 
likely mechanism for quizartinib to inhibit STAT5 phosphorylation. This may 
also be linked to the increase in the mature, fully glycosylated form of FLT3 in 
ITD-expressing cells observed following quizartinib treatment. This result 
suggests that the ITD mutation may prevent the maturation of FLT3 required 
for its surface expression and the nature of signalling by the ITD could change 
upon trafficking of the receptor from the cytoplasmic space to the cell surface. 
 
To confirm this, we re-stimulated FLT3 with FLT3L following quizartinib 
treatment and assessed the phosphorylation of ERK1/2, AKT and STAT5. 
Stimulation of surface localised ITD-FLT3 led to activation of ERK1/2 and AKT 
but not STAT5. Differential signalling as a result of altered localisation in other 
oncogenic RTKs like c-KIT can be applied to other cancers in order to 
ascertain if their signalling is similarly affected.  
 
This data not only provides insights into effect of TKIs on the cellular 
localisation of FLT3 and how this affects the spatial regulation of oncogenic 
signalling but it also allows us to understand how FLT3-targeted therapy in the 
presence of FLT3L could lead to an altered biological response. Taken 
together, the main findings include: deactivation of STAT5 by quizartinib is a 
result of a change in subcellular localisation of FLT3 from an intracellular space 
to the cell surface. Secondly, both ERK1/2 and AKT can be activated by ligand 
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stimulation of cell surface localised WT and ITD-FLT3. An explanatory model 
is presented in Figure 6.1.  
 
Figure 6.1: Signalling by different FLT3 genotypes in AML. 
 
The loss of the WT allele in ITD patients affects FLT3 dimerization, signalling 
and clinical outcome. In one study, a high ITD-to-WT ratio in patients was 
associated with a significantly worse prognosis (Thiede et al., 2002). However, 
the presence of the WT allele could also modulate receptor activation and 
therefore affect sensitivity to chemotherapy. In this situation the WT and ITD 
forms may act independently of one another but it would be interesting to 
ascertain whether the WT receptor could heterodimerize with the ITD form and 
what the consequences would be for downstream signalling. Investigating the 
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role of the WT receptor in FLT3-ITD leukemia will help to understand its 
prognostic implications and better tailor therapeutic options for 
leukemogenesis caused by FLT3-ITD mutations. 
 
6.1.2 Targeting the MAPK pathway may overcome FLT3L-mediated 
resistance to FLT inhibitors in patients with ITD mutations 
With the identification of the ITD and other FLT3 mutations as a target for AML 
therapy, several drugs have advanced into clinical trials, either as 
monotherapy or in combination with other chemotherapies. Despite the initial 
clinical efficacy of FLT3 inhibitors, resistance to single agents develops after 
only a few months of therapy, which can limit their use.  
 
One of the extrinsic resistance mechanisms to FLT3 inhibitors such as 
quizartinib is the crosstalk between the bone marrow microenvironment and 
leukemic cells which confers protection and can modulate drug responses. 
The stromal cells are a source of numerous cytokines that have been shown 
to support AML growth and proliferation including FLT3L (Wilson et al., 2012). 
Increased FLT3L levels have been observed in AML patients following 
treatment with FLT3 inhibitors or conventional chemotherapy and this could 
potentially play a role in relapse (Stirewalt and Radich, 2003).  
 
Single cell genotyping of FLT3 in AML blasts from patients indicates they 
express both ITD and WT-FLT3 complicating therapy (Stirewalt et al., 2014). 
In one study, WT- but not ITD phosphorylation was detectable in plasma 
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samples from quizartinib treated patients, and this could be augmented by 
FLT3L reducing the efficacy of FLT3 inhibitors in these patients (Cortes et al., 
2013). We found that ITD cells were still responsive to exogenous FLT3L and 
this could in turn antagonise type II FLT3 inhibitors. The elevated FLT3L levels 
in patients could act on WT-FLT3 leading to the restoration of signalling which 
would represent a significant obstacle to the clinical efficacy of some FLT3 
inhibitors.  
 
To begin to address the protective mechanisms of FLT3L we looked at the 
effects of FLT3L on four AML cell lines with varying FLT3 mutational status. 
We noticed that in the presence of FLT3L, the ITD-cell lines demonstrated 
varying degrees of resistance to quizartinib, suggesting that both homozygous 
and heterozygous genotypes can be affected. As would be expected AML cells 
with heterozygous mutations (MOLM-13) displayed a stronger response to 
FLT3L and this resulted in increased resistance to quizartinib compared to the 
homozygous cells. This was confirmed as the IC50 increased significantly with 
the addition of FLT3L. It was highly likely that this would also occur with other 
type II inhibitors, and agreeing with this both ITD cells displayed a similar 
resistance to sorafenib. Despite this, the cells retained their sensitivity to type 
I inhibitors, gilteritinib and midostaurin, under the same conditions. Given FLT3 
mutations are largely heterozygous, this suggests that type I inhibitors or some 
other way of co-targeting FLT3L signalling when using ITD selective inhibitors 




To investigate the signalling changes associated with FLT3L-mediated 
response, we looked at survival signalling pathways commonly engaged by 
FLT3. Reactivation of both AKT and ERK1/2 was associated with inhibition of 
apoptosis and occurred even in the presence of quizartinib. STAT5 is 
exclusively activated through ITD-FLT3 so does not play a role in ligand-
mediated protection (Piloto et al., 2007). Our results demonstrate that 
MAPK/ERK likely represents a nexus in the resistance conferred by FLT3L 
towards FLT3 inhibition. This result is in consistent with other works that have 
shown the implication of ERK activation in FLT3 inhibitors resistance. The high 
levels of phosphorylated ERK in leukemia blasts after treatment with 
sorafenib has been reported and this was despite the continued suppression 
of p-FLT3 (Borthakur et al., 2011). High ERK activation was also observed in 
the sorafenib–resistant cell lines and concomitantly targeting FLT3 and MEK 
with crenolanib and the MEK inhibitor CI1040 induced marked apoptosis 
(Zhang et al., 2014). 
 
While using pan-kinase inhibitors abrogates this resistance, patient tolerance 
remains an issue. Given that only type II inhibitors are affected by FLT3L, we 
propose the combination of type II FLT3 inhibitors (with more selectivity 
towards the ITD mutation) and MEK inhibitors such as trametinib, U0126 or 
imatinib may represent a novel approach in AML patients with FLT3 mutations 
who also present with elevated plasma levels of FLT3L. This combination 
triggered a dramatic pro-apoptotic effect in the ITD cells treated with FLT3L. 
This strategy may not only overcome the limitation of FLT3L reduced drug 
efficacy in ITD cells but could also prevent adaptive TKI-resistance, a frequent 
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problem in single agent TKI-treatment. Further preclinical models and clinical 
trials are needed to translate these findings into novel therapeutic approaches. 
It would be of interest to investigate the role of RAS protein in FLT3L-mediated 
resistance. ERK1/2 is a downstream protein of RAS, and RAS mutation has 
been shown to cause a persistent activation of ERK1/2 and limit the efficacy 
FLT3 inhibitors (McMahon et al., 2019). The long exposure of AML cell line to 
FLT3L or FGF2 lead to acceleration of resistance development. Indeed, 
removing FLT3L or FGF2 greatly accelerated the acquisition of KRAS 
mutations which means upon removal of cytokines the resistant cultures are 
not depended on the presence of the cytokines/growth factors anymore (Traer 
et al., 2016). RAS protein is not mutated in MV4-11 or MOLM-13, and if RAS 
mutation can be developed to quizartinib (second generation-type II) and 
sorafenib (first generation-type I) as a result of FLT3L treatment for long time 
needs more investigation with all downstream cascades related to RAS 
activation. This actually may be related to late rescue of ERK1/2 in MV4-11we 
observed in our study. 
 
6.1.3 Role of Bcl-2 family members in FLT3 signalling and Quizartinib 
cytotoxicity 
The Bcl-2 family play a crucial role in both promoting and inhibiting cell death 
in many tumor types (Warren et al., 2019). Mcl-1 is overexpressed in most 
bone marrow cell samples taken from newly diagnosed AML patients (Xiang 
et al., 2009). Additionally, Mcl-1 overexpression has been identified as 
contributing to the development of resistance to the Bcl-2 inhibitor venetoclax 
in relapsed AML (Kaufmann et al., 1998). Therefore, Mcl-1 is involved not just 
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in promoting AML survival, but also promoting drug resistance (Glaser et al., 
2012). We were interested to establish if Mcl-1 played a role in FLT3 signalling 
and FLT3L-mediated resistance. We have shown that in AML cells the 
expression of Mcl-1 is regulated by FLT3 signalling through the MAPK 
pathway. Both ITD and WT-FLT3 could induce Mcl-1 expression implicating it 
in FLT3L-mediated resistance and suggesting that targeting Mcl-1 may offer a 
potential avenue for therapy in AML.  
 
The efficacy of S63845, a potent selective Mcl-1 inhibitor, was evaluated in the 
ITD-expressing cells. Selective inhibition of Mcl-1 by S63845 was effective in 
ITD cells when used alone as the viability of MOLM-13 and MV4-11 cells was 
significantly decreased. Co-treatment with quizartinib abrogated the protective 
effect of FLT3L but cell death was only slightly increased compared to Mcl-1 
inhibition alone. Mcl-1 knockdown by siRNA sensitized MV4-11 cells to 
quizartinib and prevented resistance mediated by FLT3L. Therefore, targeting 
Mcl-1 alone may be a potential option for AML treatment. These results 
indicate that S63845 not just used as a combination with quizartinib to 
abrogate FLT3L effect but also acted as a single agent to counteract FLT3L in 
ITD cells.  
 
By using cBioportal database and TCGA data sets in the cBioPortal for Cancer 
Genomics (Figure A8, A-D), we showed that FLT3 is significantly mutated in 
AML with about 28% of patients have somatic mutations in FLT3, compared 
with other types of cancer. This is in consistent with the data showed that 
247 
 
FLT3‐ITD is found in approximately 25-30% of adult patients over 55 years of 
age (Stirewalt et al., 2001). Furthermore, this mutations is associated with the 
overexpression of FLT3 that observed in AML patients. TCGA data also 
indicated that FLT3 is significantly overexpressed in AML compared to other 
cancer types. Supporting the data we showed and others for the role of Mcl-1 
in AML, the TCGA data show that AML patents also express a high level of 
Mcl-1 among 33 cancer cell types. The higher levels of Mcl-1 expression have 
been associated with poor prognosis and can be used for disease monitoring 
(Li et al., 2019). Indeed,  there was a positive correlation between FLT3 and  
Mcl-1 expression in AML patients, and this can be further investigated for the 
rational of co-targeting FLT3 and Mcl-1 as this be can a potential therapeutic 
target in the treatment of newly diagnosed and relapsed AML (Gao et al., 2013, 
Cerami et al., 2012, Network, 2013). 
 
Sorafenib is type 2 first generation FLT3 inhibitor and has been shown to 
downregulate Mcl-1 and upregulate Bim in FLT3-ITD AML clinical trials (Zhang 
et al., 2008). Quizartinib is second generation with more selectivity toward 
mutant FLT3. We were interested to observe quizartinib exhibited the same 
effect in the context of our project and what pathway was involved. Perhaps 
the most profound effect we saw was on the pro-apoptotic Bcl-2 family 
member Bim. Following quizartinib treatment there was a significant increase 
in Bim expression, and this could be clearly antagonised in a heterozygous 
cell line by the addition of FLT3L. The importance of Bim was further supported 
with siRNA which abrogated quizartinib-mediated cell death. 
248 
 
Our data indicates a model whereby constitutive MAPK signalling through ITD-
FLT3 supresses Bim expression effectively protecting the cells from apoptosis. 
This is further aided by upregulation of Mcl-1 (Fig 4.6). Inhibition of FLT3 with 
quizartinib causes Bim upregulation and possibly downregulation of Mcl-1 
leading to apoptosis. This is antagonised in heterozygous cells by the 
presence of FLT3L which, as its unaffected by quizartinib, can still signal 
through MAPKs to supress Bim expression, protecting the cells. We were able 
to counteract this with the MEK inhibitor trametinib or U0126 which acted to 
inhibit the effect of FLT3L. This provides a potential novel therapeutic option 
when using type II inhibitors in patients with high plasma levels of FLT3L. An 
explanatory model for the role of Mcl-1 and Bim in ITD and FLT3L signalling 
is presented in Figure 6.2. 
 
Figure 6.2: ITD regulation of Mcl-1 and Bim. 
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6.1.4 Gene Editing STAT5A using a double-guide RNA CRISPR-Cas9 
system 
CRISPR is a powerful tool to precisely change the DNA sequence at a target 
location or prevent gene expression by disruption of genes. “Knock-outs” have 
several advantages over transient knockdown methods such as siRNA or 
shRNAs the main ones being the changes are permanent and following 
selection of clones, complete, whereas the knock-down efficiency can vary.  
 
A number of studies have used CRISPR library screening in AML to 
investigate drug mechanisms including examining factors required for 
quizartinib toxicity (Hou et al., 2017, Tzelepis et al., 2016). Despite this 
manipulating individual proteins in haematopoietic cells is still in its infancy 
probably due to the difficulty in introducing the components at sufficient 
efficiency to cause editing and the difficulty in the subsequent isolation of 
clonal cells. While we were unable to realise fully the potential of our CRISPR 
experiments, the tools generated will be of great use for further dissecting the 
role of FLT3 in AML. We generated Cas9-expressing MV4-11 cells and a lab 
colleague has done the same for the MOLM-13s. This enables us to study 
uniquely the effect of FLT3 genotype on the efficacy of inhibitors.  
 
One way of avoiding, at least the cell line-to-cell line heterogeneity would have 
been to use CRISPR to introduce reciprocal mutations into the MV4-11 and 
MOLM-13s or in the WT-FLT3 THP-1 cell lines. This would have the additional 
benefit of resulting in cells with what we would predict as endogenous 
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expression levels of FLT3 assuming the mutations introduced did not 
somehow affect protein stability. At least they would be subject to the control 
of the endogenous human FLT3 promoter. It would be of interest to pursue 
such experiments in future studies. It will be possible to target specifically 
mutated alleles and therefore an ITD allele in MV4-11s could be reverted to 
WT to observe whether the protective effects of FLT3L are reproducible in 
another cell background. In a similar way the ITD allele in the MOLM-13s could 
be mutated to WT variant. Whilst we identified two distinct ITDs in our cell line 
models, many others exist and these could all be modelled using the cell lines 
and tools we generated, again to ascertain the efficacy of inhibition and 
protection afforded through the WT receptor. Additionally, as FLT3 is not the 
only protein mutated in AML, these lines could also be used to investigate ITD 
signalling and the role of FLT3L on the background of other AML mutations 
such as those in NPM-1 and DNMT3A.  
 
The main objective of this work is to highlight that careful treatment strategies 
are needed for targeted FLT3 therapy in order to increase the efficacy and 
decrease resistance. The current approach in drug development is to enhance 
drug efficacy and selectivity. However, these factors are not sufficient to 
achieve remission and does not preclude development of resistance even with 
the newer highly selective FLT3 inhibitors. When using FLT3 inhibitors in 
patients presenting with ITD mutations three factors need to be closely 
monitored: FLT3 genotype, type of FLT3 inhibitors and FLT3L plasma levels. 
Our data suggests that the efficacy of the type II inhibitors in patients with 
heterozygous mutations and high plasma levels of FLT3L will be improved by 
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co-administration with a MAPK inhibitors, Mcl-1 inhibitor or, glycosylation 
inhibitors (summarised in Figure 6.3). 
 
           




6.2 Future work 
Expanding the cell line models 
Unfortunately during the course of this study, we were unable access primary 
patient samples, so it would be of great interest to characterise the response 
to FLT3L and FLT3 inhibition in actual patient samples expressing 
homozygous or heterozygous ITD-FLT3. As we already had two human lines 
containing differing ITD mutations and zygosity available it was decided to use 
these for the study. I would have preferred to have used primary patient 
samples for some of these experiments (this was the original idea) but 
unfortunately none are available in Liverpool. Obviously, there would have 
been heterogeneity across samples/lines due to differing mutational 
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“landscapes”, but it would have been nice to have had the samples to reinforce 
some of the results seen in the cell lines. Also, in this study we are assuming 
that the effect we have seen is related to FLT3 with no other RTKs involved. 
To further expand this, we could use FLT3 null cells such as BaF3, 32D and 
U937 cells, and introduce constructs expressing ITD, wild-type, and other 
FLT3 mutations in order to assess their response to inhibition and FLT3L. 
 
The Kinome and cellular adaptation to drug resistance 
Based on our results, activation of MAPKs is implicated in drug resistance as 
these kinases can activate alternate survival and proliferation pathways. It 
would be interesting to look at global kinase expression and phosphorylation 
state and how this is altered by modulating FLT3, especially on the 
background of differing FLT3 genotypes and in different cell models. To track 
possible pathways of drug-resistance, large-scale proteomics studies are 
needed. We were hoping to investigate the kinome profile of MV4-11, MOLM-
13 and patient samples exposed to FLT3L and quizartinib by nanostring 
(mRNA) and phospho-proteomics (protein level). This will allow us to validate 
dysregulated proteins by flow cytometry, qPCR, and Western blotting using 
strategies established in Chapter III/IV. Other kinases could be potential 
targets in AML might be identified and should be studied further to explore 
their potential for combination therapy. 
 
Another area of interest is the differential response of AML cells to FLT3 
inhibitors and why only type I is affected by FLT3L. Our data suggests that the 
FLT3 mutational status might not be the only factor predicting response to 
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FLT3 inhibitors. The activation of other protein kinases besides FLT3 may 
provide further insight into the AML cell responsiveness to FLT3 inhibition and 
activation. A well establish approach to investigate this is to apply mass 
spectrometry-based proteomics to monitor and quantify all phosphorylation 
sites in a single experiment. Indeed, we can apply a phosphoproteome 
analysis to study the effects of type I/II inhibitors on panel of multiple AML cell 
line models. This might open a new window for understanding different 
mechanisms of action and resistance pathways and so predicting the 
responsiveness of AML cells. 
 
Genome editing AML cells 
In this thesis, we successfully established a CRISPR/Cas9-based strategy to 
knock-out STAT5A gene. The strategy was established and validated in HEK-
293T cells. Due to time constraints we were not able to use the same strategy 
in AML cell lines e.g. MV4-11. This should be done in future experiments as it 
allows us to use these cells to elucidate the role of STAT5A in AML. The same 
strategy could be applied to understand better the role of Mcl-1 and Bim and 
their potential as an essential target in AML. Generating AML Mcl-1 or Bim 
knock-out cells is a good starting point. MOLM-13 cells that contain 
heterozygous FLT3-ITD mutation are of interest seeing that FLT3L has more 





































































Figure A1 – MV4-11, MOLM-13, and THP-1, cells were incubated with 
increasing concentrations of sorafenib or gilteritinib. Apoptosis was measured 
at indicated times using Annexin-V/PI staining. Results represent the mean +/- 















































































































Figure A2 – MV4-11, MOLM-13, and THP-1 were treated with quizartinib (0.1 
µM) in the presence of FLT3L (100 ng/ml) for 72h. Apoptosis was measured 
at indicated times using Annexin V/PI. Results represent the mean +/- SEM of 
5 independent experiments. Significance testing was done by two-tailed paired 

















Quizartinib   -    +     -   +
FLT3L           -    -     +   +
MV4-11 MOLM-13 THP-1
 -    +    -    +
 -    -     +   +
 -    +    -    +
























Figure A3 – Dose–response curve indicating viability of FLT3-ITD expressing 
cells, MV4-11 and MOLM-13 treated with different concentrations of FLT3 
inhibitors alone and in combination with FLT3L for 72h. The resulting dose-
response curves were fitted by nonlinear regression using GraphPad program. 
 
Cell line and ITD status compound IC50 (72h) nM 
































































































































Quizartinib 31  
Quizartinib + FLT3L 97  
Gilteritinib 11 
Gilteritinib+ FLT3L 16 
Midostaurin 37 
Midostaurin+ FLT3L 34 
Sorafenib 385 
Sorafenib + FLT3L 749 
MOLM-13 (FLT3-ITD-/+) 
 
Quizartinib 6  
Quizartinib + FLT3L 49  
Gilteritinib 35 
Gilteritinib+ FLT3L 47 
Midostaurin 5 
Midostaurin+ FLT3L 5 
Sorafenib 210 
Sorafenib + FLT3L 780 






Figure A4 – MOLM-13 cells were treated with gilteritinib (0.1 µM) and/or 
FLT3L (100 ng/ml) for 48h and apoptosis was assessed by Annexin V staining. 
Results represent the mean +/- SEM for 3 independent experiments. 








                  
 
 
Figure A5 – MOLM-13 cells were treated with trametinib (0.05 µM) for 48h, 
followed by immunoblotting with the indicated antibodies. Apoptosis was 
assessed by Annexin V staining. Results represent the mean +/- SEM for 3 
independent experiments. Significance testing was done by two-tailed paired 



























































Figure A6 – MV4-11 cells were transfected with STAT5A (10 nM) for 72h 
before cells were harvested and analysed by Western blotting. Apoptosis was 
assessed by Annexin V staining. Results represent the mean +/- SEM for 3 
independent experiments. Significance testing was done by two-tailed paired 




























































Figure A8 – A) cBioportal database was used to analyse mutations and copy 
number alterations of FLT3. Genetic alterations of FLT3 in different types of 
cancer showed that FLT3 was significantly mutated in AML.  Expression of 
FLT3 mRNA (B) and Mcl-1 (C) in different tumours was analysed using 
cBioportal database. D) cBioportal result showed the expression of FLT3 was 
























Figure A9 – Flow cytometry Gating: 
 


































































CFSE staining: MV4-11 untreated (UT) A) 24 h, B) 72 h and C) quizartinib 















CFSE staining: MOLM-13 untreated (UT) A) 24 h, B) 72 h and C) quizartinib 














Cell apoptosis assay: A) Representative plots of MV4-11 cells treated with 




















Figure A10 – LentiCRISPR v2 plasmid 
LentiCRISPR v2 plasmid is a lentiviral SpCas9-expressing plasmid and was 
purchased from Addgene (#52961). The original EF-1α core promotor was 
replaced with a SFFV promotor. For guide cloning, plasmid was digested with 
BsmbI to remove the stuffer region and annealed guide oligos were ligated 








Figure A11 – pLeGO plasmid 
pLeGO is a lentiviral plasmid purchased from Addgene (#27341) that 
expresses EGFP under the control of a SFFV promotor. This plasmid was 










Table A2– Purchased Reagents and Kits 
Name Supplier 
Tween-20 Thermo Fisher Scientific™ 
(Loughborough, UK) 
sodium dodecyl sulphate (SDS) Thermo Fisher Scientific™ 
(Loughborough, UK) 
page ruler plus protein ladder Thermo Fisher Scientific™ 
(Loughborough, UK) 
glycine Thermo Fisher Scientific™ 
(Loughborough, UK) 




Thermo Fisher Scientific™ 
(Loughborough, UK) 
Bovine Serum Albumin (BSA) Sigma-Aldrich (Poole, UK) 
tetramethylethylenediamine 
(TEMED) 
Sigma-Aldrich (Poole, UK) 
dimethyl sulphoxide (DMSO) Sigma-Aldrich (Poole, UK) 
ethylenediaminetetraacetic acid 
(EDTA) 
Sigma-Aldrich (Poole, UK) 
Luria Bertani (LB) Sigma-Aldrich (Poole, UK) 
Phosphate buffered saline (PBS) Sigma-Aldrich (Poole, UK) 
Propidium Iodide (PI) Sigma-Aldrich (Poole, UK) 
Trypsin/EDTA (0.25%) Sigma-Aldrich (Poole, UK) 
β-Mercaptoethanol Sigma-Aldrich (Poole, UK) 
Hybond ECL nitrocellulose 
membrane 
GE Healthcare (Amersham, UK) 
Ultrapure ProtoGel® solution Geneflow Ltd 
Acrylamide Geneflow Ltd 
Fetal bovine serum (FBS) Invitrogen 






Penicillin, Streptomycin (10 mg/ 
mL) 
Invitrogen 
Roswell Park Memorial Institute 
(RPMI) 
Invitrogen 





















































































ABDEL-WAHAB, O. & LEVINE, R. L. 2013. Mutations in epigenetic modifiers 
in the pathogenesis and therapy of acute myeloid leukemia. Blood, The 
Journal of the American Society of Hematology, 121, 3563-3572. 
ABU‐DUHIER, F., GOODEVE, A., WILSON, G., CARE, R., PEAKE, I. & 
REILLY, J. 2001. Identification of novel FLT‐3 Asp835 mutations in 
adult acute myeloid leukaemia. British journal of haematology, 113, 
983-988. 
AHSAN, A., HINIKER, S. M., RAMANAND, S. G., NYATI, S., HEGDE, A., 
HELMAN, A., MENAWAT, R., BHOJANI, M. S., LAWRENCE, T. S. & 
NYATI, M. K. 2010. Role of epidermal growth factor receptor 
degradation in cisplatin-induced cytotoxicity in head and neck cancer. 
Cancer research, 70, 2862-2869. 
ALESSI, D. R., DEAK, M., CASAMAYOR, A., CAUDWELL, F. B., MORRICE, 
N., NORMAN, D. G., GAFFNEY, P., REESE, C. B., MACDOUGALL, C. 
N. & HARBISON, D. 1997. 3-Phosphoinositide-dependent protein 
kinase-1 (PDK1): structural and functional homology with the 
Drosophila DSTPK61 kinase. Current biology, 7, 776-789. 
ALMEIDA, A. M. & RAMOS, F. 2016. Acute myeloid leukemia in the older 
adults. Leukemia research reports, 6, 1-7. 
ALVARADO, Y., KANTARJIAN, H. M., LUTHRA, R., RAVANDI, F., 
BORTHAKUR, G., GARCIA‐MANERO, G., KONOPLEVA, M., 
ESTROV, Z., ANDREEFF, M. & CORTES, J. E. 2014. Treatment with 
FLT3 inhibitor in patients with FLT3‐mutated acute myeloid leukemia is 
associated with development of secondary FLT3–tyrosine kinase 
domain mutations. Cancer, 120, 2142-2149. 
AMBROSIO, R., FIMIANI, G., MONFREGOLA, J., SANZARI, E., DE FELICE, 
N., SALERNO, M. C., PIGNATA, C., D'URSO, M. & URSINI, M. V. 
2002. The structure of human STAT5A and B genes reveals two 
regions of nearly identical sequence and an alternative tissue specific 
STAT5B promoter. Gene, 285, 311-318. 
ANDERSON, K. E. & JACKSON, S. P. 2003. Class I phosphoinositide 3-
kinases. The international journal of biochemistry & cell biology, 35, 
1028-1033. 
ANTAR, A., OTROCK, Z., EL-CHEIKH, J., KHARFAN-DABAJA, M., 
BATTIPAGLIA, G., MAHFOUZ, R., MOHTY, M. & BAZARBACHI, A. 
2017. Inhibition of FLT3 in AML: a focus on sorafenib. Bone marrow 
transplantation, 52, 344-351. 
ARBER, D. A., ORAZI, A., HASSERJIAN, R., THIELE, J., BOROWITZ, M. J., 
LE BEAU, M. M., BLOOMFIELD, C. D., CAZZOLA, M. & VARDIMAN, 
J. W. 2016. The 2016 revision to the World Health Organization 
classification of myeloid neoplasms and acute leukemia. Blood, 127, 
2391-405. 
ASHKENAZI, A., FAIRBROTHER, W. J., LEVERSON, J. D. & SOUERS, A. J. 
2017. From basic apoptosis discoveries to advanced selective BCL-2 
family inhibitors. Nature Reviews Drug Discovery, 16, 273. 
ASSI, R. & RAVANDI, F. 2018. FLT3 inhibitors in acute myeloid leukemia: 
Choosing the best when the optimal does not exist. American journal of 
hematology, 93, 553-563. 
AZAM, M., ERDJUMENT‐BROMAGE, H., KREIDER, B., XIA, M., QUELLE, 
F., BASU, R., SARIS, C., TEMPST, P., IHLE, J. & SCHINDLER, C. 
279 
 
1995. Interleukin‐3 signals through multiple isoforms of Stat5. The 
EMBO Journal, 14, 1402-1411. 
BADAR, T., KANTARJIAN, H. M., NOGUERAS‐GONZALEZ, G. M., 
BORTHAKUR, G., GARCIA MANERO, G., ANDREEFF, M., 
KONOPLEVA, M., KADIA, T. M., DAVER, N. & WIERDA, W. G. 2015. 
Improvement in clinical outcome of FLT3 ITD mutated acute myeloid 
leukemia patients over the last one and a half decade. American journal 
of hematology, 90, 1065-1070. 
BALMANNO, K. & COOK, S. 2009. Tumour cell survival signalling by the 
ERK1/2 pathway. Cell Death & Differentiation, 16, 368-377. 
BANKER, D. E., RADICH, J., BECKER, A., KERKOF, K., NORWOOD, T., 
WILLMAN, C. & APPELBAUM, F. R. 1998. The t (8; 21) translocation 
is not consistently associated with high Bcl-2 expression in de novo 
acute myeloid leukemias of adults. Clinical Cancer Research, 4, 3051-
3062. 
BAUM, C. M., WEISSMAN, I. L., TSUKAMOTO, A. S., BUCKLE, A.-M. & 
PEAULT, B. 1992. Isolation of a candidate human hematopoietic stem-
cell population. Proceedings of the National Academy of Sciences, 89, 
2804-2808. 
BEINORTAS, T., TAVORIENĖ, I., ŽVIRBLIS, T., GERBUTAVIČIUS, R., 
JURGUTIS, M. & GRIŠKEVIČIUS, L. 2016. Chronic myeloid leukemia 
incidence, survival and accessibility of tyrosine kinase inhibitors: a 
report from population-based Lithuanian haematological disease 
registry 2000–2013. BMC cancer, 16, 198. 
BENEKLI, M., BAER, M. R., BAUMANN, H. & WETZLER, M. 2003. Signal 
transducer and activator of transcription proteins in leukemias. Blood, 
The Journal of the American Society of Hematology, 101, 2940-2954. 
BENNETT, J. M., CATOVSKY, D., DANIEL, M. T., FLANDRIN, G., GALTON, 
D. A., GRALNICK, H. R. & SULTAN, C. 1976. Proposals for the 
classification of the acute leukaemias. French-American-British (FAB) 
co-operative group. Br J Haematol, 33, 451-8. 
BENNETT, J. M., CATOVSKY, D., DANIEL, M. T., FLANDRIN, G., GALTON, 
D. A., GRALNICK, H. R. & SULTAN, C. 1985. Proposed revised criteria 
for the classification of acute myeloid leukemia. A report of the French-
American-British Cooperative Group. Ann Intern Med, 103, 620-5. 
BESBES, S., MIRSHAHI, M., POCARD, M. & BILLARD, C. 2015. New 
dimension in therapeutic targeting of BCL-2 family proteins. 
Oncotarget, 6, 12862. 
BESLU, N., LAROSE, J., CASTERAN, N., BIRNBAUM, D., LECOCQ, E., 
DUBREUIL, P. & ROTTAPEL, R. 1996. Phosphatidylinositol-3′ kinase 
is not required for mitogenesis or internalization of the Flt3/Flk2 receptor 
tyrosine kinase. Journal of Biological Chemistry, 271, 20075-20081. 
BLOOMFIELD, C. D., ESTEY, E., PLEYER, L., SCHUH, A. C., STEIN, E. M., 
TALLMAN, M. S. & WEI, A. 2018. Time to repeal and replace response 
criteria for acute myeloid leukemia? Blood reviews, 32, 416-425. 
BLUME‐JENSEN, P., CLAESSON‐WELSH, L., SIEGBAHN, A., ZSEBO, K. 
M., WESTERMARK, B. & HELDIN, C.-H. 1991. Activation of the human 
c‐kit product by ligand‐induced dimerization mediates circular actin 
reorganization and chemotaxis. The EMBO journal, 10, 4121-4128. 
280 
 
BODDU, P. C., KADIA, T. M., GARCIA‐MANERO, G., CORTES, J., ALFAYEZ, 
M., BORTHAKUR, G., KONOPLEVA, M., JABBOUR, E. J., DAVER, N. 
G. & DINARDO, C. D. 2019. Validation of the 2017 European 
LeukemiaNet classification for acute myeloid leukemia with NPM1 and 
FLT3‐internal tandem duplication genotypes. Cancer, 125, 1091-1100. 
BORTHAKUR, G., KANTARJIAN, H., RAVANDI, F., ZHANG, W., 
KONOPLEVA, M., WRIGHT, J. J., FADERL, S., VERSTOVSEK, S., 
MATHEWS, S. & ANDREEFF, M. 2011. Phase I study of sorafenib in 
patients with refractory or relapsed acute leukemias. Haematologica, 
96, 62-68. 
BOUDEWIJN, M. T. & COFFER, P. J. 1995. Protein kinase B (c-Akt) in 
phosphatidylinositol-3-OH kinase signal transduction. Nature, 376, 599-
602. 
BRADBURY, D. & RUSSELL, N. 1995. Comparative quantitative expression 
of bcl‐2 by normal and leukaemic myeloid cells. British journal of 
haematology, 91, 374-379. 
BRANDTS, C. H., SARGIN, B., RODE, M., BIERMANN, C., LINDTNER, B., 
SCHWÄBLE, J., BUERGER, H., MÜLLER-TIDOW, C., CHOUDHARY, 
C. & MCMAHON, M. 2005. Constitutive activation of Akt by Flt3 internal 
tandem duplications is necessary for increased survival, proliferation, 
and myeloid transformation. Cancer research, 65, 9643-9650. 
BRASEL, K., ESCOBAR, S., ANDERBERG, R., DE VRIES, P., GRUSS, H. J. 
& LYMAN, S. D. 1995. Expression of the flt3 receptor and its ligand on 
hematopoietic cells. Leukemia, 9, 1212-8. 
BRATTON, S. B., WALKER, G., SRINIVASULA, S. M., SUN, X. M., 
BUTTERWORTH, M., ALNEMRI, E. S. & COHEN, G. M. 2001. 
Recruitment, activation and retention of caspases‐9 and‐3 by Apaf‐1 
apoptosome and associated XIAP complexes. The EMBO journal, 20, 
998-1009. 
BREITENBUECHER, F., MARKOVA, B., KASPER, S., CARIUS, B., 
STAUDER, T., BÖHMER, F. D., MASSON, K., RÖNNSTRAND, L., 
HUBER, C. & KINDLER, T. 2009a. A novel molecular mechanism of 
primary resistance to FLT3-kinase inhibitors in AML. Blood, The Journal 
of the American Society of Hematology, 113, 4063-4073. 
BREITENBUECHER, F., MARKOVA, B., KASPER, S., CARIUS, B., 
STAUDER, T., BÖHMER, F. D., MASSON, K., RÖNNSTRAND, L., 
HUBER, C. & KINDLER, T. 2009b. A novel molecular mechanism of 
primary resistance to FLT3-kinase inhibitors in AML. Blood, 113, 4063-
4073. 
BRUNELLE, J. K., RYAN, J., YECIES, D., OPFERMAN, J. T. & LETAI, A. 
2009. MCL-1–dependent leukemia cells are more sensitive to 
chemotherapy than BCL-2–dependent counterparts. Journal of Cell 
Biology, 187, 429-442. 
BRUNET, A., BONNI, A., ZIGMOND, M. J., LIN, M. Z., JUO, P., HU, L. S., 
ANDERSON, M. J., ARDEN, K. C., BLENIS, J. & GREENBERG, M. E. 
1999. Akt promotes cell survival by phosphorylating and inhibiting a 
Forkhead transcription factor. cell, 96, 857-868. 
BRUNNER, A. M., CAMPIGOTTO, F., SADRZADEH, H., DRAPKIN, B. J., 
CHEN, Y. B., NEUBERG, D. S. & FATHI, A. T. 2013. Trends in all‐
cause mortality among patients with chronic myeloid leukemia: a 
281 
 
Surveillance, Epidemiology, and End Results database analysis. 
Cancer, 119, 2620-2629. 
BUITENHUIS, M. & COFFER, P. J. 2009. The role of the PI3K-PKB signaling 
module in regulation of hematopoiesis. Cell cycle, 8, 560-566. 
BURCHERT, A., BUG, G., FINKE, J., STELLJES, M., ROLLIG, C., WÄSCH, 
R., BORNHÄUSER, M., BERG, T., LANG, F. & EHNINGER, G. 2018. 
Sorafenib as maintenance therapy post allogeneic stem cell 
transplantation for FLT3-ITD positive AML: results from the 
randomized, double-blind, placebo-controlled multicentre sormain trial. 
Blood, 132, 661-661. 
CALÒ, V., MIGLIAVACCA, M., BAZAN, V., MACALUSO, M., BUSCEMI, M., 
GEBBIA, N. & RUSSO, A. 2003. STAT proteins: from normal control of 
cellular events to tumorigenesis. Journal of cellular physiology, 197, 
157-168. 
CAO, T., JIANG, N., LIAO, H., SHUAI, X., SU, J. & ZHENG, Q. 2019. The 
FLT3-ITD mutation and the expression of its downstream signaling 
intermediates STAT5 and Pim-1 are positively correlated with CXCR4 
expression in patients with acute myeloid leukemia. Scientific reports, 
9, 1-10. 
CAPECCHI, M. R. 1989. Altering the genome by homologous recombination. 
Science, 244, 1288-1292. 
CAPECCHI, M. R. 2005. Gene targeting in mice: functional analysis of the 
mammalian genome for the twenty-first century. Nature Reviews 
Genetics, 6, 507-512. 
CAROW, C. E., LEVENSTEIN, M., KAUFMANN, S. H., CHEN, J., AMIN, S., 
ROCKWELL, P., WITTE, L., BOROWITZ, M. J., CIVIN, C. I. & SMALL, 
D. 1996. Expression of the hematopoietic growth factor receptor FLT3 
(STK-1/Flk2) in human leukemias. Blood, 87, 1089-96. 
CARROLL, D. 2011. Genome engineering with zinc-finger nucleases. 
Genetics, 188, 773-782. 
CARTER, B. Z., MAK, P. Y., MU, H., ZHOU, H., MAK, D. H., SCHOBER, W., 
LEVERSON, J. D., ZHANG, B., BHATIA, R. & HUANG, X. 2016. 
Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates 
chronic myeloid leukemia stem cells. Science translational medicine, 8, 
355ra117-355ra117. 
CASTAIGNE, S., PAUTAS, C., TERRÉ, C., RAFFOUX, E., BORDESSOULE, 
D., BASTIE, J.-N., LEGRAND, O., THOMAS, X., TURLURE, P. & 
REMAN, O. 2012. Effect of gemtuzumab ozogamicin on survival of 
adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a 
randomised, open-label, phase 3 study. The Lancet, 379, 1508-1516. 
CAUCHY, P., JAMES, S. R., ZACARIAS-CABEZA, J., PTASINSKA, A., 
IMPERATO, M. R., ASSI, S. A., PIPER, J., CANESTRARO, M., 
HOOGENKAMP, M. & RAGHAVAN, M. 2015. Chronic FLT3-ITD 
signaling in acute myeloid leukemia is connected to a specific chromatin 
signature. Cell reports, 12, 821-836. 
CEBRIAN-SERRANO, A. & DAVIES, B. 2017. CRISPR-Cas orthologues and 
variants: optimizing the repertoire, specificity and delivery of genome 
engineering tools. Mammalian Genome, 28, 247-261. 
CERAMI, E., GAO, J., DOGRUSOZ, U., GROSS, B. E., SUMER, S. O., 
AKSOY, B. A., JACOBSEN, A., BYRNE, C. J., HEUER, M. L. & 
282 
 
LARSSON, E. 2012. The cBio cancer genomics portal: an open 
platform for exploring multidimensional cancer genomics data. AACR. 
CHAGASTELLES, P. C. & NARDI, N. B. 2011. Biology of stem cells: an 
overview. Kidney international supplements, 1, 63-67. 
CHAN, P. M., ILANGUMARAN, S., LA ROSE, J., CHAKRABARTTY, A. & 
ROTTAPEL, R. 2003. Autoinhibition of the kit receptor tyrosine kinase 
by the cytosolic juxtamembrane region. Molecular and cellular biology, 
23, 3067-3078. 
CHAN, S. L. & YU, V. C. 2004. Proteins of the bcl‐2 family in apoptosis 
signalling: from mechanistic insights to therapeutic opportunities. 
Clinical and Experimental Pharmacology and Physiology, 31, 119-128. 
CHAO, Q., SPRANKLE, K. G., GROTZFELD, R. M., LAI, A. G., CARTER, T. 
A., VELASCO, A. M., GUNAWARDANE, R. N., CRAMER, M. D., 
GARDNER, M. F., JAMES, J., ZARRINKAR, P. P., PATEL, H. K. & 
BHAGWAT, S. S. 2009. Identification of N-(5-tert-butyl-isoxazol-3-yl)-
N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1 ,3]benzothiazol-2-
yl]phenyl}urea dihydrochloride (AC220), a uniquely potent, selective, 
and efficacious FMS-like tyrosine kinase-3 (FLT3) inhibitor. J Med 
Chem, 52, 7808-16. 
CHAUDRY, S. F. & CHEVASSUT, T. J. 2017. Epigenetic guardian: a review 
of the DNA methyltransferase DNMT3A in acute myeloid leukaemia 
and clonal haematopoiesis. BioMed research international, 2017. 
CHEN, C., LIU, Y., LIU, R., IKENOUE, T., GUAN, K.-L., LIU, Y. & ZHENG, P. 
2008. TSC–mTOR maintains quiescence and function of hematopoietic 
stem cells by repressing mitochondrial biogenesis and reactive oxygen 
species. The Journal of experimental medicine, 205, 2397-2408. 
CHENG, H., ZHENG, Z. & CHENG, T. 2020. New paradigms on hematopoietic 
stem cell differentiation. Protein & cell, 11, 34-44. 
CHKLOVSKAIA, E., JANSEN, W., NISSEN, C., LYMAN, S. D., RAHNER, C., 
LANDMANN, L. & WODNAR-FILIPOWICZ, A. 1999. Mechanism of flt3 
ligand expression in bone marrow failure: translocation from 
intracellular stores to the surface of T lymphocytes after chemotherapy-
induced suppression of hematopoiesis. Blood, The Journal of the 
American Society of Hematology, 93, 2595-2604. 
CHOI, Y., ZHANG, J., MURGA, C., YU, H., KOLLER, E., MONIA, B. P., 
GUTKIND, J. S. & LI, W. 2002. PTEN, but not SHIP and SHIP2, 
suppresses the PI3K/Akt pathway and induces growth inhibition and 
apoptosis of myeloma cells. Oncogene, 21, 5289-5300. 
CHONG, H. & GUAN, K.-L. 2003. Regulation of Raf through phosphorylation 
and N terminus-C terminus interaction. Journal of Biological Chemistry, 
278, 36269-36276. 
CHOUDHARY, C., BRANDTS, C., SCHWABLE, J., TICKENBROCK, L., 
SARGIN, B., UEKER, A., BÖHMER, F.-D., BERDEL, W. E., MÜLLER-
TIDOW, C. & SERVE, H. 2007. Activation mechanisms of STAT5 by 
oncogenic Flt3-ITD. Blood, The Journal of the American Society of 
Hematology, 110, 370-374. 
CHOUDHARY, C., OLSEN, J. V., BRANDTS, C., COX, J., REDDY, P. N., 
BÖHMER, F. D., GERKE, V., SCHMIDT-ARRAS, D.-E., BERDEL, W. 
E. & MÜLLER-TIDOW, C. 2009a. Mislocalized activation of oncogenic 
283 
 
RTKs switches downstream signaling outcomes. Molecular cell, 36, 
326-339. 
CHOUDHARY, C., OLSEN, J. V., BRANDTS, C., COX, J., REDDY, P. N., 
BOHMER, F. D., GERKE, V., SCHMIDT-ARRAS, D. E., BERDEL, W. 
E., MULLER-TIDOW, C., MANN, M. & SERVE, H. 2009b. Mislocalized 
activation of oncogenic RTKs switches downstream signaling 
outcomes. Mol Cell, 36, 326-39. 
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MÜLLER, C., GRÜNING, W., KRATZ-ALBERS, K., SERVE, S. & 
STEUR, C. 2000. Flt3 mutations from patients with acute myeloid 
leukemia induce transformation of 32D cells mediated by the Ras and 
STAT5 pathways. Blood, The Journal of the American Society of 
Hematology, 96, 3907-3914. 
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